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Abstract 
Introduction 
Whey-acidic-protein (WAP) four-disulfide core domain protein 2 (WFDC2) is a small, secretory 
glycoprotein that is characterised by possession of two cysteine-rich protein domains. In 
healthy tissues, WFDC2 is most abundantly expressed in the trachea and oral cavity, yet its 
function at these sites is unknown. Structural similarities to other family members suggests 
that WFDC2 may play a role in host defence, thus antimicrobial and anti-protease functions 
have been hypothesised. WFDC2 expression is exacerbated in ovarian cancer and as a result 
it is used clinically as a serum biomarker. WFDC2 is also reported to be upregulated in other 
malignancies, including lung cancer, in addition to benign diseases such as cystic fibrosis and 
renal fibrosis. It is unclear whether WFDC2 mediates tumorigenic effects. The aim of this study 
was to determine the function of WFDC2, with the primary objective of understanding whether 
it is involved in tumour progression.   
Materials and methods  
Recombinant human and murine WFDC2 were synthesised by gene cloning and transfection 
into HEK293 cells. WFDC2 protein was purified from conditioned media and utilised for 
protease inhibition and bacteria assays. The N-glycosylation site of human WFDC2 was 
elucidated via site-directed mutagenesis and enzymatic cleavage. The WFDC2 expression of 
lung and oral cancer-derived cell lines was analysed by RT-qPCR, ELISA and Western 
blotting. An oral cancer cell line was utilised for CRISPR gene editing to silence endogenous 
WFDC2 gene expression. Successful gene silencing was confirmed via sequencing, RT-PCR, 
RT-qPCR, Western blotting and ELISA. Changes in cell behaviour between wild-type and 
CRISPR edited cells were analysed via standard in vitro cell behaviour assays. WT and 
heterozygous Wfdc2-knockout mice were studied via H&E staining and 
iv 
 
immunohistochemistry. Micro-CT scans of WT and homozygous knockout mice embryos at 
E14.5 and E18.5 were compared to elucidate differences in phenotype. 
Results  
Recombinant human and murine WFDC2 were unable to inhibit the growth of any of the 
bacterial strains tested, nor were they able to inhibit protease activity. CRISPR edited cells 
showed a significant reduction in their capacity to invade Matrigel-coated Transwells 
compared to controls. Homozygous Wfdc2-knockout mice died shortly after birth as a result 
of respiratory distress while heterozygous animals survived to adulthood and had no obvious 
histological phenotype. Micro-CT analysis showed that the trachea and bronchi of homozygote 
embryos were constricted at E14.5 and E18.5.  
Conclusions  
WFDC2 is not a host defence protein and is instead involved in development of the tracheal 
and bronchial lumina during embryogenesis. WFDC2 is involved in tumorigenesis by 
promoting cancer cell invasion. This suggests that WFDC2 is a prognostic biomarker and 
could represent an interesting therapeutic target. The role of WFDC2 in development requires 
further analysis.  
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1.1. An introduction to WFDC2  
Whey-acidic-protein (WAP) four-disulfide core domain protein 2 (WFDC2) is a small, secretory 
glycoprotein characterised by its possession of two WAP four-disulfide core (WFDC) domains. 
The WFDC domain is a structural motif formed of approximately 50 amino acids, including 8 
conserved cysteine residues that form 4 interlinked disulfide bonds (Hennighausen and 
Sippel, 1982). In related proteins, WFDC domains appear to confer anti-proteinase and 
antimicrobial activities, however the exact function of the domains in WFDC2 is unknown. At 
a nucleotide level, the WFDC2 gene is approximately 12 kb and consists of five exons which 
can undergo alternative splicing to produce five different protein isoforms.  
In humans, WFDC2 is most abundantly expressed in the trachea and salivary glands where 
its expression pattern is largely restricted to the ducts and glands of mucosal surfaces. The 
presence of WFDC2 at mucosal surfaces, in addition to its structural similarity to other WFDC 
family members which exhibit host protective functions, has led to the hypothesis that WFDC2 
is capable of bacterial killing and inhibition of host-derived proteases. This theory is yet to be 
extensively researched.  
WFDC2 is primarily of interest to the scientific community because it is overexpressed in a 
number of malignancies including ovarian cancer where it is used clinically as a serum 
biomarker for disease detection. It has been reported that WFDC2 is also upregulated in a 
number of other cancer types, including lung cancer, although serum concentrations remain 
significantly lower than in patients with ovarian malignancies. Interestingly, WFDC2 appears 
to be overexpressed in some benign diseases, particularly in the case of cystic fibrosis. The 
role of WFDC2 in both malignant and benign diseases is not well understood. The effect of 
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WFDC2 on cancer cell behaviour has been studied using both WFDC2-overexpressing and -
knockdown clones, but the resultant literature is conflicted and it remains unclear whether 
WFDC2 is involved in tumorigenesis.  
1.1.1. The WFDC2 gene  
Full-length WFDC2 is located at locus 20q13.12, spanning 11.8 kb, and is capable of 
undergoing alternative splicing to form five distinct splice variants. Although WFDC2 was first 
isolated and cloned in 1991 (Kirchhoff et al., 1991), its numerous splice variants were not 
identified until 2002, whereby alignment of expressed sequence tags (ESTs) and comparison 
to genomic DNA revealed distinct exonic arrangements between transcripts (Bingle et al., 
2002). The full-length gene structure of WFDC2 consists of five exons, two of which are 
capable of existing in three forms (Figure 1.1). The gene also encodes a signal peptide, 
suggesting that its product is secretory in nature (Bingle et al., 2002).  
 
Fig 1.1. The full length human WFDC2 transcript. A schematic diagram depicting the gene structure 
of full length human WFDC2, adapted from Bingle et al (2002). The gene is 11.8 kb in size. The intron 
between exon 3 and 4 is over 8 kb long. The estimated sizes (bp) of each exon are included. The 5’ 
start sites of exon 3b and 4b are unknown and so the precise exon sizes are unknown. WFDC domains 
are encoded within exon 2 and exon 4.   
 
1.1.2. The WFDC2 splice variants  
Reverse transcription polymerase chain reaction (RT-PCR) analysis using multiple primer 
pairs and conceptual translation enabled the genomic arrangement of all five WFDC2 splice 
variants [variant (V) 0-4] to be determined. The exonic arrangements of each variant are 
depicted in Fig 1.2 (Bingle et al., 2002). The predominant isoform of WFDC2, V0, is referred 
to as full-length (FL) and is the only variant that encodes both an N- and C-terminal WFDC 
domain. V2 and V3 both encode C-terminal WFDC domains whilst V1 and V4 encode an N-
terminal WFDC domain in addition to unique C-terminal sequences. All isoforms contain a 30 
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residue signal peptide aside from V3 which appears to have an alternative promoter region 
(Bingle et al., 2002; Kirchhoff et al., 1991). The biological role of the different protein isoforms 
is yet to be explored and it is unclear whether the splice variants are differentially regulated.  
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Fig 1.2. The genomic arrangement of the five WFDC2 splice variants. A schematic diagram to show 
the genomic organisation of the five WFDC2 splice variants (V0, V1, V2, V3 and V4), adapted from 
Bingle et al (2002). The approximate length (bp) of each exon and intron are indicated, as is the putative 
length of the resultant polypeptide after splicing. The putative transcription start and stop sites are 
shown (see Key in pane of Variant 3) and the presence or absence of a signal peptide is also indicated.  
 
1.1.3. The WFDC protein family  
Proteins that are known to express a motif with four conserved disulfide bridges are loosely 
termed four-disulfide core (FDC) containing proteins. The FDC grouping is subcategorised 
into the WFDC protein family, to which WFDC2 belongs (Bingle and Vyakarnam, 2008). There 
are eighteen known human WFDC genes, fourteen of which are located at a single locus on 
chromosome 20 (Bingle and Vyakarnam, 2008; Clauss et al., 2002).  
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Proteins containing a 40-50 residue motif with a conserved arrangement of four disulfide 
bridges were first collected into a family by Drenth et al (1980), who demonstrated that FDC 
motifs existed in a broad range of proteins with largely unrelated functions, including wheat 
germ agglutinin, snake venom neurotoxins and cardiotoxins, ragweed pollen allergen and 
hevein. The subsequent discovery and cloning of mouse whey acidic protein (WAP), the major 
whey protein in murine milk, led to its allocation to the FDC group due to the presence of two 
cysteine-rich domains (Drenth et al., 1980; Hennighausen and Sippel, 1982; Piletz et al., 
1981).  
The general structure of the FDC domain was further elucidated by Ranganathan et al (1999) 
whereby 84 FDC domains from a broad range of species were aligned in order to define a 
consensus motif. The study largely focused on WAP proteins from numerous species, 
therefore the FDC consensus was defined as a signature motif for identifying new members 
of the ‘WAP-type’ family, thus marking WAP as the prototypic member of the group 
(Ranganathan et al., 1999). Alignment analysis of the 18 human FDC-containing proteins by 
Bingle and Vyakarnam (2008) led to amendment of the ‘WAP-type’ signature sequence, thus 
defining a consensus motif specifically for the human proteins. The amended signature 
demonstrated that the only residues that remain constantly conserved in all 26 human 
domains are the 8 cysteine residues (Bingle and Vyakarnam, 2008). It is important to note that 
although the domain is frequently entitled the WAP motif, it is not found exclusively in whey 
acidic protein; therefore, in this review, the domain will be more accurately entitled the WFDC 
domain.  
1.1.4. The WFDC domain 
The X-ray crystal structure of the well-studied WFDC protein secretory leukocyte protease 
inhibitor (SLPI) has provided insight into the architecture of the WFDC domain (Grütter et al., 
1988). SLPI is a protease inhibitor that contains two WFDC motifs: a C-terminal domain 
(domain 2) that has broad anti-protease activity and an N-terminal domain (domain 1) that is 
incapable of protease inhibition (Bingle and Vyakarnam, 2008; Eisenberg et al., 1990; Masuda 
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et al., 1995). Differences between the two motifs give an insight into the structural organisation 
required for successful protease inhibition. This should be carefully considered when 
analysing the domains of related WFDC proteins, including WFDC2.   
According to Grütter et al (1988), SLPI is a boomerang shaped molecule with analogous 
WFDC domains at the end of each lobe. Each domain exists as an extended planar spiral, 
resulting in a flat, wedge-like conformation. Few non-covalent interactions exist between the 
two domains, suggesting that they function independently. The polypeptide chain of each 
domain is formed of four antiparallel strands: two twisted β-sheets joined by a hairpin loop 
form the internal part of the motif, while the two outer strands are connected by a wider loop 
(Figure 1.3). In domain 2, this outer loop contains the primary enzyme-binding segment and 
scissile peptide bond. The conserved intradomain disulfide bridges that characterise the 
domain serve to anchor the internal and external strands together, stabilising the structure 
and, in the case of domain 2, ensuring that the protease binding loop remains exposed (Grütter 
et al., 1988). It is hypothesised that the analogous loop in domain 1 is unable to exhibit 
protease inhibition as a result of its alternative cysteine spacing compared to that observed in 
domain 2, which is likely to affect the capacity of the loop to bind to target enzymes (Bingle 
and Vyakarnam, 2008).  
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Fig 1.3. The architecture of the WFDC domains in human SLPI. (a) A summary of the polypeptide 
arrangement of SLPI, taken from Grutter et al (1988). Disulfide bridges are shown. The boundary 
between the two domains is residue 52. The four antiparallel segments are labelled (A1-D1 in domain 
1 and A2-D2 in domain 2). Strand C and D form a twisted β-sheet joined by a hairpin loop surrounded 
by straight chains A and B. The exterior chains (A and B) are connected to the internal chains (C and 
D) by disulfide bridges. The arrow depicts the position of the scissile peptide bond (Leu72-Met73). The 
enzyme binding loop (residues 68-74) stacks upon the internal hairpin loop, forming a globular domain. 
Residues 13-24 in domain 1 would be analogous to residues 68-74 in domain 2. (b) A ribbon diagram 
of the polypeptide chain of domain 2. The 8 conserved cysteine residues and Leu72 are shown. The 
left diagram shows the front view of the structure, and the right-hand figure shows the side view after a 
90° rotation. 
 
1.1.5. Glycosylation  
In addition to its two WFDC domains, WFDC2 is also characterised by a single N-linked 
glycosylation site, predicted to be positioned at Asn-44, which contributes around 5 kDa to the 
molecular weight of the protein (Drapkin et al., 2005; Hua et al., 2014; Wang et al., 2015) 
Glycosylation analysis carried out by Hua et al (2014) showed that WFDC2 has a complex, 
biantennary glycan structure. Fucose residues were identified at the glycan core whilst sialic 
acid residues were also identified at the terminus (see Figure 1.4). The complex glycan 
structure caused the molecular weight of WFDC2 to be larger than its theoretical mass (Hua 
et al., 2014). Glycosylation can influence a variety of key processes such as protein folding, 
secretion, turnover and trafficking, in addition to promoting protein-protein interactions and 
adhesion (Varki, 1993). The role of such extensive glycosylation in WFDC2 remains unclear. 
Glycosylation  
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Fig 1.4. Mass spectrometry analysis of the N-glycan structure of WFDC2. Data taken from Hua et 
al (2014). Recombinant WFDC2 produced in mammalian cells was subjected to enzymatic cleavage to 
remove the N-glycans and the glycan structure was then analysed by liquid chromatography-
electrospray ionisation mass spectrometry (LC-ESI-MS). The structure of the glycan from each 
chromatography peak is shown. 
 
1.1.6. The WFDC locus  
As previously mentioned, there are 18 human WFDC proteins, 14 of which are located on a 
678 kb ‘WFDC locus’ which is located on chromosome 20 at position 20q12-13.1 (Clauss et 
al., 2002). WFDC genes tend to encode small, secretory proteins, expressing one or more 
WFDC domain. The majority of WFDC genes do not express a typical TATA-box, however, 
WFDC2 exhibits a TATA-like motif, which is an attribute prevalent in housekeeping genes 
(Clauss et al., 2002).  
 The WFDC locus is organised into two clusters of WFDC genes which are separated by a 
215 kb region containing unrelated genes (Clauss et al., 2002) (Figure 1.5). The two subloci 
are thought to have evolved from a single gene duplication event that occurred more than 75 
million years ago, with further gene multiplications leading to the clustering of many WFDC 
genes (Hurle et al., 2007; Schalkwijk et al., 1999). A typical WFDC domain is encoded within 
a single exon which enables chimeric genes to form via exon shuffling; for example, elafin 
encodes a WFDC domain and a transglutaminase substrate domain (Schalkwijk et al., 1999).  
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Fig 1.5. A schematic diagram of the WFDC locus. A summary of the organisation of the WFDC locus 
found on chromosome 20 at position 20q12-13.1. Adapted from Clauss et al (2002). The positions of 
each gene are indicated. WFDC2 is found in the telomeric sublocus, whilst SLPI, elafin and the 
semenogelins are located within the centromeric sublocus.   
 
In addition to the WFDC genes, the WFDC locus also plays host to two genes that encode 
semen coagulum proteins, known as semenogelins (SEMG). The semenogelins are involved 
in crosslinking spermatozoa in human ejaculate; the matrix is subsequently broken down by 
prostate specific antigen (PSA) whereby the spermatozoa regain their motility. Interestingly, 
genomic analysis has shown that the SEMG genes share homology with the WFDC gene 
elafin, suggesting that the coagulum proteins evolved from an ancestral WFDC gene 
(Lundwall and Clauss, 2011). 
The WFDC locus has been identified as one of the most rapidly diverging genomic segments 
between the human and chimpanzee genomes (Consortium., 2005). This accelerated 
divergence is characteristic of genes involved in the innate immune system, such as α- and 
β- defensins (Wiesner and Vilcinskas, 2010). Links have thus been drawn to suggest that 
WFDC genes provide host defence within the human reproductive system (Ferreira et al., 
2013a; Ferreira et al., 2013b). An evaluation focusing on the extent of positive selection within 
the WFDC locus has shown that there is significant heterogeneity between remote human 
populations, suggesting that the heterogeneity results from a disparity in endemic pathogens 
(Ferreira et al., 2013b). 
The functions of most of the genes encoded on chromosome 20 are largely unknown aside 
from SLPI, elafin and eppin which have been relatively well studied. SLPI and elafin are 
expressed at various mucosal surfaces, including the respiratory tract, and have been shown 
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to prevent harmful inflammation by acting as protease inhibitors in addition to exhibiting 
moderate antimicrobial activity against bacteria, fungi and viruses (reviewed in(Sallenave, 
2010). Eppin is expressed within the testis and epididymis where it binds to spermatozoa, 
providing antimicrobial protection and affecting sperm motility (Wang et al., 2007).  
The four WFDC proteins located outside of chromosome 20 are more highly conserved than 
those found within the WFDC locus (even down to the level of invertebrates such as 
nematodes and insects). The genes tend to encode much larger proteins, with many other 
domains found expressed alongside the WFDC domain (Bingle and Vyakarnam, 2008).  
1.2. WFDC2 expression  
1.2.1. The expression profile of human WFDC2 
Human WFDC2 was initially considered to be exclusively expressed in the epididymis after 
Northern blot analysis failed to identify its expression in any of the other six human tissues 
tested (Kirchhoff et al., 1991; Kirchhoff et al., 1990). Northern blotting and in situ hybridisation 
showed that WFDC2 was expressed largely at the distal portion of the epididymis and vas 
deferens, where it appeared to be localised to the epithelium. More recent studies have shown 
that WFDC2 is expressed in a much broader range of tissues aside from the male reproductive 
tract, meaning that its common alias ‘human epididymis protein 4 (HE4)’ is misleading.  
High throughput sequencing techniques have identified the gene expression of WFDC2 to be 
highest in tracheal and salivary gland tissue, with significant expression also in the lung and 
kidney (Su et al., 2002; Uhlén et al., 2015) (Fig 1.6 and Fig 1.7). WFDC2 expression has also 
been identified within the female reproductive tract, particularly in the uterus, fallopian tube 
and endometrium, and in the male reproductive tract using high throughput sequencing (Uhlén 
et al., 2015).  
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Fig 1.6. Gene expression profile of human WFDC2 from BioGPS. Array data showing relative 
WFDC2 expression in human tissues published on the BioGPS portal. Accessed November 2018 (Su 
et al., 2002).   
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Fig 1.7. Gene expression profile of human WFDC2 from the Human Protein Atlas. RNA-seq data 
showing relative WFDC2 expression in human tissues published on the Human Protein Atlas database 
from the GTEx dataset, results are sorted according to expression levels: high to low. Accessed 
November 2018 (Uhlén et al., 2015).   
 
At the protein level, the expression of human WFDC2 within the upper respiratory tract, 
nasopharynx and oral cavity was largely found to be localised to glands, particularly within the 
ductular epithelium of salivary glands and nasal passages, while expression was more 
specifically localised to serous cells of submucosal glands of the bronchi (Fig 1.8) (Bingle et 
al., 2006; Galgano et al., 2006; Uhlén et al., 2015). Moderate staining was also visible in other 
cell types, for example, weak epithelial staining was found in the nasal passage and bronchi, 
while some mucous cells within the maxillary sinus also stained positively (Bingle et al., 2006; 
Uhlén et al., 2015). In major and minor salivary glands, amongst the intense ductular staining, 
there was also some positivity within serous acini (parotid gland), striated and intercalated 
ducts (submandibular gland) and serous demilunes of mucous acini (sublingual gland) (Bingle 
et al., 2006). Peripheral lung tissue was negative for WFDC2 expression (Bingle et al., 2006). 
Mammary gland acini also stained positively for WFDC2 while the adipose tissue was found 
to be negative (Uhlén et al., 2015). 
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Fig 1.8. Analysis of WFDC2 staining in the respiratory tract and salivary glands. 
Immunohistochemical analysis of WFDC2 expression in the respiratory tract and salivary glands, taken 
from Bingle et al (2006). Staining was analysed in the nasal antral mucosa (A, B), nasal polyps (C), 
airway sub-mucosal glands (D, E), epithelial cells of the airways (F), peripheral lung (G), parotid gland 
(H), submandibular gland (I), sublingual gland (J), minor glands of the tongue (K) and minor glands of 
the tonsil (L). Original magnification of the images was X100 (A, B, C, D), X200 (E, F, H, I, J) and X400 
(G, K, L). The antibody utilised was developed by Hellström et al (2003) using recombinant full-length 
WFDC2, synthesised in mammalian cells, as the immunogen. 
 
Within the female reproductive tract, WFDC2 was abundant in the epithelium and glandular 
cells of the fallopian tube, endometrium and cervix, while the ovary was negative for WFDC2 
expression (Drapkin et al., 2005; Galgano et al., 2006; Uhlén et al., 2015). The male 
reproductive tract also showed an abundance of WFDC2 in the epithelium and glandular cells 
of the epididymis, prostate and seminal vesicles (Drapkin et al., 2005; Galgano et al., 2006; 
Uhlén et al., 2015) (Fig 1.9). Positivity was detectable in the mucosal glands and goblet cells 
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of the duodenum and colon, whilst the tissues of the stomach and small intestine were largely 
negative for WFDC2 (Uhlén et al., 2015). 
 
Fig 1.9. Protein expression profile of human WFDC2 from the Human Protein Atlas. Protein 
expression data derived from quantification of positive staining in tissues analysed by 
immunohistochemistry. Tissues are given a protein score of low, medium or high and results are sorted 
according to expression level: high to low. Data published on the Human Protein Atlas database. 
Accessed November 2018 (Uhlén et al., 2015). The antibody utilised was from Atlas Antibodies 
(HPA042302) and was developed using recombinant WFDC2 (Glu31-Phe124) as the immunogen. 
 
1.2.2. Expression levels of WFDC2 splice variants 
Using primers designed to span exon-exon boundaries, Jiang et al (2013) was able to study 
the gene expression of WFDC2 splice variants (V0-V4) within RNA from a range of human 
tissues, including prostate, ovary, endometrium, lung, trachea and kidney. Real time 
quantitative PCR (RT-qPCR) analysis demonstrated that although relative expression levels 
of different isoforms varied between tissues, V0 was always significantly more abundant than 
all other variants (Jiang et al., 2013). This is the only data published regarding the expression 
of WFDC2 splice variants. Further analysis is necessary to gain a thorough insight into the 
differential expression of the variants in human tissues. 
1.2.3. WFDC2 orthologues  
WFDC2 orthologues have been identified within the epididymis of various mammalian 
species, including cow (Kirchhoff et al., 1991; Uhlenbruck et al., 1993), horse (Uhlenbruck et 
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al., 1993), pig (Schäfer et al., 2003; Uhlenbruck et al., 1993), rabbit (Xu et al., 1996), dog 
(Ellerbrock et al., 1994; Pera et al., 1994) and rat (Bingle et al., 2002; Kappler-Hanno and 
Kirchhoff, 2003). The expression patterns of the majority of WFDC2 orthologues outside of 
the male reproductive tract are yet to be explored. 
1.2.4. Rodent Wfdc2 
According to microarray data published by Su et al (2002), murine Wfdc2 was found to be 
most abundant in the lung, uterus, bladder and large intestine, although the gene was also 
expressed moderately in the ovary, salivary gland, mammary gland and kidney (Fig 1.10). 
This expression data is supported by unpublished RT-PCR data, which showed positive 
expression of Wfdc2 at the aforementioned sites, in addition to the nasal cavity, trachea, testis 
and stomach (Bingle, unpublished). In murine tracheal epithelial cells (mTEC) grown at an air-
liquid interface (ALI), Wfdc2 was the 6th most abundantly expressed gene when analysed by 
RNA-seq (Nemajerova et al., 2016). In the rat, Wfdc2 was found to be expressed in the lung, 
epididymis, kidney and liver as determined by Northern blotting (Kappler-Hanno and Kirchhoff, 
2003). At the protein level, unpublished histological analysis reported that murine Wfdc2 was 
localised to the epithelia of the bronchi, trachea and nasal cavity, as well as being present in 
major salivary glands (Bingle, unpublished).  
Mouse and rat Wfdc2 show 77% sequence alignment to one another; yet, the rodent 
orthologues share a much-reduced sequence identity to human WFDC2 due to the presence 
of an extra exon which is absent in human WFDC2 (Kappler-Hanno and Kirchhoff, 2003). The 
additional rodent exon forms a ~50 residue peptide ‘linker’ which separates exon 2 and 4, and 
is predicted to be heavily O-glycosylated (Kappler-Hanno and Kirchhoff, 2003). Although the 
most abundant rodent Wfdc2 gene transcript encodes exons 1-5 (including the additional exon 
3 linker), other splice variants have also been identified by RT-PCR and sequencing (Bingle, 
unpublished) as well as Northern blotting (Kappler-Hanno and Kirchhoff, 2003).  
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Fig 1.10. Expression profile of murine Wfdc2 from BioGPS. Array data showing relative Wfdc2 
expression in adult mouse tissues published on the BioGPS portal. Accessed August 2018 (Su et al., 
2002). 
   
1.2.5. Human WFDC proteins in secretions 
As discussed in Section 1.2.1, the expression of human WFDC2 within the respiratory tract, 
nasopharynx and oral cavity is largely localised to the glands, which suggests that WFDC2 is 
delivered into secretions at these sites e.g. into saliva or surface lining fluid. Mucosal surfaces 
within the oral cavity and respiratory tract are exposed to the external environment, so are 
concomitantly exposed to pathogens and allergens. As a result, glandular and epithelial 
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secretions are rich in proteins that provide a host-protective role to both pathogenic and host-
derived threats. If WFDC2 is present in secretions, it is conceivable that it could exhibit 
antimicrobial and/or anti-inflammatory activity. 
In the literature, there is some proteomic evidence to show that WFDC2 does indeed enter 
the glandular secretions at these sites. WFDC2 has been detected in bronchoalveolar lavage 
(BAL) fluid and in secretions from bronchial epithelial cells grown at an air-liquid interface 
(ALI), where it is the 13th most abundant protein (Peters-Hall et al., 2015; Wu et al., 2005). 
WFDC2 has also been identified in the proteome of nasal mucous (Tomazic et al., 2014), 
saliva (Denny et al., 2008; Fang et al., 2007; Ramachandran et al., 2006; Sivadasan et al., 
2015; Yan et al., 2009) and tears (Zhou et al., 2012). Reproductive tissues also appear to 
secrete WFDC2, as the protein has been identified within seminal plasma (Pilch and Mann, 
2006) and cervicovaginal lavage fluid  where it is found within the top 10% of most abundantly 
secreted proteins (Birse et al., 2013). Additionally, enzyme-linked immunosorbent assay 
(ELISA) data identifies WFDC2 in vaginal secretions at a median concentration of 108 nM with 
a range of 2.6 to 429 nM (Orfanelli et al., 2014; Pilch and Mann, 2006).  
Evidently WFDC2 protein is detectable in a number of glandular secretions, as determined by 
proteomic analysis. Unfortunately, there is no Western blot analysis available within the 
literature to support this data. 
The expression patterns of human SLPI and elafin show some crossover with WFDC2. Both 
proteins are expressed in the oral cavity and airways (Bingle et al., 2006; Lee and Downey, 
2001; Sallenave et al., 1994; Su et al., 2002; Uhlén et al., 2015; Wahl et al., 1997) yet the cell 
types expressing each protein are different; for example, while WFDC2 tends to be most 
abundant in ductular cells, SLPI is expressed in epithelial, serous and mucous cells and tends 
to be absent in ducts (Abbinante-Nissen et al., 1993; Bingle et al., 2006; Franken et al., 1989; 
Shugars, 1999; van Wetering et al., 2000). Elafin, on the other hand, is largely found in 
squamous epithelial cells, but can be found in some ducts (Lee et al., 2002; Pfundt et al., 
1996; Uhlén et al., 2015).  
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Aside from the oral cavity and airways, SLPI is also found in the kidneys, intestine and male 
and female reproductive tracts, in addition to immune cells such as mast cells, neutrophils and 
macrophages (Franken et al., 1989; Helmig et al., 1995; Mihaila and Tremblay, 2001; Ohlsson 
et al., 1995; Ohlsson et al., 2001; Sallenave et al., 1997; Si-Tahar et al., 2000; Uhlén et al., 
2015; Westin et al., 1999). SLPI is a secretory protein and resultantly can be detected in saliva, 
nasal mucous, BAL fluid, cervical mucous and seminal plasma (Helmig et al., 1995; Ohlsson 
et al., 1995; Saitoh et al., 2001; Shugars, 1999; Thompson and Ohlsson, 1986; van Wetering 
et al., 2000; Westin et al., 1994). SLPI is secreted at mucosal surfaces where it is reported to 
play a host protective role at these sites, which will be discussed in more detail in Section 1.3.   
Elafin, on the other hand, is found in the skin (and is abundant in psoriatic skin), pharynx, 
oesophagus, female reproductive tract and small intestine, in addition to various sites within 
the oral cavity, including the gingiva, tonsil and tongue (Pfundt et al., 1996; Schalkwijk et al., 
1999; Suzuki et al., 2000; Uhlén et al., 2015). It has also been found to be expressed in 
neutrophils and macrophages (King et al., 2003; Mihaila and Tremblay, 2001). Elafin can be 
detected in bronchial secretions and sputum (Sallenave et al., 1992; Sallenave and Ryle, 
1991) and is hypothesised to provide a similar host-protective role to SLPI at mucosal surfaces 
exposed to the external environment (see Section 1.3).  
Although the expression sites of WFDC2, SLPI and elafin show some correlation, each protein 
appears to exhibit some exclusivity in terms of the cell type it is expressed within. This may 
suggest that the proteins exhibit distinct functions and may indeed be under separate 
regulatory controls. As a result, it is important to recognise that WFDC2 may exhibit an entirely 
different biological function to SLPI and elafin, despite their collective possession of one or 
more WFDC domains.  
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1.3. The activities of WFDC proteins 
1.3.1. The putative functions of human WFDC2 
A role for WFDC2 in host defence is frequently hypothesised as a result of three key factors. 
Firstly, as discussed previously, WFDC2 is secreted at mucosal sites that are consistently 
exposed to the external environment and its concomitant pathogens. Secondly, the WFDC2 
gene is encoded within the rapidly diverging WFDC locus, as discussed in Section 1.1.6, and 
accelerated evolution is characteristic of genes involved in the innate immune system (Hurle 
et al., 2007). Finally, WFDC2 shares structural similarities with two related WFDC proteins, 
SLPI and elafin (Bingle and Vyakarnam, 2008), which are widely reported to exhibit anti-
inflammatory and antimicrobial activities; it is feasible that WFDC2 could exhibit similar 
functions.  
1.3.2. Antimicrobial activity of SLPI and elafin  
SLPI and elafin are small, non-glycosylated, cationic proteins, encoded around 200-300 kb 
upstream of WFDC2 on the WFDC locus (see Figure 1.5) (Clauss et al., 2002). SLPI consists 
of two WFDC domains (Grütter et al., 1988) whilst elafin encodes a single WFDC domain 
(Zeeuwen et al., 1997). Elafin initially exists as a precursor protein called pre-elafin (or trappin-
2) which has an N-terminal transglutaminase substrate-binding domain to enable binding to 
extracellular matrix components via transglutaminase crosslinking. This N-terminal domain is 
then cleaved to yield mature elafin (Zeeuwen et al., 1997). 
SLPI and elafin have both been reported to exhibit moderate antimicrobial activity, for 
instance, SLPI has been shown to reduce the in vitro growth of Escherichia coli, 
Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa, 
Streptococcus pyogenes, Salmonella typhimurium and Mycobacterium tuberculosis (Fernie-
King et al., 2002; Gomez et al., 2009; Hiemstra et al., 1996; Si-Tahar et al., 2000; Wiedow et 
al., 1998) in addition to affecting the viability of fungi, including Candida albicans and 
Aspergillus fumigatus (Tomee et al., 1997; Wiedow et al., 1998). Similarly, elafin or pre-elafin 
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can impact the growth (albeit more weakly compared to SLPI) of P. aeruginosa, S. aureus, 
Klebsiella pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae and 
Branhamella catarrhalis (Baranger et al., 2008; Meyer-Hoffert et al., 2003; Simpson et al., 
1999), in addition to fungi such as C. albicans and A. fumigatus (Baranger et al., 2008). Elafin 
has also been proposed to exhibit anti-viral activity against human immunodeficiency virus 1 
(HIV-1) by inhibiting virus binding (Drannik et al., 2012).  
The in vitro assays used to determine the effect of SLPI on bacterial and fungal viability/growth 
were largely consistent, whereby the microorganisms were incubated with increasing 
concentrations of recombinant SLPI prior to serial dilution, plating out and counting of colony 
forming units (CFU). The single exception to this method was the experiment reported by 
Payne et al (2017) who used radial diffusion assays. The concentrations of protein required to 
cause a 50% decrease in CFU are summarised in Table 1.1. SLPI was able to induce 
significant killing of many species at concentrations close to the endogenous levels recorded 
in human secretions, as summarised in Table 1.2. Little data is available regarding the 
endogenous concentrations of elafin, but it seems unlikely that they would be as high as the 
IC50 values necessary to induce significant microbial killing.  
The antibacterial activity of SLPI against Mycobacteria has received particular attention and 
has been established via in vitro and in vivo assays. Human and murine SLPI orthologues are 
reported to have IC50 values of 2.0 µM and 0.5 µM, respectively, against M. tuberculosis  
(Gomez et al., 2009; Nishimura et al., 2008). Interestingly, when mice were intranasally 
infected with Mycobacterium bovis BCG and later treated with intranasal SLPI (12.8 µM), a 
significantly lower bacterial load was recovered from the lungs in comparison to controls 
(Gomez et al., 2009). Further to this, Slpi knockout mice were found to be significantly more 
susceptible to M. tuberculosis infection compared to WT (Nishimura et al., 2008). Evidently 
SLPI has significant antimycobacterial activity; however, outside of this specific function, the 
broader antimicrobial activity of SLPI is yet to be determined using in vivo or knockout mouse 
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models. The absence of an elafin orthologue in mice makes it difficult for in vivo analysis of its 
function to be carried out. 
 
Table 1.1. The in vitro 50% inhibitory concentrations (IC50) of SLPI, elafin and pre-elafin against 
bacteria and fungi. IC50 is the concentration of protein that causes a 50% decrease in colony forming 
units. NA1 refers to cases which showed no demonstrable antimicrobial activity at any concentration 
tested. NA2 refers to cases where some antimicrobial activity was evident, but 50% killing was not 
reached at any concentration tested. Approximated values were determined by extrapolation from 
graphs in the literature. References to the relevant literature are indicated. 
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Table 1.2. The mean SLPI and elafin protein concentrations in human secretions. A summary of 
the endogenous concentrations of SLPI and elafin protein in human secretions quantified by ELISA. 
References to the relevant literature are indicated.  
 
Although the majority of reports show that SLPI and elafin are capable of antimicrobial activity, 
there is some conflicting evidence which suggests the contrary. Payne et al (2017) used radial 
diffusion assays to determine the minimum inhibitory concentration (MIC) of various 
antimicrobial peptides (AMPs), including SLPI and β-defensins, against a number of different 
cystic fibrosis-derived clinical isolates and reference strains. The group reported that SLPI was 
incapable of inducing inhibitory activity against any isolate or reference strain tested (see 
Table 1.1). It has been suggested that the difference between the SLPI activity described in 
this report compared to the results described by Wiedow et al (1997) and others was due to 
the ‘inherent antimicrobial resistance’ following ‘prolonged exposure to antibiotics’ of the 
strains tested (Payne et al., 2017). The differences could, however, be due to the different 
experimental methods used.  
The mechanisms through which SLPI and elafin exhibit antimicrobial activity are still under 
investigation. Both proteins were shown to retain antimicrobial activities when their protease 
inhibitory activity had been suppressed (i.e. by mutagenesis or heat-treatment), suggesting 
that the two functions are independent (Baranger et al., 2008; Gomez et al., 2009). In support 
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of this, preliminary evidence also suggested that the N-terminus of SLPI was responsible for 
its antimicrobial activity, although the isolated domain was much less active than the protein 
as a whole (Hiemstra et al., 1996; Tomee et al., 1997). This fits with the theory that the C-
terminus is capable of protease inhibition and suggests that the two WFDC domains of SLPI 
exhibit separate functions (Bingle and Vyakarnam, 2008; Eisenberg et al., 1990). 
It is feasible that SLPI and elafin impact bacterial and fungal viability by binding to cells and 
disrupting their membranes to induce lysis as a result of their cationic charge. Many AMPs 
carry out their killing via cationic lysis (Wiesner and Vilcinskas, 2010), including a member of 
the WFDC protein family known as eppin (Yenugu et al., 2004). Investigations into the 
bacterial-binding capacity of SLPI showed that it could coat the surface of Mycobacteria strains 
(Gomez et al., 2009). Similarly, elafin and pre-elafin were shown to bind to Gram-negative 
bacteria (P. aeruginosa), Gram-positive bacteria (S. aureus) and fungi (C. albicans), 
appearing to induce moderate membrane disruption, as visualised by scanning electron 
microscopy (SEM) (Baranger et al., 2008; Bellemare et al., 2010). After incubation with 
recombinant elafin and pre-elafin, P. aeruginosa was shown to exhibit membrane blebbing, 
blistering and the presence of pore-like structures (Bellemare et al., 2010). It should be noted, 
however, that the membrane disruption and subsequent depolarisation was moderate 
compared to the lytic effects exhibited by the control AMP, magainin 2 (Bellemare et al., 2010).  
SLPI and elafin appeared to show much weaker antimicrobial effects when compared to other 
AMPs including lysozyme, defensins and magainin (Bellemare et al., 2010; Hiemstra et al., 
1996; Payne et al., 2017; Tomee et al., 1997). The high concentrations of SLPI and elafin 
required to induce significant antimicrobial effects may suggest that such activities are not the 
primary functions of these proteins.  
Interestingly there is evidence to show that both SLPI and elafin are capable of priming innate 
immune responses. Gomez et al (2009) demonstrated that SLPI was able to coat M. bovis 
and M. tuberculosis in a process that appeared to be facilitated by interactions between SLPI 
and pathogen-associated molecular patterns (PAMPs) such as surface-associated lipids. 
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This, in turn, appeared to lead to more effective phagocytosis (Gomez et al., 2009). Similarly, 
pre-elafin was reported to coat the surface of P. aeruginosa cells to induce phagocytosis by 
macrophages, in a process seemingly mediated by interactions between pre-elafin and CD14 
(Wilkinson et al., 2009). Opsonisation with pre-elafin also appeared to induce neutrophil 
recruitment (Wilkinson et al., 2009). Clearly the antimicrobial activities of SLPI and elafin are 
complex and further analysis is required to advance the understanding of their role in the 
innate immune system. 
1.3.3. Putative antimicrobial activity of WFDC2  
In contrast to SLPI and elafin, evidence supporting an antimicrobial role for WFDC2 is sparse 
and largely consists of circumstantial evidence i.e. correlation between bacterial colonisation 
and an increase in WFDC2 expression. For instance, in vitro, when the endocervical cell line 
End1 was exposed to a bacterium associated with bacterial vaginosis (Atopobium vaginae), 
the concentration of WFDC2 in the conditioned media was significantly increased (Eade et al., 
2015). In patient samples an upregulation in WFDC2 was also apparent: the vaginal secretions 
of healthy women whose vaginal microbiomes were predominated with Gardnerella vaginalis 
(a biofilm-forming bacterium responsible for causing bacterial vaginosis) exhibited raised 
concentrations of WFDC2 compared to microbiomes dominated by commensal species 
(Orfanelli et al., 2014). Additionally, in children with cystic fibrosis (CF), those with bacterial 
colonisation of the lung had significantly higher serum WFDC2 levels compared to those 
without bacterial colonisation (Nagy et al., 2016).  
Thus far, the only analysis to directly determine whether WFDC2 is capable of antimicrobial 
activity is that described by Hua et al (2014) who used recombinant human WFDC2 for in vitro 
binding and growth inhibitory assays. Their results showed binding of a WFDC2-Fc fusion 
protein to Gram-positive strains (S. aureus and Bascillus subtilis) and minor binding to Gram-
negative strains (E. coli and P. aeruginosa). Two recombinant forms of WFDC2 were used in 
the binding assay: one produced in yeast and the other in mammalian cells; the WFDC2 
protein produced in mammalian cells appeared to have a greater propensity to bind to bacteria 
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compared to the protein produced in yeast cells, which the author suggests implicates the 
importance of glycosylation for interactions to occur.  
Despite the positive binding between WFDC2 and S. aureus described by Hua et al (2014), 
when recombinant WFDC2 was incubated with S. aureus for 12 hours, it appeared to have no 
significant effect on S. aureus growth, even at high concentrations (7.75 uM). Further analyses 
with other strains will be required to deduce the effect of human WFDC2 on bacterial growth.  
Investigations into the functions of WFDC2 orthologues are also limited. The antimicrobial 
properties of murine Wfdc2 have been investigated against attenuated Mycobacterium bovis 
(BCG) using viability and membrane permeability assays. The data showed that murine Wfdc2 
was unable to induce membrane permeabilization or killing of M. bovis (Nishimura et al., 
2008). Within the same study, it was shown that murine Slpi (1 µM) was capable of almost 
complete inhibition of three Mycobacteria strains and that incubation of Slpi with M. bovis 
caused pronounced damage to the cell surface as shown by SEM and membrane 
permeabilization assays (Nishimura et al., 2008). 
The tammar wallaby WFDC2 orthologue has also been used for in vitro assays against various 
bacteria strains. The recombinant protein elicited significant antimicrobial activity against S. 
aureus, P. aeruginosa and Salmonella enterica (Watt et al., 2012). Interestingly, when 
constructs encoding single WFDC domains were utilised in the same assays, the C-terminal 
domain alone was found to be capable of inhibiting growth at a similar rate to the full-length 
protein, while the N-terminus had no effect on bacterial growth. When the WFDC2 proteins 
were incubated with the commensal Enterococcus faecalis, no growth inhibition occurred with 
full-length WFDC2 or the single WFDC domains (Watt et al., 2012). It should be noted that the 
concentration of WFDC2 used in the assays was not described, so it is unclear whether the 
bactericidal effects occurred at physiological concentrations. Additionally, the molecular 
weight of full-length recombinant wallaby WFDC2 was reported to be 13 kDa, which is 
significantly smaller than human WFDC2 (despite being two amino acids longer than the 
human orthologue). The group have suggested that wallaby WFDC2 may be involved in 
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antimicrobial defence of the mammary gland in females during pregnancy and involution, but 
also to protect the young during lactation. An absence of the pathogenic bacterial strains (S. 
aureus, P. aeruginosa, S. enterica) in the gut of the developing young, but presence of E. 
faecalis (to which WFDC2 has no bactericidal activity) suggests that WFDC2 may be involved 
in the development and selection of commensals in the gut microbiota of developing young. 
The limited data available in the literature appears to suggest that human and murine WFDC2 
are not directly capable of antimicrobial activity, although further studies will be necessary to 
add substance to this claim. 
1.3.4. Induction of expression of WFDC proteins 
Both SLPI and elafin have been shown to exhibit increased mRNA expression and/or protein 
production in response to stimuli such as inflammatory cytokines (interleukin 1β; IL-1β and 
tumour necrosis factor α; TNF-α), bacterial PAMPs (lipopolysaccharide; LPS) and host 
proteases (neutrophil elastase), although the reported changes in expression are inconsistent 
between studies (see Table 1.3). For example, SLPI mRNA levels were shown to be 
upregulated in two pulmonary cell lines following exposure to TNF-α and IL-1β (Sallenave et 
al., 1994), and an intestinal epithelial cell line secreted higher concentrations of SLPI protein 
following TNF-α and IL-1β exposure (Si-Tahar et al., 2000). In contrast, primary 
tracheobronchial epithelial (TBE) cells and primary alveolar epithelial pneumocytes (Type II 
cells) showed no change in SLPI mRNA expression following exposure to TNF-α and IL-1β 
(Bingle et al., 2006), and primary murine macrophages showed no increase in murine Slpi 
expression after exposure to the same agents (Jin et al., 1998). These discrepancies may 
demonstrate cell type-specific differences in SLPI responses or may simply reflect differences 
in experimental techniques. Although many differences between results were apparent, some 
consistencies were also found; for example, elafin mRNA levels have been shown to be 
upregulated in response to IL-1β in all experiments described (Bingle et al., 2006; Bingle et 
al., 2001; Reid et al., 1999; Sallenave et al., 1994) (see Table 1.3). The type of mediators that 
can affect SLPI and elafin expression support the proteins’ hypothesised dual role of defence 
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against pathogenic threat from the external environment and protection against excessive 
host-derived inflammation.  
 
Table 1.3. The effects of pro-inflammatory stimuli on SLPI and elafin expression. SLPI/elafin 
mRNA expression or protein production were monitored following cell treatment with different pro-
inflammatory stimuli. The target cell type, treatment and results are summarised for each study. 
References to the relevant literature are given. *Murine Slpi expression was assessed in the primary 
mouse macrophages.  
 
 
When similar exposure assays were used to monitor WFDC2 expression, there was little 
evidence to suggest that its expression was stimulated in response to cytokines or LPS. Bingle 
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et al (2006) exposed primary TBE and Type II cells to IL-1β, TNF-α and LPS and studied the 
effect on WFDC2 expression via RT-PCR. No change in WFDC2 mRNA level was observed 
in TBE cells following any of the treatments, while the Type II cells showed a slight increase 
in WFDC2 following exposure to IL-1β only (but it is unclear if this change was statistically 
significant). In another exposure study, ovarian cancer cells were exposed to IL-1β and TNF-
α and changes in gene expression were monitored by RT-PCR. No changes in WFDC2 mRNA 
levels were observed following cytokine exposure, while elafin expression was shown to be 
upregulated by both cytokines (Clauss et al., 2010).  
Aside from the two semi-quantitative RT-PCR studies, the direct effect of inflammatory 
mediators upon WFDC2 expression has not been investigated. Further analysis is required to 
determine what factors influence its transcriptional regulation, given that the WFDC2 protein 
is overexpressed in a number of inflammatory diseases including various cancers, cystic 
fibrosis and renal fibrosis, as discussed in more detail in Sections 1.4 and 1.5.  
1.3.5. Anti-protease activity in the WFDC family 
Although SLPI and elafin have been shown to exhibit some antimicrobial activity, they are best 
known for their anti-inflammatory role as protease inhibitors in the respiratory tract. Anti-
proteases impose a level of control over the host immune system by preventing inappropriate 
inflammation. SLPI and elafin are classified as ‘alarm’ protease inhibitors (Sallenave, 2000), 
and are thus produced locally in response to ‘alarms’, or danger signals, such as proteases, 
LPS and cytokines. The group of WFDC proteins encoded on chromosome 20 are assumed 
to inhibit proteases as a result of their similarity to SLPI and elafin, but this theory is yet to be 
extensively tested for the majority of WFDC proteins, including WFDC2 (Clauss et al., 2002).  
SLPI and elafin have had their anti-protease activity thoroughly established over the last 40 
years, and are proven to be active against a variety of proteases including elastase (Ying et 
al., 1994; Ying and Simon, 1993), cathepsin G (Smith and Johnson, 1985), trypsin (Smith and 
Johnson, 1985), chymotrypsin (Franzke et al., 1996; Smith and Johnson, 1985), proteinase-3 
29 
 
(Wiedow et al., 1991) and chymase (Walter et al., 1996). Both proteins exhibit identical 
positioning of their conserved cysteine residues within the active site, which appears to be a 
requirement for successful protease inhibition (Grütter et al., 1988; Kramps et al., 1990; 
Tsunemi et al., 1996). WFDC2 does not exhibit the same consensus of cysteines as SLPI’s 
C-terminal domain and elafin; resultantly, it has been suggested that WFDC2 is incapable of 
protease inhibition (Bingle and Vyakarnam, 2008).  
Nonetheless, some data in the literature argues that WFDC2 is indeed capable of protease 
inhibition despite its alternative structure. Hua et al (2014) showed that recombinant WFDC2 
produced in mammalian cells was capable of limiting trypsin and elastase activity in vitro. 
Incubation with 6.4 µM of WFDC2 induced a 45% reduction in elastase activity, whereas 10.4 
µM of WFDC2 caused a 30% decrease in trypsin activity. Within these assays, WFDC2 
concentrations as high 29.9 µM were used to demonstrate increasing inhibition of enzyme 
activity. There is limited data in the literature describing the physiological concentrations of 
WFDC2 at sites in the human body, therefore it is difficult to determine whether the 
concentrations of protein used in these assays are physiologically relevant. 
Zymography was also used to analyse WFDC2 inhibition towards matrix metalloproteases 
(MMPs). The results showed that MMP9 gelatin degradation could be inhibited by WFDC2, 
while WFDC2 had no effect on MMP2 activity; however, there is no information given 
regarding the concentration of protein utilised in the assay (Hua et al., 2014).  
During the same study, Hua et al (2014) used the disk diffusion technique to determine 
whether WFDC2 is capable of inhibiting the activity of proteases derived from B. subtilis and 
P. aeruginosa. Bacteria plated upon a skim-milk plate incubated alongside WFDC2 exhibited 
a 40% reduction in proteolytic clearing upon the plate compared to controls.  
Protease inhibitory activity was also ascribed to WFDC2 in another study, whereby Chhikara 
et al (2012) demonstrated that WFDC2 could inhibit trypsin, chymotrypsin, PSA, protease K, 
pepsin and papain. Although their data showed a greater than 70% reduction in activity for all 
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proteases tested, even at 0.4 uM, the results lack appropriate negative controls to show 
enzyme activity when WFDC2 is absent which impacts the reliability of the data. Additionally, 
the WFDC2 protein used in the study was isolated from seminal plasma and proposed to exist 
as a 14 kDa monomer and as a 42 kDa trimer in native conditions (Chhikara et al., 2012). 
Given that the glycosylated, monomeric form of WFDC2 is commonly observed as being 
around 20 kDa in size, an observed size of 14 kDa is unusual, however, the authors suggest 
that the discrepancies in size are due to tissue-specific differences i.e. between ovarian and 
prostate cell lines.  
Fibrotic kidney samples express enhanced serine protease expression compared to healthy 
tissues which causes enhanced collagen degradation and thus exacerbates the symptoms of 
fibrosis. The relationship between WFDC2 and proteases in renal fibrosis was investigated by 
LeBleu et al (2013) using colorimetric assays to analyse residual protease activity in fibrotic 
tissue following incubation with recombinant WFDC2. The data showed that protease activity 
in fibrotic renal tissue was significantly higher than in non-fibrotic tissue, however, following 
incubation with recombinant WFDC2 the protease activity of fibrotic tissue decreased to a 
level close to the non-fibrotic baseline. Similarly, collagen digestion by trypsin, Prss35, Prss23, 
MMP2 and MMP9 was measured via hydroxyproline release and was found to be significantly 
reduced when WFDC2 (390 nM) was added to the assay (LeBleu et al., 2013).  
The concentrations of WFDC2 required to induce successful protease inhibition vary greatly 
between studies.  For example, in the case of trypsin, a 25-fold higher concentration of 
WFDC2 was used by Hua et al (2014) to significantly reduce protease activity to a level 
comparable to that described by LeBleu et al (2013). These variances perhaps reflect the 
experimental methods used, including differences in substrates.  
Evidently there is some data supporting a protease inhibitory role for WFDC2, however, further 
analysis is required to give a greater understanding of WFDC2’s effect on enzyme activity and 
to determine whether it is directly capable of inhibition.     
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1.4. WFDC2 and cancer 
WFDC2 is markedly upregulated in a range of diseases. Its expression is known to be 
amplified in a number of cancers including ovarian, lung and endometrial cancer. In the case 
of ovarian cancer, WFDC2 is expressed to such an extent that it is used clinically as a 
biomarker for detection of the disease (Moore et al., 2010; Moore et al., 2009; Ruggeri et al., 
2011). Such biomarkers are valuable clinical tools as serum assessment is simple, low cost, 
non-invasive and allows long-term monitoring of disease status.  
1.4.1. WFDC2 as a biomarker for ovarian cancer 
Ovarian cancer is the fifth most common cause of cancer death in women in the UK, with an 
expected 10-year survival rate of 35% (Cancer-Research-UK, 2018b). Around 3/4 of patients 
are diagnosed at an advanced stage, largely due to an absence of disease-specific symptoms, 
by which point anti-cancer therapies are markedly less effective and mortality rates are high 
(Thibault et al., 2014). As a result, biomarkers for cancer detection are an extremely valuable 
resource when used alongside transvaginal ultrasonography for detection of the disease at an 
early stage.  
Cancer antigen 125 (CA125), an epitope of mucin 16 (MUC16), has been widely used over 
the past three decades as an FDA-approved biomarker for ovarian cancer detection (Bast et 
al., 1983). MUC16 is a high molecular weight glycoprotein that is expressed at healthy 
epithelial surfaces but is abundantly shed from ovarian cancer cells and can be subsequently 
detected in patient serum (Argüeso et al., 2003; Bast et al., 1983; Davies et al., 2007; Yin and 
Lloyd, 2001). Although CA125 has proven to be an effective biomarker, particularly for 
detection of advanced disease, its sensitivity is low and false positive results are frequently 
found in benign diseases such as endometriosis and due to natural fluctuations in CA125 
associated with menstruation (Díaz-Padilla et al., 2012; Medeiros et al., 2009; Nustad et al., 
1996). Subsequently, research has been ongoing to identify more sensitive and reliable 
biomarkers. 
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Serial analysis of gene expression (SAGE) technology has been a powerful tool in the 
identification of potential biomarkers for ovarian cancer, allowing the differential expression of 
thousands of genes to be quantified and compared between healthy and malignant cells 
(Hough et al., 2000; Ismail et al., 2000; Ono et al., 2000; Schummer et al., 1999; Welsh et al., 
2001). This technology resulted in the identification of WFDC2 as a gene that is elevated in 
ovarian tumours and subsequently monoclonal antibodies were developed and used for 
WFDC2 quantification by ELISA (Hellström et al., 2003).  
Analyses of WFDC2 concentrations in serum showed that approximately 80% of ovarian 
cancer patients have serum WFDC2 levels over 150 pM (Molina et al., 2011; Ruggeri et al., 
2011). The cut-off point used to identify patients with an ovarian malignancy is generally 
around 70 pM (Braicu et al., 2013). High serum WFDC2 concentrations correlated with poor 
prognosis and surgical outcome (Bandiera et al., 2011; Braicu et al., 2013; Chen et al., 2014; 
Molina et al., 2011; Moore et al., 2014). 
As a result of these findings, WFDC2 is currently being used as a predictive biomarker for 
ovarian cancer alongside CA125 in the FDA-approved algorithm known as the Risk of Ovarian 
Malignancy Algorithm (ROMA). ROMA takes into account the serum concentration of CA125 
and WFDC2 alongside menopausal status to predict the likelihood of ovarian cancer (Moore 
et al., 2009; Moore et al., 2011). Studies analysing the efficacy of ROMA have reported mixed 
results, with some arguing that WFDC2 improves sensitivity compared to CA125 alone, 
particularly in detecting disease at an early stage and in differentiating between benign and 
malignant pelvic masses (Bandiera et al., 2011; Chan et al., 2013; Karlsen et al., 2012; Molina 
et al., 2011; Ruggeri et al., 2011). Conversely, other studies claim that the combination of 
biomarkers does not improve upon their individual sensitivity and specificity (Jacob et al., 
2011; Van Gorp et al., 2011).  
When histologically studying WFDC2 expression in ovarian carcinomas, staining was often 
diffuse throughout the tumour and localised to the cytoplasm/secretions (Georgakopoulos et 
al., 2012; Uhlen et al., 2017) (Fig 1.11). WFDC2 staining was more prevalent in serous and 
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endometrioid tumours, whereas more variable positivity was seen in clear cell and mucinous 
carcinomas (Drapkin et al., 2005; Galgano et al., 2006; Georgakopoulos et al., 2012; Schaner 
et al., 2003). Interestingly, this difference in positive WFDC2 expression appeared to be 
reflected in the serum concentrations of patients with different tumour subtypes (Hertlein et 
al., 2012). The variability in expression between ovarian cancer subtypes impacts its reliability 
as a biomarker; nonetheless, WFDC2 has proven to be effective in distinguishing between 
benign and malignant disease (Anastasi et al., 2013; Drapkin et al., 2005; Georgakopoulos et 
al., 2012; Ortiz-Muñoz et al., 2014; Zhang et al., 2014).  
 
Fig 1.11. WFDC2 staining in ovarian malignancies. Immunohistochemical analysis of WFDC2 
expression in ovarian malignancies, taken from Protein Atlas (Uhlén et al., 2017). Staining was 
analysed in serous (a), endometrioid (b) and mucinous (c) ovarian malignancies. Patient IDs: 2347 (a), 
2568 (b) and 1844 (c). The antibody utilised was from Atlas Antibodies (HPA042302) developed using 
recombinant WFDC2 (Glu31- Phe124) as the immunogen. Accessed in December 2018. Data available 
from: https://www.proteinatlas.org/ENSG00000101443-WFDC2/pathology/tissue/ovarian+cancer#img  
 
1.4.2. WFDC2 as a biomarker for other cancer types 
WFDC2 was also found to be upregulated in the serum of patients with other types of cancer 
compared to controls, for instance, those suffering from endometrial (Brennan et al., 2014; 
Capriglione et al., 2015; Wang et al., 2017) and lung cancer (Choi et al., 2017; Liu et al., 2013). 
WFDC2 upregulation was also evident when endometrial and lung cancer tissues were 
analysed by immunohistochemistry (Fig 1.12). Although the serum levels in patients with 
ovarian cancer are often significantly higher than in patients with other types of cancer, 
WFDC2 still appears to show promise for use as a biomarker. 
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Fig 1.12. WFDC2 staining in endometrial and lung malignancies. Immunohistochemical analysis of 
WFDC2 expression in non-ovarian malignancies, taken from Protein Atlas (Uhlén et al., 2017). Staining 
was analysed in endometrial carcinoma (a, b) and adenocarcinoma of the lung (c, d). Patient IDs: 2607 
(a), 2118 (b), 1847 (c) and 3391 (d). The antibody utilised was from Atlas Antibodies (HPA042302) 
developed using recombinant WFDC2 (Glu31- Phe124) as the immunogen. Accessed in December 
2018. Endometrial cancer data available from:  
https://www.proteinatlas.org/ENSG00000101443-WFDC2/pathology/tissue/endometrial+cancer#ihc  
Lung cancer data available from: 
https://www.proteinatlas.org/ENSG00000101443-WFDC2/pathology/tissue/lung+cancer#ihc  
 
 
 
In endometrial carcinomas WFDC2 is frequently heightened in patient serum and 
concentrations have been reported to reflect disease stage (Abbink et al., 2018; Brennan et 
al., 2014; Capriglione et al., 2015; Dewan et al., 2017; Wang et al., 2017; Yılmaz et al., 2017; 
Zanotti et al., 2012). High WFDC2 levels have been hypothesised to correlate with poor 
prognosis. Unlike ovarian cancers, endometrial malignancies are often symptomatic and 
detected at an early stage, therefore the 10 year survival rate is 78% (Cancer-Research-UK, 
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2018c). Nonetheless, biomarkers are still a valuable tool for assessing patient prognosis and 
for customising treatment. CA125 has been investigated for its use as an endometrial cancer 
biomarker, but its sensitivity and specificity are often poor (Abbink et al., 2018; Moore et al., 
2008; Powell et al., 2005), therefore WFDC2 is currently being studied as a potential candidate 
biomarker to be used alone or in combination with other biomarkers such as CA125 (Abbink 
et al., 2018; Brennan et al., 2014; Dewan et al., 2017; Wang et al., 2017).  
WFDC2 is also being investigated as a potential biomarker for detection of lung cancer. As 
with ovarian cancer, lung cancer is often asymptomatic and prognosis is poor, with a 10 year 
survival rate of only 5% (Cancer-Research-UK, 2018a). A number of proteins are under 
investigation for use as serum biomarkers for detecting lung carcinomas, including 
carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), cytokeratin-19 fragment 
CYFRA 21.1 and WFDC2 (Kulpa et al., 2002; Liu et al., 2017; Lou et al., 2014; Tas et al., 
2000; Zhang et al., 2017). WFDC2 has been shown to be upregulated in both small cell lung 
cancer (SCLC) and non-small cell lung cancer (NSCLC) (Jiang et al., 2014; Liu et al., 2013; 
Wang et al., 2014), and serum concentrations of WFDC2 appeared to correlate with disease 
progression and poor prognosis (Choi et al., 2017; Iwahori et al., 2012; Lamy et al., 2015; 
Yamashita et al., 2012). Additionally, high WFDC2 levels appeared to be associated with a 
lack of responsiveness to chemoradiotherapy in patients with advanced NSCLC (Lan et al., 
2016).  
Immunohistochemical staining of lung tumour tissue showed that NSCLC tissues, particularly 
adenocarcinomas and bronchioalveolar carcinomas, more frequently stained positively 
(>80%) for WFDC2 expression than any other pulmonary tumour type and staining tended to 
be distributed throughout the tumour (Bingle et al., 2006). WFDC2 may be a valuable 
biomarker for detection of NSCLC and SCLC to be used independently or in combination with 
other promising biomarkers such as CYFRA 21.1, CEA and NSE.  
Oligonucleotide microarray analysis performed by Galgano et al (2006) to quantify the gene 
expression of WFDC2 in 11 different carcinoma types showed that, as may be expected, 
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WFDC2 mRNA levels were most abundant in serous ovarian cancers, followed by lung 
adenocarcinomas. Additionally, the microarray data showed moderate WFDC2 levels in 
pancreatic, breast, gastric and renal malignancies. This expression data is supported by 
histopathological analyses which showed an abundance of positive WFDC2 staining in tumour 
tissues derived from breast (Kamei et al., 2010), stomach (Guo et al., 2015) and salivary gland 
(Galgano et al., 2006), demonstrating a significant upregulation of WFDC2 in many non-
gynaecological malignancies.  
Although WFDC2 expression is upregulated to a moderate extent in many malignant diseases 
(i.e. gastric, pancreatic and breast cancer), it appears that the increase in gene expression 
does not result in an increase in serum WFDC2 levels to allow reliable differentiation between 
healthy and diseased patients. This is evidenced by Hertlein et al (2012), who measured 
serum WFDC2 concentrations from hundreds of patients with benign and malignant disorders 
and compared them with those of healthy patients (Fig 1.13). Patients with ovarian cancer 
showed a median WFDC2 level of 242 pM, which is over 6-fold higher than in healthy 
volunteers, while patients with lung cancer showed a 2-fold higher median concentration of 
WFDC2 than controls. Gastric and renal cancer show only slightly elevated WFDC2 levels 
compared to healthy patients, with concentrations being comparable to those reported in 
patients with benign gastrointestinal disease or renal insufficiency, thus evidencing WFDC2’s 
lack of sensitivity or specificity in detecting such malignancies (Fig 1.14) (Hertlein et al., 2012). 
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Fig 1.13. The serum concentration of WFDC2 in patients with malignant disease. A graph to show 
the median serum WFDC2 concentration (pM) in patients with malignant disease, as described by 
Hertlein et al (2012). The number of samples per group is listed (number above each bar).  
 
Fig 1.14. The serum concentration of WFDC2 in patients with benign disease. A graph to show 
the median serum WFDC2 concentration (pM) in patients with benign disease, as described by Hertlein 
et al (2012). The number of samples per group is listed (number above the bar). 
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1.4.3. Amplification of the 20q13 locus 
In many different cancer types, the process of tumorigenesis appears to correlate with 
upregulated WFDC2 expression and elevated protein secretion. This process is particularly 
evident in ovarian and gastric malignancies, as healthy tissues at these sites appear to be 
completely devoid of WFDC2 expression, yet when gastric and ovarian cells become 
malignant they are shown to positively express WFDC2 (Guo et al., 2015; Uhlen et al., 2017; 
Uhlén et al., 2015). One explanation for the change in WFDC2 expression is the frequent 
amplification of the WFDC2-expressing locus, 20q13, which is one of the most common 
genomic aberrations that occurs in many cancer types. 
In ovarian tumours, locus 20q13 has been consistently reported to be one of the most 
frequently amplified loci when analysed via comparative genomic hybridisation (CGH) (Israeli 
et al., 2005; Kiechle et al., 2001; Sonoda et al., 1997; Tanner et al., 2000). Frequent DNA 
amplification has been reported in low and high grade ovarian carcinomas but appears to be 
absent in benign masses (Iwabuchi et al., 1995; Tominaga et al., 2010).  
Copy number aberrations at the 20q13 locus have also been linked to many non-ovarian 
cancers including gastric (Nishimura, 2008), lung (Zhu et al., 2007), breast (Larramendy et al., 
2000), salivary gland (Uchida et al., 2010), prostate (Tabach et al., 2011) and cervical tumours 
(Scotto et al., 2008), in addition to brain metastases (Petersen et al., 2000), following CGH 
analysis of cancer cell lines or primary tumour tissue. 
The amplification of locus 20q13 has been reported to result in genome instability, a factor 
that may go some way to explaining the frequent correlation between high WFDC2 expression 
and malignancy (Savelieva et al., 1997). The recurrent amplification suggests that genes 
encoded at this locus may be involved in tumour progression, however, candidate genes are 
yet to be identified.  
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1.4.4. WFDC2 and metaplasia 
Interestingly, WFDC2 has also been implicated in cases of metaplasia. Microarray analysis of 
murine gastric cells induced to undergo metaplastic transition indicated that Wfdc2 was one 
of the most highly upregulated factors in metaplastic cells (Nozaki et al., 2008; Weis et al., 
2014). Histological and microarray analysis has also shown that WFDC2 becomes 
upregulated in human gastric and intestinal metaplasias (Weis and Goldenring, 2009). It is 
possible that WFDC2 becomes upregulated in gastric metaplasia as a result of the instability 
of the 20q13 locus.  
1.4.5. WFDC2 and cancer cell behaviours 
Evidently WFDC2 is overexpressed in a number of cancers and some cases of metaplasia, 
but it is yet to be determined whether the gene is actively involved in downstream tumour-
promoting activities or whether it is simply an innocent bystander.  
WFDC2 is expressed in a number of cancer cell lines, including those derived from ovarian 
and endometrial tumours (Bingle et al., 2006; Drapkin et al., 2005), providing a suitable tool 
for knockdown studies. Various attempts to engineer stable WFDC2 overexpression and 
knockdown cell lines have been described in the literature, with the aim of ascertaining the 
potential impact of WFDC2 expression on the behaviour of cancer cells.  Unfortunately, a 
considerable proportion of the literature fails to suitably evidence the successful 
knockdown/overexpression of WFDC2, or otherwise shows a mildly altered cell phenotype in 
the resultant clones. Within the better-evidenced studies, the reported effects of WFDC2 on 
cellular behaviour are described below. 
Studies using WFDC2 overexpressing ovarian and endometrial cancer cell lines have shown 
enhanced proliferation rates in comparison to controls (Li et al., 2013; Zhu et al., 2016). 
Similarly, endometrial and pancreatic cancer cell lines treated endogenously with recombinant 
WFDC2 appear to proliferate more rapidly than untreated cells (Lu et al., 2016). This in vitro 
data is supported by in vivo analyses using xenograft mouse models, whereby animals 
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injected with WFDC2 overexpression clones developed tumours that were significantly larger 
than those derived from controls (Li et al., 2013; Zhu et al., 2016). Conversely, cancer cell 
lines that had endogenous WFDC2 expression knocked-down using RNA interference 
exhibited reduced proliferation/viability rates compared to controls (Guo et al., 2015; Zhu et 
al., 2016). Xenograft tumours derived from WFDC2-knockdown clones were also significantly 
smaller (Lu et al., 2012; Zhu et al., 2016). 
Interestingly, within the scope of their xenograft studies, Zhu et al (2016) also monitored the 
formation of metastatic lung nodules and found that animals injected with WFDC2-
overexpressing ovarian cancer cells had significantly greater metastatic nodules than control 
animals. Correspondingly, no metastatic lung nodules were found in animals that had been 
injected with WFDC2-knockdown ovarian cancer cells, whereas 40% of mock controls 
exhibited metastasis, and 100% of animals injected with WFDC2-overexpressing ovarian 
cancer cells had lung nodules (Zhu et al., 2016). These observations of changes in invasive 
capacity are further supported by in vitro wound healing and Transwell assays, which show 
that WFDC2-overexpressing ovarian cancer clones appear to be more migratory and invasive 
(Lu et al., 2012; Zhu et al., 2016). A WFDC2-knockdown gastric cancer cell line was also 
reported to exhibit reduced migration compared to controls (Guo et al., 2015).  
Although the results from these studies are, for the most part, in agreement with each other, 
one study using WFDC2-overexpression clones reported opposing findings whereby mice 
injected with WFDC2-overexpressing ovarian cancer cells exhibited significantly smaller 
tumours than animals injected with mock-transfected cells. (Gao et al., 2011). Within the same 
study, in vitro assays showed that overexpression clones also had increased rates of 
apoptosis compared to controls, in addition to a reduced capacity to migrate and invade (Gao 
et al., 2011). Lu et al (2012) also showed that overexpression of WFDC2 did not have an effect 
on proliferation compared to the controls.  
Largely, the in vitro evidence appears to be consistent in reporting an increase in cell 
proliferation, invasion and migration when WFDC2-overexpressing clones are analysed, with 
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downstream xenograft studies replicating this result in vivo, showing increased tumour growth 
and metastasis. The converse was frequently reported when WFDC2-knockdown clones were 
assessed in in vitro and xenograft models.   
1.5. WFDC2 and benign diseases 
Upregulation of WFDC2 is also evident in benign diseases such as cystic fibrosis (CF) (Bingle 
et al., 2006; Nagy et al., 2016), idiopathic pulmonary fibrosis (Raghu et al., 2018) and renal 
fibrosis (LeBleu et al., 2013). Although several fibrotic diseases do express high levels of 
WFDC2, its expression is not upregulated in liver fibrosis or cirrhosis, so cannot be viewed as 
a universal marker of fibrosis, per se (Zhang et al., 2018). Nonetheless, the wide range of 
benign diseases characterised by WFDC2 overexpression only serves to heighten the 
ambiguity surrounding its function.  
1.5.1. WFDC2 and benign lung diseases 
Elevated levels of WFDC2 have been identified in the serum of patients with a number of 
benign lung diseases, including pulmonary tuberculosis, pneumonia, idiopathic pulmonary 
fibrosis and CF (Liu et al., 2013; Nagy et al., 2016; Raghu et al., 2018; Yamashita et al., 2012). 
Consequently, if WFDC2 was to be considered as a potential biomarker for lung cancer, a 
higher serum cut-off concentration would be required in order to distinguish between patients 
with malignant and benign disease, compared with healthy individuals and cancer patients 
(Liu et al., 2013). 
Histological studies carried out by Bingle et al (2006) have been used to further analyse the 
upregulation of WFDC2 that occurs in patients with CF. Chronically inflamed tissue derived 
from the peripheral lung of CF patients exhibited extensive staining compared to disease-free 
peripheral lung sections (Fig 1.15), yet little difference in expression was identified between 
CF and healthy tissue sections derived from the large airways (Bingle et al., 2006). The pattern 
of expression within these lung sections suggests that WFDC2 is secreted into the lumen of 
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diseased airways; a theory supported by the elevated level of WFDC2 in the sputum of CF 
patients compared to healthy controls (Nagy et al., 2016).  
 
Fig 1.15. Analysis of WFDC2 staining in the cystic fibrosis lung. Immunohistochemical analysis of 
WFDC2 expression in normal lung tissue (a) compared to cystic fibrosis lung (b, c, d), taken from Bingle 
et al (2006). Original magnification of the images was X100 (a) and X200 (b, c, d). The antibody utilised 
was developed by Hellström et al (2003) using recombinant full-length WFDC2 synthesised in 
mammalian cells as the immunogen. 
 
More recently the value of WFDC2 as a serum biomarker for CF has been under investigation. 
In a study involving 144 CF patients, graded with mild, moderate or severe disease, the serum 
concentration of WFDC2 was measured and compared to that of 94 patients with non-CF lung 
disease (e.g. patients with chronic bronchitis, asthma, pneumonia or bronchiectasis) and 117 
healthy controls (Nagy et al., 2016). The authors reported elevated median serum levels in all 
CF patients compared to normal controls, regardless of age or genotype. Compared to healthy 
controls, patients without CF but afflicted with other lung diseases had higher average WFDC2 
levels than healthy controls, however, serum concentrations were still significantly lower in 
non-CF lung disease patients compared to CF patients (Nagy et al., 2016). This hierarchy of 
WFDC2 expression enables the identification of two WFDC2 concentration cut-off points to 
be determined, with one value to discriminate between CF patients and normal controls (49.3 
pM), and another cut-off value to distinguish between CF and non-CF diseased patients (98.4 
pM). These values are comparable with those suggested by Liu et al (2013) when studying 
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differences in serum concentrations between patients with lung malignancies and those with 
pulmonary tuberculosis or pneumonia.  
In a trend comparative to that seen in advanced stage cancer patients, WFDC2 concentration 
appeared to be positively correlated with disease severity in CF patients, as demonstrated in 
adult and child cohorts (Nagy et al., 2016).  
Interestingly, the WFDC2 levels in juvenile CF patients diagnosed with chronic bacterial 
colonisation (n=54) were significantly raised in sera compared to patients lacking colonisation 
(n=23) (Nagy et al., 2016). This preliminary evidence could suggest that WFDC2 is 
overexpressed in CF lung tissue as a result of chronic infections, and that expression is 
induced by exposure to bacteria, although there are many other factors that could be involved, 
including disease severity.  
When CF bronchial epithelial (CFBE) cells cultured in vitro were exposed to LPS, no change 
in WFDC2 secretion was induced (Nagy et al., 2016). This data supports the evidence 
discussed in Section 1.3.4 which describes a lack of WFDC2 induction following exposure of 
TBE cells to inflammatory stimuli (Bingle et al., 2006).  
Further investigations will be necessary to determine the role that WFDC2 plays in CF and to 
understand why exacerbated WFDC2 levels correlate with increasing disease severity. It is 
possible that the upregulation results from an alteration in cellular phenotype in the inflamed, 
fibrotic pulmonary tissue.  
1.5.2. WFDC2 and renal fibrosis 
A significant upregulation in WFDC2 expression has been observed in patients with renal 
fibrosis or renal dysfunction compared to healthy controls and higher serum WFDC2 levels 
correlate with advanced kidney disease (Escudero et al., 2011; LeBleu et al., 2013; Nagy et 
al., 2012; Wan et al., 2016; Yuan and Li, 2017). Thus, WFDC2 has been proposed to be a 
potential biomarker of renal fibrosis. 
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Mouse models of renal fibrosis have been used to analyse Wfdc2 expression in murine fibrotic 
kidneys compared to normal kidneys using RT-qPCR and Western blotting (Chen et al., 2017; 
LeBleu et al., 2013). The studies using mouse models report an upregulation of Wfdc2 in 
fibrotic renal tissue. LeBleu et al (2013) specifically shows the abundant expression of Wfdc2 
in murine fibrosis-associated fibroblasts compared to normal fibroblasts, although it should be 
noted that recombinant human WFDC2 was used as a positive control for Western blot 
analysis alongside murine samples, with the results showing both human and mouse 
orthologues to be the same size (approximately 20 kDa) which is not the case. Similarly, Chen 
et al (2017) used Western blotting to confirm the expression of murine Wfdc2 in fibrotic 
kidneys; according to the manufacturer the antibody detects human WFDC2 as a 22 kDa 
band, which is identical to that reported for murine Wfdc2 in this study. The reliability of the 
Western blotting data described is, therefore, not confirmed. 
If WFDC2 is indeed capable of protease inhibition, as discussed in Section 1.3.5, this may 
provide sound reasoning as to why the protein is abundant in fibrotic tissues. Fibrosis is a self-
perpetuating process, and secretion of protease inhibitors can prevent the degradation of 
collagen, which resultantly inhibits the turnover of collagen within the tissue. Accumulation of 
extracellular matrix (ECM) components and immune cells leads to the formation of scar-tissue, 
which limits kidney function and leads to kidney failure (LeBleu et al., 2013). Interestingly 
LeBleu et al (2013) use cell staining, protease assays and zymography to show that inhibition 
of WFDC2 with neutralising antibodies leads to a reduction in fibrosis severity in murine fibrotic 
kidneys. The authors suggest WFDC2 exacerbates fibrosis by inhibiting proteases that are 
required for the efficient turnover of collagen, resultantly causing type I collagen to accumulate 
(LeBleu et al., 2013). 
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1.6. Main hypotheses and aims 
Hypotheses:  
1. WFDC2 is a host defence protein that is capable of antibacterial activity against 
bacteria endogenous to the oral cavity and lung.  
2. Wfdc2-knockout mice exhibit a similar phenotype to Slpi-knockout animals, whereby 
the mice appear phenotypically normal but are more susceptible to bacterial infection.  
3. Silencing of WFDC2 expression causes significant changes to cancer cell behaviour, 
including increased cell proliferation and invasion. 
The work described in this thesis aims to address the shortfalls and inconsistencies in the 
literature to elucidate the function of WFDC2 in both healthy and diseased tissues. 
Recombinant WFDC2 will be used to identify whether the protein is capable of antibacterial or 
anti-protease activity, as is frequently hypothesised. To identify whether WFDC2 expression 
exhibits tumorigenic activity, CRISPR gene edited cell lines will be used to analyse the effect 
of WFDC2 silencing on cancer cell behaviour. Finally, the phenotype of Wfdc2-knockout mice 
will be analysed, with a view to identifying the role of Wfdc2 in development and physiology. 
Utilisation of these molecular and genetic tools will provide insights into the function of WFDC2 
in humans and mice. 
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Chapter 2 
Materials and methods 
 
 
2.1. Cell culture 
Cancer cell lines and primary human sublingual gland cells were routinely cultured in T75 
flasks. The culture media was changed 3 times a week and cells were passaged once a week. 
All cells were incubated at 37°C with 5% CO2 in a humidified chamber. The derivation and 
source of the cell lines used in this study are summarised in Table 2.1.  
Cell line 
name: 
Tissue origin: Provided by: 
H357 
Established from human squamous 
cell carcinoma of the tongue 
Dr. Simon Whawell (Academic Unit of Oral and 
Maxillofacial Pathology, School of Clinical Dentistry, 
University of Sheffield, UK) 
CAL27 
Established from human squamous 
cell carcinoma of the tongue 
Dr. Craig Murdoch (Academic Unit of Oral and 
Maxillofacial Pathology, School of Clinical Dentistry, 
University of Sheffield, UK) 
FaDu 
Established from human squamous 
cell carcinoma of the hypopharynx 
Dr. Craig Murdoch (Academic Unit of Oral and 
Maxillofacial Pathology, School of Clinical Dentistry, 
University of Sheffield, UK) 
D20 
Established from human dysplastic 
cells of the lateral tongue 
Dr. Keith Hunter (Academic Unit of Oral and 
Maxillofacial Pathology, School of Clinical Dentistry, 
University of Sheffield, UK) 
NCI-H292 
Established from human 
mucoepidermoid carcinoma of the lung 
Prof. John Carmichael (University of Nottingham, UK) 
NCI-H647 
Established from human 
adenosquamous carcinoma of the lung 
Prof. John Carmichael (University of Nottingham, UK) 
NCI-H226 
Established from human squamous 
cell carcinoma of the lung 
Prof. John Carmichael (University of Nottingham, UK) 
NCI-H358 
Established from human 
adenocarcinoma of the lung 
Prof. John Carmichael (University of Nottingham, UK) 
NCI-H441 
Established from human papillary 
adenocarcinoma of the lung 
Prof. John Carmichael (University of Nottingham, UK) 
NCI-H322 
Established from human 
bronchioalveolar carcinoma of the lung 
Prof. John Carmichael (University of Nottingham, UK) 
HEK293 
Established from human embryonic 
kidney 
Prof. James Stewart (the Institute of Infection and 
Global Health, University of Liverpool, UK) 
HuSL 
Established from explanted tissues of 
human sublingual gland 
Zulaiha Rahman (Academic Unit of Oral and 
Maxillofacial Pathology, School of Clinical Dentistry, 
University of Sheffield, UK). Ethics code STH 17021. 
Table 2.1. Cell lines. 
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2.1.1. Culture media 
H357, FaDu, NCI-H292, NCI-H647 and HEK393-T cell lines were cultured in low glucose 
DMEM (Sigma-Aldrich) supplemented with 10% (v/v) foetal bovine serum (FBS; Gibco), 2 mM 
L-glutamine (Sigma-Aldrich), 100 μg/ml of Penicillin and 100 U/ml of Streptomycin (Sigma-
Aldrich). 
The CAL27 cell line was cultured in high glucose DMEM (4500 mg/L glucose) with 10% (v/v) 
FBS, 2 mM L-glutamine, and 100 μg/ml of Penicillin and 100 U/ml of Streptomycin.  
NCI-H322, NCI-H441, NCI-H358 and NCI-H226 cell lines were grown in RPMI-1640 (Sigma-
Aldrich) with 10% (v/v) FBS, 2 mM L-glutamine, and 100 μg/ml of Penicillin and 100 U/ml of 
Streptomycin. 
The D20 cell line and HuSL primary cells were cultured in KGM media. KGM media consists 
of DMEM supplemented with 23% Ham’s F12 (Sigma-Aldrich), 10% (v/v) FBS, 100 μg/ml 
Penicillin and 100 U/ml Streptomycin, 2 mM L-glutamine, 180 μM adenine (Sigma-Aldrich), 
0.5 μg/ml of hydrocortisone (Sigma-Aldrich), 100 pM cholera toxin (Sigma-Aldrich) and 10 
ng/ml of epidermal growth factor (EGF; Sigma-Aldrich). 
2.1.2. Collection of conditioned media  
Cultured cells were seeded at a density of 1 x 106 cells per T75 flask and grown for 3-5 days 
to reach ~70% confluency. Cells were then washed three times in PBS (Sigma-Aldrich) and 
incubated with 6 ml serum-free media with 2 mM L-glutamine for 24 hours. The media was 
then collected and stored at -20°C for use within 1 month. Total protein content was measured 
via BCA assay (see Section 2.3.2) and protein concentrations were standardised prior to 
analysis by Western blot or ELISA. 
2.1.3. Harvesting cells 
Cultured cells were washed twice in PBS and harvested using trypsin/EDTA (Sigma-Aldrich). 
Trypsin was neutralised with media containing 10% (v/v) FBS. Cells were collected by 
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centrifugation at 1,000 x g for 5 minutes. For crude Western blot analysis, pelleted cells were 
lysed directly in 2X SDS loading buffer and stored at -20°C. For RNA extraction the cell pellet 
was flash frozen at -80°C for up to 1 month. 
2.2. DNA analysis  
2.2.1. RNA extraction 
Total RNA was extracted from cultured cells using TRI reagent according to the 
manufacturer’s protocol. The resultant RNA pellet was resuspended in 50 µl of nuclease-free 
H2O and the yield was determined using the NanoDrop 1000 Spectrophotometer 
(ThermoFisher Scientific). RNA was stored at -80°C.  
Total RNA to be used for downstream RT-qPCR was extracted from cultured cells using the 
Monarch Total RNA Miniprep Kit (NEB) as per the manufacturer’s instructions. Optional 
DNase I treatment steps for removal of residual genomic DNA were carried out.  
2.2.2. Reverse transcription 
Complementary DNA (cDNA) was synthesised from 1 µg of total RNA template using the High-
Capacity cDNA Reverse Transcription Kit (ThermoFisher Scientific) as per the manufacturer’s 
protocol. cDNA was stored at -20°C.  
2.2.3. Polymerase chain reaction 
Polymerase chain reaction (PCR) was performed using 1 µl of template cDNA, 100 ng of 
forward and reverse oligonucleotide primers and 2X DreamTaq Green PCR Master Mix 
(ThermoFisher Scientific) in a total reaction mixture of 20 µl. The primer pair sequences are 
summarised in Table 2.2. Cycling conditions were as follows: 5 minutes at 95°C, 35 cycles of 
95°C for 1 minute, 60°C for 1 minute, 72°C for 1 minute, followed by 7 minutes at 72°C. 
Annealing temperatures at 55°C, 60°C and 65°C were originally tested; 60°C was found to be 
optimal and used for all subsequent PCRs.  Resultant PCR products were analysed by 
agarose gel electrophoresis.  
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Table 2.2. Primer sequences utilised for RT-PCR. Primer sequences and the expected PCR product 
size (bp) are shown. 
 
2.2.4. DNA agarose gel electrophoresis 
DNA samples and PCR products were visualised on a 1 or 2% agarose gel (percentage 
dependent on expected product size) containing 0.2 µg/ml of ethidium bromide. Gels were run 
in 1X TAE buffer at 80 V and visualised using the InGenius3 gel documentation system 
(Syngene). See Appendix for further details. 
2.2.5. Quantitative polymerase chain reaction  
Quantitative polymerase chain reaction (qPCR) was performed using a 20X TaqMan probe 
mix for detection of human WFDC2 variant 1 exons 2-3 (ThermoFisher, Hs00899484_m1) and 
2X qPCRBIO Probe Blue Mix Lo-ROX master mix (PCR Biosystems). A 20X β-2 macroglobin 
(B2M) control probe mix (Life Technologies) was used as the endogenous control. Each 
reaction was performed in triplicate using 0.5 µl of template cDNA in a total reaction mixture 
Gene target Sequence (5’-3’) Product size (bp) 
Human WFDC2 (V0) 
F CCGACAACCTCAAGTGCTG 
105 
R CGAGCTGGGGAAAGTTAAT 
Human WFDC2 (V1) 
F AATGGCCAACTGGCTGAG 
132 
R TTTGAGAGAGTCCCCAGCTC 
Human WFDC2 (V2) 
F CCATGCCTGCTTGTCGCC 
97 
R CAGGAACCCTCCTTATCTGA 
Human WFDC2 (V3) 
F GCCATGCTGCAGGTACAAGT 
75 
R ATCTGGGTAGAAAAAGGAGTAAGG 
Human WFDC2 (V4) 
F CCCAATGCACTGTTCCACT 
85 
R AGTCCCAAGTGGGCCTTC 
Human WFDC2 (full-length)* 
 
*can amplify multiple splice variants 
F CGGCTTCACCCTAGTCTCAG V0: 450 
V1: 579 
V2: 306 
R AAAGGGAGAAGCTGTGGTCA 
Human OAZ1  
F CCAACGACAAGACGAGGGATT 
164 
R AGCGAACTCCAGGAGAACTG 
Murine Wfdc2 (FL) 
F AGGTGGACAGCCAGTGTTCT 
196 
R GACCAGGAAGAAATGCAA 
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of 10 µl. Thermal cycling was carried out using a 7900 HT Fast Real-Time PCR machine. 
Cycling conditions were as follows: 40 cycles of 95°C for 15 seconds, 60°C for 1 minute, 95°C 
for 15 seconds. Data was shown as fold-change in gene expression compared to the 
endogenous control or values were normalised to the untreated controls. 
Quantification of expression was calculated using the delta delta CT (2-ΔΔCT) method (Livak 
and Schmittgen, 2001). The cycle threshold (CT) is the cycle number that causes the 
fluorescent signal to reach a fixed threshold. The ΔCT value represents the difference in CT 
values between WFDC2 target gene and B2M endogenous control. The calculated 2-ΔΔCT 
values represent the relative fold change in gene expression between samples.  
2.3. Protein analysis 
2.3.1. Human and mouse samples 
Whole human saliva samples were collected from healthy, non-smoking volunteers from the 
School of Clinical Dentistry (University of Sheffield). Parotid gland secretions were collected 
from one healthy, non-smoking volunteer using a Carlson-Crittenden cup. 
Submandibular/sublingual secretions were collected from the same volunteer using a custom-
made device. Samples were centrifuged at 13,000 rpm to remove cells and debris prior to 
analysis. Collection of saliva samples had full ethical approval (ethics number: 003166). 
Human lung epithelial secretions were kindly donated by Dr Michael Campos (Division of 
Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Miami, USA). Secretions 
were collected from healthy bronchial cells (derived from bronchial brushings) grown at an air-
liquid interface (ALI). Samples were centrifuged at 13,000 rpm to remove cells and debris prior 
to analysis. 
Mouse tracheal epithelial secretions were kindly donated by Dr Khondoker Akram 
(Department of Infection, Immunity and Cardiovascular Disease, Medical School, University 
of Sheffield, UK). Murine tracheal epithelial cells were isolated from mice, cultured at an ALI 
and apical secretions were collected. Mouse nasal epithelial secretions were kindly donated 
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by Priyanka Anujan (Department of Infection, Immunity and Cardiovascular Disease, Medical 
School, University of Sheffield, UK). Cells were isolated from mice and cultured (as outlined 
in (Akram et al., 2018 and Mulay et al., 2016). Samples were centrifuged at 13,000 rpm to 
remove cells and debris prior to analysis. 
Antibodies 
The antibodies used for Western blotting are summarised in Table 2.3. 
Primary 
antibody 
Manufacturer 
and catalogue 
number 
Description 
Working 
concentration 
or dilution 
Secondary 
antibody 
Immunogen 
Anti-
WFDC2 
R&D Systems 
AF6274 
Sheep 
polyclonal to 
human 
WFDC2 
1.75 µg/ml 
Anti-sheep-
HRP 
NS0-derived recombinant 
human WFDC2 
Thr28-Phe124 
Anti-
WFDC2 
Abcam 
ab200828 
Rabbit 
monoclonal to 
human 
WFDC2 
1.5 µg/ml 
Anti-rabbit-
HRP 
Recombinant fragment within 
human WFDC2 Met1–
Phe124 
Anti-
Wfdc2 
Antiserum 
kindly donated 
by Ronny 
Drapkin1 
Rabbit 
polyclonal to 
mouse Wfdc2 
1:1000 
Anti-rabbit-
HRP 
Not disclosed 
Anti-
FLAG 
Sigma 
F3165 
Mouse 
monoclonal to 
FLAG-tagged 
proteins 
1.0 µg/ml 
Anti-mouse-
HRP 
FLAG peptide sequence 
DYKDDDDK 
Anti-
MUC7 
Novus 
NBP2-50391  
Mouse 
monoclonal to 
human MUC7 
1.5 µg/ml 
Anti-mouse-
HRP 
KLH conjugated peptide 
EGRERDHELRHRRHHHQ 
in the N-terminus of MUC7 
 
Table 2.3. Antibodies for Western blotting. Catalogue number, working concentration, secondary 
antibody required and immunogen are summarised. 1Ronny Drapkin (Perelman School of Medicine, 
University of Pennsylvania, USA). 
 
 
2.3.2. BCA assay 
Total protein concentration in samples was determined using the Pierce BCA Protein Assay 
Kit (ThermoFisher Scientific) according to the manufacturer’s instructions. Bovine serum 
albumin (BSA) (ThermoFisher Scientific) was used to generate a standard curve and the 
absorbance of standards and samples was measured at 570 nm using the POLARstar Galaxy 
Spectrophotometer (BMG LabTech). Only phenol red-free conditioned media was analysed 
via BCA assay as phenol red is known to interfere with the assay.  
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2.3.3. Western blotting 
For general details of Western blotting reagents see the Appendix. Samples to be analysed 
by Western blotting were lysed in 2X SDS loading buffer or 5X loading buffer (National 
Diagnostics) and heated at 95°C for 5 minutes. As standard, proteins were separated on a 
12% acrylamide gel against an EZ-Run Prestained Rec protein ladder (ThermoFisher 
Scientific). In some instances, alternative gel percentages were used depending on the 
molecular weight of the sample being resolved. Proteins were transferred to a nitrocellulose 
membrane (GE Healthcare) sandwiched between 3 sheets of filter paper soaked in semi-dry 
transfer buffer. Transfer conditions were as follows: 1.0 A and 25 V for 30 minutes, using a 
Western blotting transfer system (BioRad, Trans-Blot Turbo). The presence of transferred 
protein bands was detected using Ponceau stain (Sigma Aldrich). Membranes were blocked 
for 1 hour using 5% skimmed milk in Tris buffered saline (1X TBS) on a rolling platform at 
room temperature. Primary antibodies were diluted in 5% skimmed milk in 1X TBS plus 0.1% 
Tween 20 (1X TBS-Tween). Diluted antibodies were incubated with the membrane overnight 
at 4°C on a rolling platform. The membrane was washed with 1X TBS-Tween 3 times for 10 
minutes and then incubated with diluted secondary antibody conjugated with horseradish 
peroxidase (HRP) for 1 hour at room temperature on a rolling platform. Membranes were 
washed again with 1X TBS-Tween 3 times for 10 minutes. Protein was visualised using 
enhanced chemiluminescence (ECL) Western blotting substrate (ThermoFisher Scientific). 
Signal was detected by exposure to X-ray film (ThermoFisher Scientific) and subsequent 
passage through a Compact X4 automatic X-ray film processor (Xograph) or alternatively 
using a Li-Cor C-Digit Western Blot Scanner and Image Studio Software.  
2.3.4. Densitometry 
Western blots developed using the Li-Cor C-Digit Western Blot Scanner were analysed by 
densitometry using Image Studio Software. Bands were manually drawn around and the signal 
within each area of focus was measured. 
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2.3.5. SDS-PAGE analysis 
Twelve percent acrylamide gels were used for SDS PAGE analysis. To visualise protein 
bands, gels were incubated in InstantBlue protein stain (Sigma-Aldrich) overnight at room 
temperature with agitation. The following day, gels were washed in H2O and then imaged 
using the InGenius3 gel documentation system (Syngene). 
2.3.6. Native PAGE analysis 
Ten percent acrylamide discontinuous native PAGE gels were used for Western blotting of 
native protein samples. The PAGE gel, running buffer and sample buffer lacked SDS to 
prevent protein denaturation. The standard Western blotting protocol (see 2.3.3) was carried 
out using these native reagents. See the Appendix for more details. 
2.3.7. Enzyme-linked immunosorbent assay 
Human WFDC2 protein concentration was quantified using the Human HE4/WFDC2 
Quantikine ELISA Kit (R&D Systems), a sandwich ELISA that uses a monoclonal and 
polyclonal antibody, both raised against recombinant WFDC2. Saliva, secretions from primary 
lung cell culture and conditioned media from cell lines were prepared by centrifugation at 
13,000 x g for 5 minutes to remove cells/debris and diluted 1,000-fold, 300-fold and 250-fold, 
respectively, in Calibrator Diluent RD5-26 (1X) provided. The ELISA was carried out following 
the manufacturer’s protocol. WFDC2 standards (made using provided recombinant NS0-
derived WFDC2) were used to generate a standard curve in GraphPad Prism 7. The WFDC2 
concentration was extrapolated from the standard curve and resultant values were multiplied 
by the dilution factor to determine the concentration of WFDC2 in the original sample.       
2.4. Synthesis of recombinant WFDC2 
2.4.1. Primer design and polymerase chain reaction 
Primers were designed to amplify full length human WFDC2 V0 and mouse Wfdc2 V0. A NotI 
enzyme restriction site and a Kozak consensus sequence were incorporated into the forward 
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primer. A BglII restriction site and a FLAG-tag sequence (DYKDDDDK) were incorporated into 
the reverse primer. Primer sequences are summarised in Table 2.4. Primers amplified the 
desired cloning insert from the template cDNA via PCR as described in Section 2.2.3. cDNA 
was derived from RT-PCR and provided by Prof. Colin Bingle (the Department of Infection, 
Immunity and Cardiovascular Disease, University of Sheffield, UK). PCR conditions were as 
follows: 4 minutes at 95°C, 35 cycles of 94°C for 1 minute, 60°C for 1 minute, 72°C for 1 
minute, followed by 7 minutes at 72°C. PCR products were visualised on a 1% agarose gel. 
Gene 
transcript 
Sequence (5’-3’) 
Product 
size (bp) 
Human 
WFDC2 
F 
ATGCGGCCGCCGCCGCCACCATGCCTGCTTGTCGCCTA
GGCCCGCT 
427 
R 
GCAGATCTTTACTTGTCATCGTCGTCCTTGTAGTCGAAAT
TGGGAGTGACACAGGA 
Mouse 
Wfdc2 
F 
ATGCGGCCGCCGCCGCCACCATGCCTGCCTGTCGCCTC
TGCTT 
577 
R 
GCAGATCTTTACTTGTCATCGTCGTCCTTGTAGTCGAATT
TGGGTGTGGTGCAGGCCAT 
 
Table 2.4. Primer sequences utilised for gene cloning. Primer sequences and the expected PCR 
product size (bp) are shown. 
 
 
2.4.2. TOPO TA subcloning 
TOPO TA cloning (ThermoFisher Scientific) was performed to sub-clone amplified WFDC2 
PCR products directly into a pCR®II-TOPO® 4.0 kb vector (ThermoFisher Scientific). Cloning 
was carried out according to the manufacturer’s protocol. Plasmids were transformed into NEB 
5-alpha competent E. coli cells (NEB) and successful transformants were selected on LB-agar 
plates containing ampicillin (50 μg/ml). Transformed colonies were picked, inoculated into 2 
ml of LB-broth containing ampicillin (50 μg/ml) and grown overnight at 37°C and 220 rpm. 
Plasmid DNA was isolated from the bacterial culture using the Isolate II Plasmid Mini Kit 
(Bioline) and DNA yield was measured using a NanoDrop 1000 Spectrophotometer 
(ThermoFisher Scientific). 
55 
 
2.4.3. Isolation of insert DNA 
To isolate the WFDC2 inserts, TOPO vector DNA was digested with BglII and NotI restriction 
enzymes (NEB) in 10X NEBuffer 3.1 (NEB). Restriction digestion reactions were incubated 
overnight at 37°C. Digested products were separated on a 1% agarose gel to confirm expected 
fragment sizes of the human WFDC2 (416 bp) and mouse Wfdc2 (566 bp) inserts. The 
WFDC2 inserts were extracted from the gel using a GeneJET Gel Extraction Kit 
(ThermoFisher Scientific) and kept at 4°C for short-term storage. 
2.4.4. Vector preparation 
The target vector for WFDC2 cloning was the pVR1255 plasmid (from Prof. James Stewart, 
the Institute of Infection and Global Health, University of Liverpool), mapped in Figure 2.1.  
 
Fig 2.1. The pVR1255 vector. A plasmid map of the target vector, pVR1255. Labelled cassettes include 
the promoter (HCMV pro), the kanamycin resistance gene (Kan) and the luciferase gene (LUX) which 
was excised and replaced with the gene of interest (WFDC2). Restriction sites are also shown. The 
plasmid vector is 6413 bp in size. 
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pVR1255 was prepared by digestion with NotI and BglII to excise the luciferase cassette and 
produce compatible sticky ends for the insertion of the WFDC2 insert. The double-cut vector 
(~4.7 kb) with luciferase (~1.6 kb) excised was resolved on a 1% agarose gel and isolated 
using a GeneJET Gel Extraction Kit (ThermoFisher Scientific). DNA yield was determined 
using a NanoDrop 1000 Spectrophotometer (ThermoFisher Scientific). Vector cut with BglII 
only (single-cut) was isolated in the same way and used as a ligation control. 
 
2.4.5. Ligation 
A sample of WFDC2 insert isolated by gel extraction (described in Section 2.4.3) was resolved 
on a 1% agarose gel and quantified by comparison against PCR Ranger 100 bp DNA ladder 
(Norgen) reference bands to estimate the DNA concentration. WFDC2 insert was ligated into 
the double-cut VR1255 vector using T4 DNA Ligase (Promega) and Ligase 10X Buffer 
(Promega) following the manufacturer’s protocol in a total reaction volume of 10 μl. 
2.4.6. Transformation 
Five microlitres of ligated pVR1255-WFDC2 vector was mixed with 10 μl of NEB 5-alpha 
competent E. coli cells (NEB) and the mixture was left on ice for 30 minutes. Cells were then 
heat-shocked for 45 seconds at 42°C and immediately placed back on ice for 5 minutes. One 
hundred microlitres of SOC medium (NEB) was added to the mixture, followed by incubation 
for 1 hour at 37°C. Cells were plated onto LB-agar plates containing kanamycin (30 μg/ml) 
and incubated overnight at 37°C in order to select for successful transformants. Single 
colonies of transformants were picked and inoculated into 2 ml LB-broth with kanamycin (30 
μg/ml) and incubated at 37°C and 220 rpm overnight. 
The overnight broth culture was then used for plasmid isolation. Glycerol stocks were also 
made from 0.5 ml of bacterial culture with 0.5 ml of 50% glycerol and kept at -80C. 
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2.4.7. Plasmid isolation ‘miniprep’ 
Vector DNA was isolated from 1 ml of transformed cells using the Isolate II Plasmid Mini Kit 
(Bioline). DNA yield was determined using a NanoDrop 1000 Spectrophotometer 
(ThermoFisher Scientific) and DNA stored at -20°C.  
2.4.8. Plasmid isolation ‘maxiprep’ 
For higher DNA yields, 100 ml of LB-broth with kanamycin (30 μg/ml) was inoculated with 0.5 
ml of transformant culture from stocks kept at 4°C. The bacterial culture was incubated at 37°C 
with shaking (220 rpm) overnight. Plasmid DNA was harvested using a Plasmid Maxi Kit 
(Qiagen). DNA yield was determined using a NanoDrop 1000 Spectrophotometer 
(ThermoFisher Scientific) and then aliquoted and stored at -20°C. 
2.4.9. Confirmation of target insertion 
Plasmid DNA was digested using restriction enzymes and expected fragment sizes were 
confirmed by agarose gel electrophoresis to show that the insert was successfully 
incorporated into the vector.  
2.4.10. Sequencing of clones 
The nucleotide sequence of the WFDC2 insert in the VR1255 vector was further validated by 
DNA sequencing (Research Core Facility, the Medical School, University of Sheffield, UK). 
2.4.11. FuGENE transfection 
HEK293 cells were seeded into a 24-well plate at a density of 3 x 105 cells per well and 
incubated overnight at 37°C and 5% CO2. Prior to transfection, cells were washed and media 
was changed to Opti-MEM reduced serum media (Gibco). Cells were co-transfected with 
pVR1255 with human or mouse insert (500 ng) and pEGFP-N1 (100 ng; ClonTech 
Laboratories) using 3 µl of FuGENE HD transfection reagent (Promega) in 200 μl of Opti-MEM 
media as per the manufacturer’s recommendation and incubated overnight at 37°C and 5% 
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CO2. Media was changed the following day. After a further 24 hours, cells were lysed in 2X 
SDS lysis buffer directly in the well and stored at -20C for downstream analysis. 
2.4.12. Calcium phosphate transfection 
HEK293 cells were seeded into a 24-well plate at a density of 3 x 105 cells per well and 
incubated overnight at 37°C and 5% CO2. Two hours prior to transfection, media was changed 
with fresh DMEM supplemented with 10% (v/v) FBS. Cells were co-transfected with pVR1255-
WFDC2 (500 ng) and pEGFP-N1 (100 ng). DNA was mixed with 3.75 μl of CaCl2 (2.5 M) and 
made up to 30 μl with H2O. The DNA-CaCl2 mixture was added to 30 μl of 2X HEPES buffered 
saline (HBS; see Appendix) and mixed by pipetting. The reaction mixture was incubated for 
15 minutes at room temperature and then added drop-wise to the cells. Transfection reactions 
were incubated overnight at 37°C and 5% CO2. Media was changed the following day. After a 
further 24 hours, cells were lysed in 2X SDS lysis buffer directly in the well and stored at -20C 
for downstream analysis. 
For transfection of HEK293 cells in T75 flasks, cells were seeded at a density of 4.5 x 106 cells 
per flask and incubated at 37°C and 5% CO2 for 48 hours. Media was changed two hours prior 
to transfection with fresh DMEM supplemented with 10% (v/v) FBS. Cells were co-transfected 
with pVR1255-WFDC2 (15 µg) and pEGFP-N1 (3.75 µg). DNA was mixed with 140.6 μl of 
CaCl2 (2.5 M) and made up to 1.125 ml with H2O. The DNA-CaCl2 mixture was added to 1.125 
ml of 2X HEPES buffered saline (HBS), mixed by pipetting, and incubated for 15 minutes at 
room temperature. The mixture was then added drop-wise to the cells. Transfection reactions 
were incubated overnight at 37°C and 5% CO2. Media was changed for fresh DMEM 
supplemented with 10% (v/v) FBS the following day. After 24 hours, cells were washed 3 times 
with PBS and then incubated with serum-free DMEM. Media was collected and replaced with 
fresh serum-free DMEM after 24 hours. This was repeated for a further 3 days. All collected 
conditioned media was stored at -20°C. For analysis by Western blotting, the serum-free 
conditioned media was concentrated 6-fold using Vivaspin 6 centrifugal concentrators with a 
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10 kDa molecular weight cut-off point (Sartorius). Serum-free conditioned media was not 
concentrated when used for affinity gel purification.  
2.4.13. Anti-FLAG M2 affinity gel purification  
FLAG-tagged recombinant WFDC2 proteins were purified from the serum-free conditioned 
media of transiently transfected HEK293 cells using Anti-FLAG M2 affinity gel (Sigma) as per 
the manufacturer’s instructions. Conditioned media was prepared for purification by adjusting 
the salt concentration to 0.15 M with NaCl. Debris was removed by centrifugation at 15,000 x 
g for 15 minutes followed by filtration through a 0.22 µm sterile filter (Sartorius). The affinity 
gel was washed in 0.1 M glycine-HCl (pH 3.5) and then TBS prior to use. Typically, 100 µl of 
affinity gel was added to 6 ml of conditioned media and kept at 4°C for 2 hours. Bound protein 
was eluted from the affinity gel using 150 µl of FLAG peptide (150 ng/µl) (Sigma). Eluted 
protein was aliquoted and stored at -20°C. The presence of WFDC2 protein was confirmed by 
Western blotting and protein yield was quantified by BCA. A standard 150 µl elution would 
produce ~25 µg of purified protein. Aliquots of affinity gel were reused for purification of the 
same protein construct up to 3 times before disposal, by washing in 0.1 M glycine-HCl (pH 
3.5) and storage in 50% glycerol with TBS containing 0.02% sodium azide. 
2.4.14. Immunofluorescence microscopy  
NCI-H292 cells were seeded into a 12-well plate at a density of 1.6 x 106 cells per well and 
were transfected the following day with pVR1255-WFDC2 or empty vector using the FuGENE 
transfection method (Section 2.4.11). Cells were transfected with pVR1255 (1 µg) using 6 µl 
of FuGENE HD transfection reagent (Promega) in 400 μl of Opti-MEM media. Following 
transfection, the cells were incubated overnight at 37°C and 5% CO2. Cells were washed in 
PBS and then incubated in DMEM supplemented with 10% (v/v) FBS for 6 hours. Transfected 
cells were trypsinised and seeded into Nunc Lab Tek II chamber slides (ThermoFisher 
Scientific) at a density of 3.5 x 104 and incubated overnight at 37°C and 5% CO2. 
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The following day, media was aspirated from each chamber of the slide and cells were fixed 
by immersion in ice-cold 100% methanol (ThermoFisher Scientific) for 10 minutes. Cells were 
rinsed in PBS and incubated for 5 minutes in 0.5% Triton-X-100 in PBS (Sigma-Aldrich) to 
permeabilise the cells. Cells were then washed 3 times in PBS. 
For the blocking step, cells were incubated in 10% serum (Sigma-Aldrich) in PBS for 1 hour 
at room temperature with gentle rocking. The blocking buffer was aspirated and cells were 
washed 3 times in PBS. Primary antibody was diluted in 10% serum and cells were incubated 
with diluted antibody for 2 hours in a humidified chamber at room temperature with gentle 
rocking. See Table 2.5 for details of the appropriate blocking serum and antibody 
concentrations used. The primary antibody was aspirated and cells were washed 3 times in 
PBS. Alexa Fluor-488 conjugated secondary antibodies were diluted in PBS and cells were 
incubated for 1 hour at room temperature with gentle rocking and were protected from light. 
The secondary antibody was aspirated and cells were washed 3 times in PBS. The media 
chamber frame was then removed and the slide was inverted onto a coverslip with 
VECTASHIELD Mounting Media with DAPI (Vector Laboratories). The edges of the coverslip 
were sealed using transparent nail polish and left to dry in the dark. 
 
Table 2.5. Antibodies for immunofluorescence microscopy. Working concentration, secondary 
antibody and blocking serum required are summarised. 
 
When staining cells transfected with murine Wfdc2, a Mouse-On-Mouse (M.O.M) 
Immunodetection Kit (Vector Laboratories) was required to reduce background staining as 
anti-FLAG is raised in mouse. M.O.M Mouse IgG blocking reagent (90 μl of M.O.M Mouse IgG 
Blocking Reagent in 2.5 ml of PBS) was used to block for 1 hour at room temperature and the 
Primary (1
o
) 
antibody 
1
o
 antibody 
concentration 
(µg/ml) 
Secondary (2
o
) antibody 
2
o
 antibody 
concentration 
(µg/ml) 
Appropriate 
serum for 
blocking step 
Anti-WFDC2 
polyclonal 
(R&D systems) 
3.5 
Rabbit anti-goat IgG (H+L) 
Alexa Fluor 488 conjugate 
(Invitrogen) 
2.0 10% rabbit serum 
(Sigma-Aldrich) 
Anti-FLAG 
monoclonal 
(Sigma-Aldrich) 
2.0 
Goat anti-mouse IgG (H+L) 
Alexa Fluor 488 conjugate 
(Life Technologies) 
2.0 10% goat serum 
(Sigma-Aldrich) 
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cells were then washed with PBS and incubated with diluted M.O.M Protein (600 μl of Protein 
concentrate in 7.5 ml of PBS) for 2 minutes. Anti-FLAG primary antibody was also diluted in 
the M.O.M Protein concentrate. The rest of the staining protocol remained as standard 
(described above).  
Cells were imaged using an Axiovert 200M fluorescent microscope (Zeiss) and AxioCam 
camera (Zeiss). Each field was imaged using a DAPI and GFP filter, in addition to an image 
taken in white light. 
The images captured were in black and white so to visualise the DAPI and GFP staining 
together within a single field, the two images were merged and colour was imitated using Fiji 
by ImageJ software (Schneider et al., 2012).  
2.5. Glycosylation analysis 
2.5.1. Site-directed mutagenesis 
Site directed mutagenesis (SDM) was used to remove the predicted N-glycosylation site (Asn-
44) from the human WFDC2 gene. Mutagenic primers were designed with two nucleotide 
substitutions to produce an amino acid change [Asn (AAC) to Gln (CAA)]. Primer sequences 
are summarised in Table 2.6. 
 
 
 
Table 2.6. Primer sequences utilised for SDM. 
 
SDM was carried out using the QuikChange II Site-Directed Mutagenesis Kit (Agilent) and the 
manufacturer’s protocol was followed accordingly. pVR1255 containing the human WFDC2 
insert was used as template DNA for the PCR. Plasmid DNA from successful SDM 
transformants was isolated by miniprep (see Section 2.4.7) and sequenced to confirm the 
Gene target Sequence (5’-3’) 
SDM 
targeting  
F primer CTCCAGGCTGACCAGCAATGCACGCAAGAGTGC 
R primer GCACTCTTGCGTGCATTGCTGGTCAGCCTGGAG 
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presence of the desired mutation (Research Core Facility, the Medical School, University of 
Sheffield, UK). 
2.5.2. PNGase F enzyme treatment 
PNGase F enzyme (NEB) was used to cleave N-linked glycans from target proteins. Reactions 
were carried out as per the manufacturer’s recommendation, using 1 μl of PNGase F enzyme 
and 1-20 μg of glycoprotein substrate in a total reaction volume of 20 μl. PNGase F-treated 
products were lysed in 2X SDS lysis buffer and analysed by Western blotting. 
2.5.3. Sialidase enzyme treatment 
Recombinant sialidase enzyme with the sequence derived from Tannerella forsythia was 
kindly donated by Marianne Satur and Dr Andrew Frey (School of Clinical Dentistry, University 
of Sheffield; method used to produce recombinant sialidase described in(Frey et al., 2018). 
Sialidase was used to cleave sialic acid residues from WFDC2. Twenty microlitres of each 
purified WFDC2 orthologue were incubated with sialidase (500 nM) diluted in PBS for 1 hour 
at 37C. Samples were then lysed in 2X SDS lysis buffer and analysed by Western blotting to 
visualise molecular weight shifts due to cleavage of sialic acid.          
2.6. Protease inhibition assays 
2.6.1. Enzyme optimisation for protease inhibition assay  
Trypsin from porcine pancreas (Sigma) was solubilised in 1 mM HCl solution and then its 
activity at 0, 260, 520, 780, 1040 and 1300 nM was assessed by incubation with 830 µM of 
Nα-Benzoyl-DL-arginine 4-nitroanilide hydrochloride (BAPNA; Sigma). BAPNA was 
solubilised in DMSO and then diluted in triethanolamine (TEA) buffer (125 mM TEA with 13 
mM CaCl2, pH 7.8).  
In a 96-well plate, 25 µl of trypsin (0-1300 nM) and 75 µl of BAPNA (830 µM) were incubated 
together in 50 µl of TEA buffer for 15 minutes at 37°C. Fifty microlitres of 30% acetic acid was 
added to stop the reaction and then the absorbance was read at 405 nm using a POLARstar 
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Galaxy Spectrophotometer (BMG LabTech). The mean absorbance value for BAPNA alone 
was subtracted from all readings to account for background.  
Elastase from porcine pancreas (Sigma) was solubilised in HEPES buffer (100 mM HEPES, 
500 mM NaCl, 10% DMSO) and its activity at 0, 65, 130 and 195 nM was assessed by 
incubation with 465 µM of N-Succinyl-Ala-Ala-Ala-p-nitroanilide (SAPNA; Sigma). SAPNA was 
solubilised and diluted in HEPES buffer. Enzyme activity was measured using the same 
protocol as for trypsin, but HEPES buffer was used in place of TEA buffer.  
2.6.2. Serine protease inhibition assay 
Purified recombinant human and mouse WFDC2, recombinant human SLPI (R&D Systems) 
and solubilised cOmplete™, Mini, EDTA-free Protease Inhibitor (PI) tablets (Sigma) were 
analysed for their capacity to inhibit trypsin and elastase activity. WFDC2 proteins and SLPI 
were diluted in TBS and used at a final concentration of 0, 100, 200, 500 and 1000 nM. Each 
PI tablet was solubilised in 1.16 ml of TBS to give a 6X solution and sequentially increasing 
volumes were assayed for enzyme inhibition (0, 1.25, 2.5, 6.25 and 12.5 µl).  
In a 96-well plate, 25 µl of inhibitor was pre-incubated with 25 µl of trypsin (1.3 µM) or elastase 
(130 nM) for 15 minutes at room temperature. Seventy-five microlitres of appropriate substrate 
was added (830 µM of BAPNA for trypsin, 465 µM SAPNA for elastase) and the reaction made 
up to 150 µl with buffer (TEA buffer for trypsin, HEPES buffer for elastase). The 96-well plate 
was incubated at 37°C for 15 minutes and then the reaction was quenched with 30% acetic 
acid. The absorbance was read at 405 nm using a POLARstar Galaxy Spectrophotometer 
(BMG LabTech). The mean absorbance value for substrate alone was subtracted from all 
readings to account for background. Results are expressed as a percentage reduction in 
enzyme activity whereby enzyme and substrate with no inhibitor represents 100% activity.  
2.6.3. Zymography 
Samples to be analysed by zymography were incubated at 37°C for 10 minutes prior to 
resuspension in 5X non-reducing sample buffer. Samples were separated on a 7.5% 
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acrylamide gel containing gelatin for ~2 hours at 150 V in 1X Tris-glycine running buffer (Bio-
rad). Resolved gels were washed twice for 30 minutes in washing buffer to remove SDS from 
the gel. Gels were rinsed for 10 minutes in incubation buffer at 37°C with agitation. Gels were 
placed in fresh incubation buffer and left for 24 hours at 37°C to enable the gelatinase reaction 
to occur. Gels were stained in InstantBlue stain (Sigma-Aldrich) for 1 hour, rinsed in H2O and 
then imaged using the InGenius3 gel documentation system (Syngene). Areas of enzyme 
activity appear as white bands. See the Appendix for details of zymography reagents. 
2.7. Bacteria assays 
2.7.1. Bacterial strains 
Bacterial species Strain Provided by: 
Streptococcus 
mutans  
Ingbritt 
Academic Unit of Oral and Maxillofacial Pathology, 
School of Clinical Dentistry, University of Sheffield, UK 
Streptococcus 
gordonii  
Challis 
Academic Unit of Oral and Maxillofacial Pathology, 
School of Clinical Dentistry, University of Sheffield, UK 
Streptococcus 
pneumoniae  
D39 
Department of Infection, Immunity & Cardiovascular 
Disease, University of Sheffield, UK 
Escherichia coli  
Clinical isolate 
from urinary tract 
Academic Unit of Oral and Maxillofacial Pathology, 
School of Clinical Dentistry, University of Sheffield, UK 
 
Table 2.7. Bacterial strains.  
2.7.2. Bacterial culture 
All strains were maintained on Colombia blood agar (BA) plates. Liquid cultures of all strains 
were grown using Brain-Heart Infusion (BHI) broth. Bacterial assays were performed using 
bacteria grown overnight in BHI. E. coli was incubated at 37C in aerobic conditions. S. mutans 
and S. gordonii were incubated at 37C and 5% CO2. S. pneumoniae was incubated at 37C 
in 80% N2, 10% H2, 10% CO2 using an anaerobic cabinet (miniMACS Anaerobic Workstation, 
Don Whitley Scientific, UK). 
BA plates were made by adding 7.8 g of Colombia blood agar powder (Oxoid) to 200 ml of 
distilled H2O. Agar was sterilised by autoclaving at 121C for 15 minutes, cooled to 55C, 
supplemented with 7% oxalated horse blood (ThermoFisher Scientific) and then poured into 
Petri dishes to set. Plates were stored at 4C.  
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BHI broth was made by adding 14.8 g of BHI powder (Oxoid) and 2.5 g of yeast extract (Oxoid) 
to 400 ml of distilled H2O and 20 ml aliquots were sterilised by autoclaving.  
2.7.3. Colony polymerase chain reaction and 16S sequencing  
To confirm the species of bacteria being cultured, colony PCR and 16S sequencing were used. 
A colony of bacteria was picked from a plate, resuspended in 25 µl nuclease-free H2O and 
heated at 95C for 10 minutes.  
PCR was performed using 5 µl of lysed pellet solution alongside final concentrations of 0.5 
µM of forward and reverse oligonucleotide primers, 5X Phusion buffer, 200 µM of dNTPs and 
0.02 U/µl of Phusion High-Fidelity DNA polymerase. Universal primers sequences for targeting 
16S rDNA are summarised in Table 2.8.  
 
 Table 2.8. Primer sequences utilised for 16S sequencing. Primer sequences and the expected 
PCR product size (bp) are shown. 
 
The cycling conditions were as follows: initial denaturation of 98C for 30 seconds, 30 cycles 
of 98C for 10 seconds, 65C for 30 seconds and 72C for 30 seconds, final extension of 72C 
for 2 minutes. Resultant PCR products were analysed by agarose gel electrophoresis.  
Five microlitres of amplified PCR products with 5 µl of forward or reverse 16S primer were 
analysed by Sanger sequencing (GATC Biotech, Eurofins Genomics). Bacterial species were 
confirmed by BLAST searching using the NCBI blastn Suite. Glycerol stocks were made from 
the cultures that were confirmed by 16S sequencing.  
2.7.4. Pull down assay 
The optical density of an overnight broth culture was adjusted to an OD600 of 1.0. One millilitre 
of culture was used per sample to be analysed. Each 1 ml aliquot of cells was washed 3 times 
Gene target Sequence (5’-3’) Product size (bp) 
16S rDNA  
Universal primer 27 F AGAGTTTGATYMTGGCTCAG 
~500 bp 
Universal primer 519 R GWATTACCGCGGCKGCTG 
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in sterile PBS by centrifugation (all spins at 13,000 rpm for 3 minutes). The cell pellet was then 
resuspended in 20 µl of purified protein (diluted 1:1 in PBS) or 20 µl of control FLAG peptide 
elution solution (150 ng/µl; diluted 1:1 in PBS) or 20 µl of PBS alone and incubated at 37C 
for 2 hours. After 2 hours had elapsed the cells were pelleted and the unbound protein was 
removed and lysed in 2X SDS lysis buffer. The pellet was washed once in PBS and then 
transferred to a fresh Eppendorf. The bacteria were washed twice more and the pellet was 
resuspended in 10 µl of PBS and lysed in 20 µl of 2X SDS lysis buffer. The unbound protein 
and bacterial pellet in 2X SDS lysis buffer were heated at 95°C for 5 minutes and then 
analysed by Western blotting (see 2.3.3).   
2.7.5. Miles-Misra viability assay 
Ten microlitres of bacterial culture with an OD600 of 0.05 was incubated with 1.0 µM of purified 
WFDC2 protein diluted in PBS, in a total volume of 20 µl. An equal volume of FLAG peptide 
elution solution (150 ng/µl) or 10 µl of PBS alone were used as controls. The culture was 
incubated at 37°C for 3 hours and then plated out using the Miles-Misra technique (10 µl of 
serial dilutions) to determine the number of colony forming units (CFU) in the bacterial 
suspension. When plated, E. coli and S. gordonii plates were maintained at room temperature 
overnight whereas slower growing S. mutans and S. pneumoniae were kept at 37°C. Colonies 
were counted at the lowest dilution factor where distinct colonies were visible.   
2.7.6. TECAN growth curve viability assay 
Wells of a 96-well plate were loaded with 5 µl of bacterial culture adjusted to an OD600 of 1.0 
and either 1.0 µM or 3.0 µM of purified WFDC2 protein in a total volume of 200 µl of BHI broth. 
An equal volume of FLAG peptide elution buffer (150 ng/µl) and PBS alone were used as 
controls. Bacteria with BHI only and bacteria in BHI with ampicillin (60 µg/ml) were also used 
as controls. Bacterial culture optical density was measured at 600 nm every 30 minutes for 12 
hours using a microplate reader (TECAN).  
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2.7.7. Overnight bacterial incubation analysis 
One millilitre of bacterial culture adjusted to an OD600 of 1.0 was pelleted and resuspended in 
10 µl of purified WFDC2 and incubated overnight at 37°C. The following day the bacteria were 
pelleted and WFDC2 protein in the supernatant was collected. The protein was lysed in 2X 
SDS lysis buffer and analysed by Western blotting to determine whether the proteins were 
digested by bacteria when incubated overnight.  
2.7.8. Agglutination assay optimisation  
The optical density of an overnight broth culture was adjusted to an OD600 of 1.0. Aliquots of 
0.3 ml, 0.5 ml, 0.7 ml and 0.9 ml of each bacterial strain were pelleted, washed in sterile PBS 
by centrifugation (13,000 rpm for 3 minutes) and then resuspended in 1 ml of PBS. Each 1 ml 
aliquot of cell suspension was inoculated with 1 µl of fluorescein isothiocyanate (FITC; 0.1 
µg/ml; Sigma) and kept in darkness for 15 minutes at 4°C with agitation. Cells were washed 4 
times with 1.5 ml of PBS to remove excess FITC and then pelleted. Each pellet was 
resuspended in 1 ml of PBS and then 100 µl of cell suspension was added to a U-bottomed 
96-well plate (Greiner). Plates were kept at 4°C in darkness overnight. Images were captured 
using the InGenius3 gel documentation system (Syngene). The smallest starting volume of 
bacteria with a visible pellet of non-agglutinated cells was used for future assays.  
2.7.9. Agglutination assay 
The optical density of an overnight broth culture was adjusted to an OD600 of 1.0. Aliquots of 
the following volumes were used for each bacterial strain: 0.5 ml of E. coli, 0.9 ml of S. gordonii 
and S. mutans and 0.7 ml of S. pneumoniae. FLAG peptide elution buffer (150 ng/µl) and PBS 
were used as negative controls. Whole saliva centrifuged at 13,000 rpm to remove cells and 
debris was used as an agglutinating positive control. The same protocol was used as 
described in Section 2.7.8. After the washing steps to remove excess FITC, cells were pelleted 
and resuspended in 1 ml of PBS. One hundred microlitres of FITC-stained bacterial 
suspension was aliquoted (per sample or control to be tested) and pelleted. The pellet was 
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resuspended in 100 µl of purified WFDC2 (1 µM) diluted in PBS or in 100 µl of control. Each 
100 µl suspension was added to a U-bottomed 96-well plate (Greiner) and kept at 4°C in 
darkness overnight. Images were taken using the InGenius3 gel documentation system 
(Syngene) to visualise FITC-stained bacteria. A pellet of cells shows no agglutination has 
occurred, while no visible pellet suggests agglutination has occurred and cells instead exist 
as a film of agglutinated bacteria.  
2.7.10. Biofilm formation assay 
The optical density of an overnight broth culture was adjusted to an OD600 of 1.0. Two hundred 
microlitres of culture was added to wells of a 96-well plate. Sterile PBS was added to the 
peripheral wells to avoid water loss in wells containing bacteria as this can affect biofilm 
formation. Purified WFDC2 protein (1 µM) or an equal volume of FLAG peptide elution buffer 
(150 ng/µl), PBS or saliva (healthy whole saliva centrifuged at 13,000 rpm to remove cells and 
debris) controls were immediately added to the bacteria. Sterile BHI was used as a negative 
control. Plates were incubated at 37°C for 48 hours to allow biofilms to form. After 48 hours, 
the broth culture containing planktonic bacteria was aspirated and wells were washed twice 
with PBS. The remaining biofilms were stained with 200 µl/well of 0.1% crystal violet for 10 
minutes at room temperature. Wells were washed 3 times with PBS to remove excess dye 
and plates were left to air dry. The bacteria-bound crystal violet was then solubilised in 200 
µl/well of 33% acetic acid and mixed by pipetting up and down. Plates were read at OD570 
using a microplate reader (Tecan) to measure biofilm formation. The absorbance readings 
from wells incubated with sterile BHI broth alone were used to determine background staining 
and were subtracted from all other readings. 
2.7.11. Biofilm disruption assay 
Biofilm disruption was measured as described in Section 2.7.10 but the purified WFDC2 
protein or control was added 24 hours after bacteria were seeded into the 96 well plates i.e. 
when biofilms had already begun to form. Following addition of protein or control, the plates 
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were incubated for a further 24 hours at 37°C and the biofilms were stained with crystal violet 
and analysed as before.   
2.8. Cytokine exposure assay 
HuSL, CAL27 and H357 cells were seeded into a 6-well plate at a density of 3 x 105, 4 x 105, 
5 x 105 respectively, and incubated for 24 hours at 37°C and 5% CO2. Cells were washed 
twice in PBS and then serum-starved for 24 hours. Cells were then exposed to TNF-α (20 
ng/ml), IFN-γ (5 ng/ml), LPS (50 µg/ml) and IL-1β (20 ng/ml) (all purchased from ThermoFisher 
Scientific) in 3 ml of serum-free high glucose DMEM for 24 hours. Untreated cells were used 
as a control. After 24 hours had elapsed, the media was removed from the cells and 0.6 ml of 
1X Monarch RNA Protection Reagent (NEB) was added to each well. Plates were stored at -
80°C. RNA was extracted from the cells using the Monarch Total RNA Miniprep Kit (NEB) as 
per the manufacturer’s instructions. One microgram of RNA was reverse transcribed to cDNA 
as previously described (Section 2.2.2). cDNA was used for RT-qPCR with TaqMan probes 
against human WFDC2 and B2M was used as the endogenous control probe as previously 
described (Section 2.2.5).   
2.9. CRISPR/Cas9 gene editing 
CRISPR/Cas9 gene editing was performed based on the protocol outlined by Ran et al (2013). 
2.9.1. Single-guide RNA design  
Oligos (~20 bp) were designed to be complementary to target sites within human WFDC2 
genomic DNA. The target sites were required to be directly upstream of a 5’-NGG sequence 
which is the protospacer adjacent motif (PAM site). An additional 5’CACC sequence was 
added to the F primer and a 5’AAAC sequence was added to the R primer: when the oligos 
are annealed to form the single-guide RNA (sgRNA) these additional sequences provide 
overhangs which are complementary to the overhangs of the cut target plasmid. The sgRNA 
sequences are summarised in Table 2.9. 
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Table 2.9. Single-guide RNA sequences. 
 
2.9.2. Single-guide RNA preparation 
Oligos were resuspended in nuclease-free H2O to a final concentration of 100 µM. Both 
sgRNA1 and sgRNA2 were prepared by annealing 1 µl of forward oligo and 1 µl of reverse 
oligo together in the presence of 1X T4 ligation buffer and nuclease-free H2O. Annealing was 
carried out using the following PCR conditions: 5 minutes at 95°C, 75°C for 10 minutes, 50°C 
for 10 minutes and 25°C for 10 minutes. 
2.9.3. Vector preparation 
The target plasmid, pSpCas9(BB)-2A-GFP (abbreviated to pX458) was a gift from Feng Zhang 
(AddGene) and encodes the guide RNA scaffold, in addition to the Cas9 endonuclease, GFP 
and ampicillin resistance cassettes as depicted in Fig 2.2 (Ran et al., 2013). To prepare the 
vector, pX458 was cut with BbsI-HF (NEB) restriction enzyme and resolved on a 1% agarose 
gel. The cut plasmid was then extracted from the gel and isolated using a GeneJET Gel 
Extraction Kit (ThermoFisher Scientific). DNA yield was determined using a NanoDrop 1000 
Spectrophotometer (ThermoFisher Scientific). 
 
Oligos Sequence (5’-3’) 
Construct 1 (sgRNA1) 
F CACCGGCACAGGAGCAGAGAAGAC 
R AAACGTCTTCTCTGCTCCTGTGCC 
Construct 2 (sgRNA2) 
F CACCGGGCGTGTGCCCCGAGCTCC 
R AAACGGAGCTCGGGGCACACGCCC 
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Fig 2.2. The pX458 vector. A plasmid map of the target vector, pX458. Labelled cassettes include the 
U6 promoter, the gRNA scaffold, Cas9 endonuclease gene, GFP gene and ampicillin resistance gene. 
Restriction sites are also shown. The plasmid vector is 9288 bp in size. Taken from Addgene: plasmid 
#48138; http://n2t.net/addgene:48138; RRID: Addgene_48138.  
 
2.9.4. Ligation 
The annealed oligos, sgRNA1 and sgRNA2, were diluted 1:200 in nuclease-free H2O and then 
ligated into the cut pX458 vector using T4 DNA Ligase (Promega) and Ligase 10X Buffer 
(Promega) following the manufacturer’s protocol. The total 10 μl reaction was incubated 
overnight at 4°C. Vector incubated without sgRNA was included as a control.  
2.9.5. Transformation 
Following overnight incubation, ligated vectors (pX458-sgRNA1 and pX458-sgRNA2) were 
transformed into competent E. coli cells as described in Section 2.4.6 and selected using LB-
agar plates containing ampicillin (100 μg/ml). Successful transformants were picked, 
inoculated into 2 ml LB-broth with ampicillin (100 μg/ml) and incubated at 37°C, 220 rpm 
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overnight. The overnight broth culture was then used for subsequent plasmid isolation (see 
Section 2.4.7). Glycerol stocks were also made and kept at -80C for future use.  
2.9.6. Confirmation of target insertion 
Plasmid DNA was digested using restriction enzymes. Expected fragment sizes were 
confirmed by agarose gel electrophoresis to show that the plasmid had been successfully 
transformed into bacteria. The pX458 plasmid was then confirmed to contain the expected 
sgRNA sequences by DNA sequencing (Research Core Facility, the Medical School, 
University of Sheffield, UK). 
2.9.7. Clonal isolation test 
CAL27 cells were serially diluted in a 96-well plate in order to test their capacity to grow from 
a single cell. One hundred microlitres of media was added to all wells aside from well A1. Well 
A1 was seeded with 4,000 CAL27 cells in 200 μl of media. One hundred microlitres of media 
from well A1 was transferred to well B1, mixed by pipetting, and the process repeated down 
the column. The 100 μl of media transferred from well H1 was discarded. An additional 100 μl 
of fresh media was added to all wells of column A. One hundred microlitres of media from 
column A was transferred to column B, mixed by pipetting, and repeated across all columns 
of the plate. The 100 μl of media from column 12 was discarded. All wells had 100 μl of media 
added to bring the final well volume to 200 μl. A half media change was carried out every 2 
days. After 7 days at 37°C and 5% CO2 the cells were fixed in 70% ethanol and stained using 
0.1% crystal violet to visualise single cell colonies.  
2.9.8. Transfection using JetPrime 
CAL27 cells were seeded into a 6-well plate at a density of 3.75 x 105 cells per well and 
incubated overnight at 37°C and 5% CO2. Prior to transfection, a media change was 
performed. Four wells of CAL27 cells were co-transfected with pX458 with sgRNA1 insert (1 
μg) and pX458 with sgRNA2 insert (1 μg) using 200 μl of JetPrime buffer (Polyplus) and 4 μl 
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JetPrime transfection reagent (Polyplus) per the manufacturer’s recommendations. Media was 
changed the following day. 
2.9.9. Fluorescence activated cell sorting 
Transfected CAL27 cells were trypsinized and then sorted using fluorescence activated cell 
sorting (FACS). A BDFACSAria Ilu cell sorter (Research Core Facility, the Medical School, 
University of Sheffield, UK) was used to separate and collect the GFP positive and GFP 
negative cells from the transfected population. Cell sorting was performed by Sue Clark (Flow 
Cytometry Core Facility technician). Non-transfected wild-type CAL27 cells were used to 
calibrate the machine and set a baseline for fluorescence. The GFP negative sorted cells were 
used as an internal control for all downstream assays. 
2.9.10. Single cell colony growth and expansion 
GFP positive and GFP negative FACS sorted cells were serially diluted for clonal isolation in 
96-well plates, as described in Section 2.9.7. A half media change was carried out every 2-3 
days. After 7 days growth, rounded colonies radiating from a central point were identified as 
potential clonal colonies and were marked. Clonal colonies were grown for a further 7 days, 
passaged into 24-well plates and then expanded into T25 flasks. Stocks of cells were made 
in 10% DMSO and stored in liquid nitrogen for future use.  
2.9.11. Confirmation of positive CRISPR edited colonies 
Genomic DNA (gDNA) was extracted from the clonal colonies (multiple GFP positive colonies 
and a GFP negative control) using the Wizard Genomic DNA Purification Kit (Promega). DNA 
was quantified using a Nanodrop 1000 Spectrophotometer (ThermoFisher Scientific) and 
stored at 4C.  
To determine whether the clonal colonies had been successfully gene edited, primers were 
designed to amplify the nucleotide sequence surrounding and including the sgRNA target site. 
The GFP negative FACS sorted colony was used as a negative control. Two different primer 
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pairs were designed, both with an F primer in intron 1, 50-100 bp upstream of the sgRNA 
target site, and an R primer in exon 2, 50-80 bp downstream of the sgRNA target. Primer 
sequences are summarised in Table 2.10.  
 
 
 
 
 
Table 2.10. Primer sequences utilised for gene editing analysis. Primer sequences used to probe 
upstream and downstream of the CRISPR target site are summarised. The expected PCR product sizes 
(bp) are shown. 
 
Five hundred nanograms of gDNA was used in the PCR reaction with Phusion High-Fidelity 
PCR Master Mix (NEB). Thermocycling conditions were as follows: 30 seconds at 98°C, 30 
cycles of 98°C for 10 seconds, 65°C for 30 seconds, 72°C for 30 seconds, followed by 2 
minutes at 72°C. PCR products were resolved on a 2% agarose gel for 80 minutes at 80 V 
and visualised using the InGenius3 gel documentation system (Syngene). 
Colony 11 produced a smaller PCR product compared to the negative control and was thus 
identified as a potential gene edited colony. The PCR product was ‘cleaned-up’ using an 
Isolate II PCR and gel kit (Bioline) according to the manufacturer’s instructions and the purified 
product was resolved on a 2% agarose gel for 120 minutes at 80 V and visualised using the 
InGenius3 gel documentation system. The resultant bands were individually extracted from 
the gel using an Isolate II PCR and gel kit (Bioline) and then a sample of each eluted product 
was resolved on a 2% agarose gel for 120 minutes at 80 V to ensure single products had been 
successfully extracted.  
Five microlitres of each gel extracted and purified PCR product with 5 µl of forward or reverse 
primer was analysed by Sanger sequencing (GATC Biotech, Eurofins Genomics). Successful 
Gene target Sequence (5’-3’) Product size (bp) 
CRISPR target site in 
WFDC2 
F1 GACTCCTAGGGCCAGAGACT 
226 bp 
R1 CTGCAGCACTTGAGGTTGTC 
F2 TGGGGTTAAGGTTTGGAGCA 
223 bp 
R2 AGAGAGCAGAAGGTGGCAC 
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CRISPR gene editing was confirmed by BLAST searching using NCBI blastn Suite to compare 
the CRISPR target sequence with the WT sequence. 
2.9.12. Analysis of WFDC2 expression in CRISPR edited cells 
RNA was extracted from gene edited colony 11 cells and the FACS sorted negative control 
cells at passage 1, 2 and 3 (post-FACS) using a Monarch Total RNA Miniprep Kit (NEB) as 
per the manufacturer’s instructions. A batch of WT CAL27 cells was also used as a control 
and had RNA extracted at the same time-points, however, this batch had not been FACS 
sorted. RNA yield was quantified using a Nanodrop 1000 Spectrophotometer (ThermoFisher 
Scientific) and cDNA was synthesised from 1 µg of total RNA template using the High-Capacity 
cDNA Reverse Transcription Kit (ThermoFisher Scientific) according to the manufacturer’s 
protocol.  
Resultant cDNA was used for downstream qPCR analysis using a TaqMan probe for human 
WFDC2 variant 1 and a B2M probe as the endogenous control (for method see Section 2.2.5).  
cDNA was also used for PCR using the protocol described in Section 2.2.3. Primers against 
the full length WFDC2 gene, V0, V2 and OAZ1 were used (see Table 2.2 for primer pairs). 
PCR thermocycling conditions are described in Section 2.2.3. PCR products were resolved 
on a 2% agarose gel (see Section 2.2.4) and visualised using the InGenius3 gel 
documentation system (Syngene).  
Conditioned media from the colony 11 cells, negative control cells and WT cells was collected 
as described in Section 2.1.2 and concentrated 10-fold using a Vivaspin 6 centrifugal 
concentrator with a 10 kDa molecular weight cut-off point (Sartorius). Protein concentration 
was quantified via BCA assay as described in Section 2.3.2 and then 45 µg of total protein 
was analysed by Western blotting (see Section 2.3.3) using a monoclonal antibody against 
human WFDC2 (Abcam). Protein was detected by exposure to X-ray film and passage through 
a Compact X4 automatic X-ray film processor (Xograph).   
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The concentration of WFDC2 protein in the conditioned media was also quantified using a 
Human HE4/WFDC2 Quantikine ELISA Kit (R&D Systems). Samples were diluted 250-fold 
and assayed as described in Section 2.3.7.  
2.10. CRISPR cell functional assays 
All functional assays were performed in triplicate, with three technical repeats within each 
experiment. Results are shown as the mean of the triplicate experiments and error bars 
represent standard error of the mean (SEM). Statistical significance was analysed by one-way 
analysis of variance (ANOVA).  
2.10.1. Cell morphology 
Cell morphology was visualised using a light microscope (Olympus CKX41) with a 10X lens 
and four random fields of view were imaged using a Nikon Coolpix camera. 
2.10.2. Viability assay 
Cell viability was determined using CellTiter 96 Aqueous One Solution (Promega). Cells were 
serum-starved overnight and then seeded into a 96-well plate at a density of 5 x 103 cells per 
well in 100 µl of high glucose DMEM supplemented with 10% (v/v) FBS. Cells were incubated 
for 72 hours at 37°C and 5% CO2. After 72 hours had elapsed, media was changed to 100 µl 
of serum-free high glucose DMEM and 20 µl of CellTiter 96 Aqueous One Solution was added 
to each well avoiding exposure to direct light. Empty wells were treated the same way and 
used as a negative control. The plate was incubated for 2 hours at 37°C, protected from the 
light. The absorbance was read at 490 nm using a microplate reader (TECAN). The mean 
absorbance of the empty control wells was subtracted from each reading to account for 
background.   
2.10.3. Manual cell counting 
Cells were seeded in a 6-well plate at a density of 3 x 105 cells per well in 3 ml of high glucose 
DMEM supplemented with 10% (v/v) FBS and incubated for 48 hours. Cells were then 
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trypsinized, resuspended in 2 ml of media and manually counted using a haemocytometer to 
give a total cell count. 
2.10.4. Adhesion assay 
Cell adherence was measured by coating 96-well plates with 100 µl/well of rat tail collagen 
type I (30 µg/ml; Corning) or bovine fibronectin protein (30 µg/ml; ThermoFisher Scientific) for 
1 hour at 37°C. Plates were then blocked for 1 hour at 37°C using 100 µl/well of BSA in PBS 
(10 mg/ml). Each well was seeded with 25,000 cells per well in serum-free media for 1 hour 
at 37°C. Cells had been serum-starved overnight. After 1 hour elapsed, unbound cells were 
removed by washing each well with 200 µl of PBS. Cells remaining bound to the plate were 
quantified by adding 100 µl of serum-free media and 20 µl of CellTiter 96 Aqueous One 
Solution per well, avoiding exposure to direct light. Empty wells were treated the same way 
and used as a negative control. The plate was incubated for 2 hours at 37°C, protected from 
the light. The absorbance was read at 490 nm using a microplate reader (TECAN). The mean 
absorbance of the empty control wells was subtracted from each reading to account for 
background.   
2.10.5. Migration assay 
Cell migration was measured using a Transwell assay. Cells were serum-starved overnight. 
The following day, cells were trypsinized and resuspended in 0.1% BSA in serum-free high 
glucose DMEM.  Each 12 mm, 8 µm pore Transwell insert (Falcon) was seeded with 50,000 
cells in 200 µl of 0.1% BSA serum-free media and the well beneath the insert was filled with 
0.5 ml of high glucose DMEM supplemented with 10% (v/v) FBS. Cells were left to migrate for 
7 hours. Non-migrated cells within the insert were wiped away with a cotton bud. Cells that 
had migrated through the insert pores were fixed using 0.5 ml of ice-cold 100% methanol for 
10 minutes. Inserts were rinsed with PBS and then migrated cells were stained using 0.1% 
(w/v) crystal violet for 20 minutes. Inserts were washed multiple times with distilled H2O to 
remove excess stain and were left to dry. Each insert was imaged across 7 fields of view and 
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the number of migrated cells were manually counted using a plugin available on ImageJ 
named ‘Cell Counter’. The mean number of migrated cells per field of view was calculated for 
each insert.   
2.10.6. Invasion assay 
Cell invasion was measured using a Matrigel assay. Cells were serum-starved overnight. 
Matrigel aliquots (Corning) were pre-thawed for 2 hours at 4°C prior to use and were 
subsequently kept on ice. Pre-chilled pipette tips and media were used when diluting the 
Matrigel.  Each 12 mm, 8 µm pore Transwell insert (Falcon) was filled with 100 µl of Matrigel 
(0.25 mg/ml) in serum-free high glucose DMEM and left to set overnight at 37°C. The following 
day, cells were trypsinized and resuspended in 0.1% BSA in serum-free high glucose DMEM.  
Each Matrigel-coated insert was seeded with 100,000 cells in 200 µl of 0.1% BSA serum-free 
media and the well beneath the insert was filled with 0.5 ml of high glucose DMEM 
supplemented with 10% (v/v) FBS. Cells were left to invade for 24 and 48 hours, respectively. 
Non-invaded cells and Matrigel within the insert were wiped away with a cotton bud. Cells that 
had invaded through the insert pores were fixed using 0.5 ml of ice-cold 100% methanol for 
10 minutes. Inserts were rinsed with PBS and then invaded cells were stained using 0.1% 
(w/v) crystal violet for 20 minutes. Inserts were washed multiple times with distilled H2O to 
remove excess stain and were left to dry. Stained cells were solubilized using 200 µl of 33% 
acetic acid for 20 minutes. The absorbance was measured at 570 nm using a microplate 
reader (Tecan).  
2.11. Tissue specimen preparation and histological analysis 
2.11.1. Wfdc2-knockout mouse tissues 
Homozygous and heterozygous WFDC2-knockout mice were established at the MCR Harwell 
Institute under the International Mouse Phenotyping Consortium (IMPC) project 
(http://www.mousephenotype.org/data/genes/MGI:1914951). Mice were bred and maintained 
by the Mary Lyon Centre, MRC Harwell and were housed in specific-pathogen free conditions. 
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All animal experimentation was approved by the Animal Welfare and Ethical Review Body at 
MRC Harwell. The humane care and use of mice in this study was under the authority of the 
appropriate UK Home Office Project Licence.  
WFDC2 silencing was established by CRISPR-induced mutation using two sgRNAs. A 2431 
nucleotide region of genomic DNA spanning intron 2 to intron 4 was deleted to induce a null 
allele in C57BL/6N mice. Heterozygote animals were culled between ages of 112-115 days. 
Six WT and six heterozygote animal tissues were donated to this study, with a ratio of 1:1 of 
male and female animals in each phenotypic group. Salivary gland, trachea, lung, stomach, 
gastrointestinal tract, kidney, testis, epididymis and ovary tissues from WT and heterozygote 
animals were histologically analysed.  
Homozygote animals were analysed at the MRC Harwell Institute and the results were 
communicated to researchers within this study. The volume and crown-to-rump length of 
embryos at embryonic day E14.5 and E18.5 were measured. Micro computed tomography 
(micro-CT) analysis was used to perform 3D visual assessments of the embryos. 
Morphological differences between WT and homozygote embryos were recorded. Trachea 
diameter was also determined from the micro-CT scans.  
2.11.2. Wfdc2-knockout mouse tissue processing 
Mouse tissues were received from the MRC Harwell Institute in 10% neutral buffered formalin. 
Kidneys and stomach were cut with a scalpel in the ‘butterfly’ manner while the ‘Swiss rolled’ 
intestines were also cut into smaller slices. All other tissues were small enough to be 
processed whole so were omitted from the grossing step. Grossed and whole tissues were 
placed into labelled cassettes. Smaller tissues were held in place within the cassette with 
sponge. Tissues were processed overnight using an automated Shandon Citadel 2000 tissue 
processor (ThermoFisher Scientific). The processing schedule is summarised in Table 2.11.  
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Stage Solution Processing time 
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70% alcohol 1 h 
80% alcohol 1 h 
90%alcohol 1 h 30 mins 
Absolute alcohol I 1 h 30 mins 
Absolute alcohol II 1 h 30 mins 
Absolute alcohol III 2 h 
C
le
a
ri
n
g
 
Toluene I 1 h 30 mins 
Toluene II 2 h 
Xylene PASS 
W
a
x
 
in
fi
lt
ra
ti
o
n
 
Wax I 2 h 
Wax II 2 h 
 
Table 2.11. Tissue processing schedule.  
 
2.11.3. Tissue sectioning 
After processing, tissues were infiltrated with paraffin wax (Paraplast) using an embedding 
centre (Leica EG1160H). Care was taken to orientate each tissue to ensure optimal positioning 
of the plane when sectioning. Tissues were left to solidify in wax on a cooling plate (Leica 
EG1150C). A rotary microtome (Leica RM2235) was used to cut 4 µm thick ribbons from the 
paraffin blocks which were ‘floated out’ onto a floatation bath (Electrothermal) set at 38°C. 
Tissue ribbons were then mounted onto SuperFrost Plus microscope slides (ThermoFisher 
Scientific) and then oven-dried for 15 minutes at 60°C. Sectioning was carried out by Hayley 
Stanhope (School of Clinical Dentistry, University of Sheffield). 
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2.11.4. Human tumour tissue  
Paraffin-embedded human oral carcinoma tissue was derived from the Oral Pathology tissue 
bank (School of Clinical Dentistry, University of Sheffield). Tissue blocks were sectioned using 
a microtome as described in Section 2.11.3.  
2.11.5. Haematoxylin and eosin staining  
Tissues were haematoxylin and eosin (H&E) stained using an automated linear staining 
machine (Shandon). The staining schedule is summarised in Table 2.12.  
Step Solution  Step Solution 
1 Xylene  15 Running tap water 
2 Xylene  16 Scott’s tap water substitute 
3 Xylene  17 Running tap water 
4 99% IDA  18 Eosin Y (Shandon) 
5 99% IDA  19 Eosin Y (Shandon) 
6 70% IDA  20 Eosin Y (Shandon) 
7 Distilled water  21 Running tap water 
8 Distilled water  22 99% IDA 
9 Harris’ haematoxylin (Shandon)  23 99% IDA 
10 Harris’ haematoxylin (Shandon)  24 99% IDA 
11 Harris’ haematoxylin (Shandon)  25 Xylene 
12 Harris’ haematoxylin (Shandon)  26 Xylene 
13 Running tap water  27 Xylene 
14 0.1% acid alcohol  28 Xylene 
 
Table 2.12. Haematoxylin and eosin staining schedule.  
 
Following staining, slides were mounted in DPX mountant (ThermoFisher Scientific) with a 
coverslip. Tissues were visualised and imaged using an Olympus BX51 microscope, Colour 
View Illu camera and Cell^D software (Olympus Soft Imaging Solutions).  
2.11.6. Immunohistochemistry 
Slides were de-waxed by immersion in xylene (2 x 5 minutes) and rehydrated in 100% ethanol 
(2 x 5 minutes). Endogenous peroxidase activity was blocked by immersion in 3% hydrogen 
peroxide in methanol for 20 minutes and then slides were rinsed in PBS. Antigen retrieval was 
carried out by heating in 0.01 M sodium citrate tribasic for 8 minutes in the microwave on full 
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power. Slides were washed for 5 minutes in PBS and then blocked for 30 minutes in 100% 
normal serum (Sigma) at room temperature in a humidified chamber. The blocking serum used 
was derived from the same animal that the secondary antibody was raised in. Slides were 
incubated in primary antibody diluted in 100% normal serum overnight at 4°C in a humidified 
chamber. Primary antibodies and the appropriate secondary antibody and blocking serum 
used are summarised in Table 2.13. All antibodies required antigen retrieval. 
Primary 
antibody 
Manufacturer or 
source 
Description 
Working 
concentration 
or dilution 
Secondary 
antibody 
Blocking serum 
Anti-WFDC2 
Abcam 
(ab200828) 
Rabbit 
monoclonal to 
human WFDC2 
2.30 µg/ml 
Anti-rabbit-
HRP 
 
100% goat 
serum (Sigma-
Aldrich) 
 
Anti-Wfdc2 
Antiserum kindly 
donated by Ronny 
Drapkin1 
Rabbit 
polyclonal to 
mouse Wfdc2 
1:800 
Anti-Slpi 
RayBiotech  
(DS-PB-02937) 
Rabbit 
polyclonal to 
human/mouse 
SLPI 
1.10 µg/ml 
Anti-CCSP 
Antiserum 
developed by 
Lynne Bingle2 
Rabbit 
polyclonal to 
mouse CCSP 
1:1000 
Anti-MUC5B 
Santa Cruz  
(sc-21768) 
Rabbit 
polyclonal to 
human MUC5B 
0.4 µg/ml 
 
Table 2.13. Antibodies for immunohistochemistry. Catalogue number, working dilution, secondary 
antibody and blocking serum required are summarised. 1Ronny Drapkin (Perelman School of Medicine, 
The University of Pennsylvania, USA), 2Lynne Bingle (School of Clinical Dentistry, University of 
Sheffield, UK). 
 
The following day slides were washed in PBS (2 x 5 minutes) with agitation and then incubated 
with secondary biotinylated antibody (Vector Laboratories) for 30 minutes at room temperature 
in a humidified chamber. Slides were washed in PBS (2 x 5 minutes) with agitation and then 
incubated with Vectastain ABC solution (Vector Laboratories) for 30 minutes at room 
temperature in a humidified chamber. Slides were washed in PBS (2 x 5 minutes) with 
agitation. Positive antibody reaction was detected following incubation with DAB substrate 
(Vector Laboratories) for 3 minutes and the reaction stopped by submerging the slides in 
distilled H2O for 5 minutes. Slides were counterstained in haematoxylin using an automated 
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linear staining machine (Shandon; steps 11 to 17 and 21 to 28 only, as described in Table 
2.12). Slides were mounted in DPX mountant (ThermoFisher Scientific) with a coverslip. 
Tissues were visualised and imaged using an Olympus BX51 microscope, Colour View Illu 
camera and Cell^D software (Olympus Soft Imaging Solutions).  
IHC analysis of Wfdc2, Slpi and CCSP expression in heterozygote knockout mouse tissues 
was performed by Jessica-Leigh Tallis (Sheffield Undergraduate Research Experience 
scheme student, University of Sheffield) under the supervision of Hannah Armes. 
2.11.7. Picrosirius red staining 
To visualise collagen, slides were de-waxed by immersion in xylene (2 x 5 minutes), 
rehydrated in 100% ethanol (2 x 5 minutes) and then counterstained in haematoxylin (Table 
2.12, steps 11-13 only). Slides were incubated with picrosirius red stain (0.1% w/v of Sirius 
red F3B in saturated aqueous picric acid) for 1 hour at room temperature in a humidified 
chamber. Slides were washed in 0.1% acid alcohol (Table 2.12, step 14, passed through 
twice) and Scott’s tap water substitute and then dehydrated (Table 2.12, steps 15-16 and 21-
28). Slides were mounted and imaged as described in Section 2.11.5.  
2.11.8. Quantification of immunohistochemical staining 
Stained slides were scanned and digitalised (SITraN, University of Sheffield). DAB and 
Picrosirius staining were quantified using Aperio ImageScope software (Leica Biosystems) 
whereby sections of tissue to be analysed were highlighted using a drawing tool and then 
analysed using the Positive Pixel Count v9 algorithm (see Appendix for visual representation 
of this process). When analysing the stomach and intestines, chyme was excluded from the 
analysis due to it staining non-specifically, to avoid skewing the results. Positively stained 
pixels were counted and used to determine percentage of positivity from all pixels. Sites on 
the slide without tissue are not recognised as pixels due to the pre-set colour saturation 
threshold which blank space does not meet. Percentage positivity was determined using the 
following equation: (
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑙𝑦 𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑝𝑖𝑥𝑒𝑙𝑠
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑒𝑟 𝑜𝑓 𝑝𝑜𝑠𝑖𝑡𝑣𝑒𝑙𝑦 𝑎𝑛𝑑 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑙𝑦 𝑠𝑡𝑎𝑖𝑛𝑒𝑑 𝑝𝑖𝑥𝑒𝑙𝑠
) 𝑥100   
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2.12. Online resources 
Human and murine WFDC2 DNA and peptide sequences were established from Ensembl 
genome browser [www.ensembl.org].  
The presence of N-linked glycans and O-linked glycans in human and murine WFDC2 were 
predicted using NetNGlyc and NetOGlyc online glycan predictor software, respectively 
[http://www.cbs.dtu.dk/services/NetNGlyc/] [http://www.cbs.dtu.dk/services/NetOGlyc/]. The 
inputted WFDC2 peptide sequences were recovered from Ensembl genome browser.  
Nucleotide BLAST was used to identify regions of similarity between the WT WFDC2 
sequences and Sanger sequencing results during WFDC2 gene cloning and WFDC2 CRISPR 
gene editing. Nucleotide BLAST was also used to identify bacterial strains derived during 16S 
sequencing [https://blast.ncbi.nlm.nih.gov/Blast.cgi].  
ExPASy translate tool was used to identify changes in peptide sequence resulting from 
CRISPR gene editing. Sequencing data from PCR products of colony 11 were inputted into 
ExPASy to identify any CRISPR-induced premature stop codons or other mutations 
[https://web.expasy.org/translate/]. 
ExPASy Compute pI/Mw tool was used to compute the theoretical isoelectric point (pI) and 
molecular weight (MW) from peptide sequences (Bjellqvist et al., 1994). The tool was used to 
identify differences in pI and MW between human/murine WFDC2 and SLPI. 
[https://web.expasy.org/compute_pi/]. 
2.13. Statistics 
GraphPad Prism 7 software was used to determine statistical significance. An unpaired t-test 
was used to compare two groups. One-way analysis of variance (ANOVA) was used to 
analyse more than two groups. A P-value of <0.05 was considered to be statistically 
significant. The number of biological repeats are shown as ‘N=’. Technical repeats are 
represented as ‘n=’. 
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Chapter 3 
Synthesis and analysis of recombinant WFDC2 
 
3.  
3.1. Introduction  
Several reports in the literature have utilised recombinant human or murine WFDC2 to carry 
out in vitro functional assays with the aim of understanding more about the protein’s function 
(Chhikara et al., 2012; Hua et al., 2014; LeBleu et al., 2013; Nishimura et al., 2008). The 
results frequently vary between reports, for instance, significantly different concentrations of 
protein are used to exhibit similar effects (as described in Section 1.3.5). One of the potential 
reasons for discrepancies between reports is the inconsistency in the size of the recombinant 
protein being used, which suggests that the protein is either not WFDC2, or that it lacks the 
appropriate post-translational modifications, both of which could significantly affect the results. 
The recombinant WFDC2 orthologues synthesised in this chapter will be subjected to multiple 
analyses to ensure that they are the correct protein and that they are appropriately 
glycosylated. Importantly, the recombinant protein will be compared to endogenous protein 
via Western blotting to ensure that it is the correct size. To further the understanding of the 
structure of human WFDC2, the gene construct will be subjected to site-directed mutagenesis 
(SDM) to confirm the N-glycosylation site. Finally, the concentration of WFDC2 in saliva and 
bronchial cell secretions will be analysed to identify the endogenous levels of WFDC2 as the 
literature is lacking in quantitative analysis of WFDC2 protein expression outside of the serum 
values identified in diseased patients (Molina et al., 2011; Ruggeri et al., 2011).  
3.2. Aims and objectives 
The overall aim of the work presented in this chapter was to synthesise recombinant human 
and mouse WFDC2 by gene cloning of their predominant splice variants followed by 
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transfection into mammalian cells. The glycosylated proteins were synthesised with the main 
objective of analysing their activities in downstream in vitro studies. SDM and enzymatic 
glycan cleavage were used to elucidate the presence of the correct post-translational glycan 
modifications. The molecular weight of the recombinant protein was compared against 
endogenous WFDC2 in oral- and lung-derived secretions via Western blot.  
3.3. Materials and methods 
To access the relevant materials and methods utilised in this chapter, please refer to the 
sections below: 
• Gene cloning of human and murine WFDC2 was carried out as described in Section 
2.4. 
• The transfection method was optimised as described in Sections 2.4.11 and 2.4.12. 
Transfections were subsequently carried out as per Section 2.4.12. Transfected cells 
were analysed by immunofluorescence microscopy as described in Section 2.4.14. 
• Protein was purified from conditioned media using a FLAG affinity resin as defined in 
Section 2.4.13. The purified products were analysed by Western blotting and native 
PAGE gel as described in Sections 2.3.3 and 2.3.6, respectively. Protein concentration 
was quantified via BCA assay as per Section 2.3.2.  
• Glycosylation analysis was carried out via SDM as outlined in Section 2.5. Enzymatic 
analysis coupled with Western blotting was also used for analysis of glycans, as 
described in Section 2.5.2 and 2.5.3.  
• Endogenous WFDC2 protein was analysed by Western blotting and also quantified 
using ELISA analysis using the method described in Section 2.3.7.  
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3.4. Synthesis of recombinant WFDC2 orthologues 
3.4.1. Cloning  
Recombinant human and murine WFDC2 were synthesised via conventional cloning 
techniques. Primers were designed to span the whole coding region of the predominant splice 
variant (V0) of both orthologues. The primers were also designed to incorporate a FLAG tag 
sequence at the terminus of each gene immediately before the stop codon and enzyme 
restriction sites upstream and downstream of the coding DNA. PCR was used to amplify target 
cDNA encoding the V0 splice variant of both WFDC2 orthologues. The resultant PCR products 
were confirmed to be of the expected size by DNA gel electrophoresis (Fig 3.1).   
 
Figure 3.1. Resolution of PCR products for cloning of WFDC2 orthologues. Primers were designed 
to amplify the whole coding region of human and mouse WFDC2 orthologues in addition to attaching a 
FLAG tag at the gene terminus. Amplified PCR products were resolved on a 1% agarose gel. Lane 1: 
mouse Wfdc2 PCR product (516 bp); Lane 2: human WFDC2 PCR product (416 bp). 
 
PCR products were sub-cloned into a pCR®II-TOPO® vector to remove the 3’ adenine 
overhang resulting from Taq polymerase amplification. The DNA inserts were excised from 
the vector by restriction digestion and subsequently ligated into the pVR1255 target vector. 
Following transformation into competent E. coli cells, the plasmid DNA was isolated from 
single colonies and digested with restriction enzymes to confirm that the insert was ligated into 
the plasmid. Successful incorporation of WFDC2 was confirmed by the presence of bands of 
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the expected sizes when analysed by DNA gel electrophoresis. The results show that multiple 
plasmid preparations contained a successfully incorporated insert of the expected size (Fig 
3.2). The WFDC2 inserts were further validated by DNA sequencing which confirmed the 
nucleotide sequences were identical to the V0 sequences published in online genome 
databases (Ensembl). 
 
Figure 3.2. Resolution of digested pVR1255 vector for validation of gene insertion. pVR1255 
vector DNA was isolated from individual colonies of E. coli transformants and digested with restriction 
enzymes (KpnI and EcoRV). The resultant DNA fragments were resolved on a 1% agarose gel to 
confirm successful incorporation of the human (a) and mouse (b) WFDC2 insert.  Lanes 1-6 represent 
digested vector DNA isolated from different colonies of successful E. coli transformants. The expected 
band size for successful insertion of the gene of interest was 493 bp for human WFDC2 and 643 bp for 
murine Wfdc2. The upper band represents the rest of the pVR1255 vector (~4.6 kb).    
 
3.4.2. Protein synthesis and analysis  
To produce recombinant protein, pVR1255 vector containing either human or murine WFDC2 
was transfected into a mammalian cell line. The calcium phosphate and FuGENE® methods 
were used to co-transfect a human embryonic kidney cell line (HEK293), seeded in a 24-well 
plate, with the pVR1255 vector (500 ng) and a vector encoding green fluorescent protein 
(pEGFP-N1; 100 ng). Co-transfection with pEGFP-N1 was carried out to give an indication of 
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transfection success and efficiency. Following transfection, cells were lysed and analysed by 
Western blotting.  
Both human and murine WFDC2 were detectable in the transfected HEK293 cell lysate when 
analysed by Western blotting (Fig 3.3). Human WFDC2 resolved at a molecular weight of ~20-
25 kDa, appearing to exist as two distinct bands. Murine Wfdc2 resolved at a molecular weight 
of ~26-34 kDa. For both human and mouse WFDC2, the band intensity appeared to be 
stronger in cells that had been transfected using the FuGENE® method compared to those 
transfected with calcium phosphate.  
 
Figure 3.3. Western blot analysis of cell lysate from HEK293 cells transfected with human and 
mouse WFDC2 using two different transfections methods. HEK293 cells were transfected with 
pVR1255 vector containing human (a) or mouse (b) WFDC2. FuGENE® and calcium phosphate 
transfection methods were tested. Expression of recombinant WFDC2 in the cell lysate was analysed 
by Western blotting using anti-FLAG monoclonal antibody. Lane numbers represent the following: 1 – 
HEK293 cells transfected with WFDC2 using FuGENE®, 2 – HEK293 cells transfected with empty 
vector using FuGENE®, 3 – HEK293 cells transfected with WFDC2 using calcium phosphate, 4 – 
HEK293 cells transfected with empty vector using calcium phosphate.   
 
Following successful calcium phosphate transfection of HEK293 cells in a 24-well plate, the 
transfection method was scaled up in order to collect larger quantities of recombinant protein. 
HEK293 cells were seeded into a T75 flask and transfected using the calcium phosphate 
method with pVR1255 (18.75 µg) and pEGFP-N1 (3.75 µg). Culture media was changed to 
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serum-free media (6 ml) 48 hours post-transfection and then conditioned media was collected 
the following day. This process of conditioned media collection and replacement with fresh 
serum-free media (6 ml) was continued for a further 3 days (i.e. 6 days post-transfection). A 
representative image of WFDC2 transfection efficiency in HEK293 cells is shown in Fig 3.4. 
After 4 days of media collection had elapsed cells were lysed for analysis by Western blotting. 
Conditioned media was concentrated 6-fold using centrifugal concentrator columns and then 
denatured for downstream analysis.  
 
Fig 3.4. HEK293 cells transfected with WFDC2 and eGFP-N1 in a T75 flask using the calcium 
phosphate method. Representative images show human (a) and murine (b) WFDC2 transfected 
HEK293 cells 48 hours post-transfection. Cells were co-transfected with eGFP-N1 and the calcium 
phosphate method was used. Cells were cultured in a T75 flask. Original magnification was 5X.  
 
When conditioned media from transfected HEK293 cells was analysed by Western blotting it 
was evident that both human and mouse WFDC2 protein were secreted in abundance into the 
media. Human WFDC2 was visualised as two separate bands, ~18 kDa and ~24 kDa in size 
respectively. Murine Wfdc2 appeared as a single smeared band from ~26 to 34 kDa. A second 
~50 kDa band could be seen when analysing murine Wfdc2 which potentially represents a 
protein dimer.  
The transfected cells continued to secrete protein up to 6 days post-transfection as shown by 
the continued presence of a positive band when analysed by Western blotting (Fig 3.5). 
Expression of recombinant WFDC2 in the cell lysate was significantly lower than in the 
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conditioned media and was often undetectable. All further transfection experiments were 
carried out to the same time-scale, whereby conditioned media was collected from transfected 
cells for up to 4 days. HEK293 cells were also transfected with empty pVR1255 vector and 
the conditioned media collected to act as a control.   
 
Figure 3.5. Western blot analysis of conditioned media from HEK293 cells transfected with 
human and mouse WFDC2. HEK293 cells were seeded into a T75 flask and transfected with pVR1255 
vector containing the human or mouse WFDC2 insert. Serum-free conditioned media from transfected 
cells was collected 3 to 6 days post-transfection and analysed by Western blot using a polyclonal 
antibody against human WFDC2 (R&D Systems) or mouse Wfdc2 (Drapkin), respectively. Lane 
numbers represent the following: 1 – media collection 1 (day 3), 2 – media collection 2 (day 4), 3 – 
media collection 3 (day 5), 4 – media collection 4 (day 6), 5 – transfected HEK293 cell lysate, 6 – 
conditioned media from cells transfected with empty pVR1255 vector. 
 
In order to enrich and purify WFDC2 protein from transfected HEK293 conditioned media, a 
FLAG affinity resin was used. Conditioned media was incubated with the resin for 2 hours and 
then FLAG-tagged WFDC2 was eluted using FLAG peptide buffer (150 ng/µl). Each batch of 
eluted protein was analysed by Western blotting and quantified by BCA assay. The results 
show that the amount of protein was significantly enriched in purified human WFDC2 
(P=0.007) and mouse Wfdc2 (P=0.005) compared to the original media sample (Fig 3.6), as 
shown by a significant increase in signal when it was quantified by densitometry (Fig 3.7).  
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Figure 3.6. Western blot of WFDC2 enrichment from conditioned media to purified protein. 
Human (a) and mouse (b) WFDC2 was purified and enriched from conditioned media using a FLAG 
affinity resin and the eluted product was analysed by Western blotting using anti-FLAG monoclonal 
antibody. Equal volumes of sample were loaded per lane. Lane numbers represent the following: 1 – 
unconcentrated conditioned media before purification, 2 – unconcentrated conditioned media after 
purification, 3 – purified protein (N=2). (c) Purified human (4) and murine (5) WFDC2 loaded on the 
same Western blot for size comparison (N=3).  
 
 
Figure 3.7. Densitometry of Western blot for purified protein.  Densitometry results derived from 
analysis of Western blots comparing the protein expression in media before purification, after 
purification and the purified product for human (a) and mouse (b) recombinant protein (mean ± SD, 
N=2); ** P ≤ 0.01.  
 
To determine the intracellular localisation of WFDC2 when transfected into mammalian cells, 
NCI-H292 cells were transfected with human and mouse WFDC2 constructs. Cells were fixed 
and stained with anti-FLAG monoclonal antibody or anti-WFDC2 polyclonal antibody and 
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fluorescently labelled secondary antibody. Mock transfected cells were used as a negative 
control. NCI-H292 cells, rather than HEK293 cells, were chosen for transfection and imaging 
due to their more adherent nature. The cells are also larger so protein localisation within the 
cytoplasm is easier to visualise.   
The transfected cells showed an abundance of WFDC2 staining within the cytoplasm when 
analysed by immunofluorescence microscopy (Fig 3.8). Both human and mouse WFDC2 
appeared to exhibit a similar staining pattern.  
 
Figure 3.8. Immunofluorescence microscopy of NCI-H292 cells transfected with human and 
mouse WFDC2 constructs. Cells were transfected with human (a, c, d) or mouse (b) WFDC2 or empty 
vector (e, f) and then fixed and stained with anti-FLAG monoclonal antibody (Sigma) (a, b, e) or 
polyclonal anti-human WFDC2 (R&D systems) (c, d, f). Original magnification is 100X.  
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To determine the native conformation of the recombinant WFDC2 protein, both human and 
mouse WFDC2 were analysed by native PAGE gel and then analysed by Western blotting. 
Reaction conditions permitted the protein to retain its native conformation. 
The Western blot results show that recombinant human WFDC2 migrates through the native 
gel at ~26 kDa which is similar to denatured glycosylated WFDC2 protein (~24 kDa) (Fig 3.9a). 
Recombinant mouse Wfdc2 resolves at ~70 kDa in its native conformation (Fig 3.9b) 
compared to ~30 kDa in the denatured form.  
 
Figure 3.9. Western blot of recombinant WFDC2 analysed by native PAGE gel. Western blot 
analysis of recombinant human (a) and mouse (b) WFDC2 following resolution on a native PAGE gel. 
Western blots were probed using polyclonal antibodies against human WFDC2 and murine Wfdc2, 
respectively. Lane 1 and 2 represent the same gel of human WFDC2 but with different exposure times. 
Lane 3 shows murine Wfdc2 (N=1).  
 
3.5. WFDC2 glycosylation analysis 
Recombinant human WFDC2 resolved as two separate bands when analysed by Western 
blotting which is suggestive of glycosylated and non-glycosylated protein isoforms. To identify 
possible glycosylation sites, the peptide sequence of human WFDC2 (as described in the 
Ensembl database) was inputted into NetNGlyc and NetOGlyc glycan predictor software. 
Asparagine-44 was identified as a potential N-glycosylation site, as well as Threonine-33 as 
an O-glycosylation site – both glycosylated residues reside in exon 2 (see Appendix).  
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To confirm whether the ~24 kDa band of human WFDC2 represented glycosylation at Asn-
44, site-directed mutagenesis (SDM) was carried out using pVR1255 plasmid with human 
WFDC2 gene insert as the target sequence to substitute asparagine-44 for a glutamine 
residue. The SDM modified plasmid was isolated, sequenced and then subsequently 
transfected into mammalian cells. Conditioned media containing mutated WFDC2 was 
collected and analysed by Western blotting.  
The results show that SDM-modified WFDC2 resolves at the same molecular weight as the 
smaller ~18 kDa band of wild-type (WT) WFDC2 (Fig 3.10). WT WFDC2 digested with a 
glycosidase enzyme, PNGase F, to remove all N-glycans also resolves at a molecular weight 
of ~18 kDa with no upper 24 kDa visible. SDM-treated WFDC2 resolves at the same molecular 
weight as the glycosidase-treated control.    
 
Figure 3.10. Western blot of SDM-modified human WFDC2 protein compared to wild-type 
protein. SDM-modified WFDC2 compared to wild-type WFDC2 analysed by Western blotting using 
anti-FLAG monoclonal antibody. WFDC2 digested with PNGase F used as a control.  Lane numbers 
represent the following: 1 – human WFDC2 digested with PNGase F, 2 – SDM-modified human 
WFDC2, 3 – wild-type human WFDC2 (N=2).  
 
To further analyse the glycan structure of human WFDC2, the recombinant protein was 
digested with sialidase enzyme to remove any sialic acid residues present. The digested 
product was analysed by Western blotting. The results show that incubation of WFDC2 with 
sialidase induces a shift in molecular weight compared to the untreated control (Fig 3.11). 
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Figure 3.11. Western blot of human WFDC2 protein digested with sialidase enzyme compared 
to untreated control. Human WFDC2 digested with sialidase enzyme compared to untreated WFDC2 
analysed by Western blotting using anti-FLAG polyclonal antibody.  Lane numbers represent the 
following: 1 –untreated SDM-modified WFDC2, 2 – untreated wild-type WFDC2, 3 – wild-type WFDC2 
digested with sialidase enzyme (N=3).  
 
To determine whether the intracellular expression pattern of SDM-modified WFDC2 was 
affected compared to the WT protein, transfected NCI-H292 cells were analysed using 
immunofluorescence microscopy. SDM-modified WFDC2 was detected using anti-WFDC2 
polyclonal antibody followed by a fluorescently labelled secondary antibody. Mock transfected 
cells were used as a negative control. No change in intracellular localisation was visualised 
between cells transfected with WT WFDC2 and those transfected with SDM-modified WFDC2 
(Fig 3.12).    
 
Figure 3.12. Immunofluorescence microscopy image of NCI-H292 cells transfected with human 
SDM-modified WFDC2. Cells were transfected with SDM-modified WFDC2 and then fixed and stained 
with anti-FLAG monoclonal antibody (Sigma) (a) or polyclonal antibody reactive against human WFDC2 
(R&D systems) (b). Original magnification is 100X.  
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Recombinant murine Wfdc2 resolves as a single smeared band 26-34 kDa in size (see Fig 
3.6). This is distinctive to human WFDC2, which forms two separate bands due to the 
presence of an N-glycosylation site. The peptide sequence of murine Wfdc2 was analysed 
using NetNGlyc and NetOGlyc online glycan predictor software which predicted that the 
protein has 17 O-glycosylation sites, 15 of which are found in exon 3. There are no predicted 
N-glycosylation sites. When murine Wfdc2 was incubated with sialidase and analysed by 
Western blotting there was a visible shift in molecular weight between the digested and non-
digested forms (Fig 3.13). 
 
Figure 3.13. Western blot of murine Wfdc2 protein digested with sialidase enzyme compared to 
untreated control. Mouse Wfdc2 digested with sialidase enzyme compared to untreated Wfdc2 
analysed by Western blotting using anti-FLAG monoclonal antibody.  Lane numbers represent the 
following: 1 – untreated Wfdc2, 2 – Wfdc2 digested with sialidase enzyme (N=3).  
 
3.6. Endogenous expression of human WFDC2  
To assess whether WFDC2 is present in human saliva, 4 whole saliva samples from healthy 
non-smoking volunteers were analysed by Western blotting. Parotid gland saliva and 
submandibular/sublingual gland saliva from 1 healthy non-smoking volunteer were also 
analysed.  
The results show that human WFDC2 is present in all 4 human saliva samples, existing as 
what appears to be a glycosylated isoform at a molecular weight of ~25 kDa (Fig 3.14). Some 
non-glycosylated WFDC2 also appears to be present in saliva sample 2 (Lane 2). The parotid 
and submandibular/sublingual saliva are negative for WFDC2 as no band is visible at the 
expected molecular weight (~25 kDa).  
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A second band is also present at a molecular weight of ~150 kDa in all samples except for the 
parotid saliva. This may be due to non-specific antibody binding to another large protein within 
the saliva. Alternatively, it could represent binding of WFDC2 to a large protein causing the 
protein band for WFDC2 to shift. Mucins are abundant in saliva and have a high molecular 
weight. Mucin 7 (MUC7), a mucin abundant in saliva, has a predicted molecular weight of 130-
180 kDa. To determine whether the 150 kDa band in Fig 3.14 represented MUC7, the four 
WFDC2-positive whole saliva samples were also probed with anti-MUC7. The result shows 
that positive bands of ~150 kDa size are visible in blots probed with anti-MUC7 and anti-
WFDC2 (Fig 3.15).  
 
Figure 3.14. Western blot of WFDC2 expression in human saliva samples. Four whole saliva 
samples (1-4), a submandibular/sublingual saliva sample (5) and a parotid gland saliva sample (6) 
analysed by Western blotting against a control of recombinant human WFDC2 (7). Anti-WFDC2 
polyclonal antibody used for detection of protein (N=2).  
 
 
Figure 3.15. Western blot of MUC7 expression in human saliva samples. Four whole saliva 
samples (1-4), a submandibular/sublingual saliva sample (5) and a parotid gland saliva sample (6) 
analysed by Western blotting. Anti-MUC7 polyclonal antibody used for detection of protein (N=2).  
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To ensure that the ~25 kDa band in Western blots of saliva truly represented human WFDC2, 
a saliva sample was digested with PNGase F to remove all N-glycans. 
The Western blot analysis shows that glycosidase-digested saliva resolves on the gel at the 
same molecular weight as the non-glycosylated isoform of recombinant WFDC2 (~18 kDa), 
while the untreated saliva sample resolves at a similar molecular weight to the N-glycosylated 
isoform of recombinant WFDC2 (Fig 3.16). 
 
Figure 3.16. Western blot of human saliva digested with PNGase F compared to untreated saliva 
and recombinant WFDC2. Saliva digested with PNGase F was analysed by Western blotting using 
anti-WFDC2 polyclonal antibody and compared to an untreated saliva control and recombinant WFDC2. 
Lane numbers represent the following: 1 – recombinant human WFDC2, 2 – human saliva digested 
with PNGase F, 3 – untreated human saliva (N=2).  
 
To quantify the endogenous salivary concentration of WFDC2, saliva samples from 21 healthy, 
non-smoking volunteers were analysed using a WFDC2 ELISA. The mean concentration of 
WFDC2 in whole saliva was 139.3 nM with a range of 62.9 - 338.2 nM (Fig 3.17). The sample 
size for saliva analysis was not large enough to identify any differences in WFDC2 levels 
based on the age or gender of volunteers.  
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Figure 3.17. ELISA analysis of the concentration of WFDC2 in human saliva. ELISA analysis was 
used to indicate the endogenous expression levels of WFDC2 in saliva (n=21) derived from healthy 
volunteers. Samples were centrifuged to remove cells/debris and diluted according to the 
manufacturer’s recommendation prior to ELISA analysis. The mean ± SD of each data set are shown.  
 
To determine whether WFDC2 is secreted from healthy human lung cells, apical secretions 
from bronchial cells (derived from bronchial brushings) grown at an air-liquid interface (ALI) 
were analysed by Western blotting. Two apical secretions derived from cells of independent 
donors were analysed.  
The results show that WFDC2 is present in secretions from bronchial cells grown at an ALI 
(Fig 3.18). Both samples appeared to be abundantly glycosylated as the protein resolved at a 
molecular weight of ~25 kDa, which is comparable with the larger N-glycosylated band in the 
recombinant control. To support this hypothesis, an apical secretion sample (Lane 2 in Fig 
3.18) was digested using PNGase F to cleave away all N-glycans. The results show that the 
glycosidase-treated apical wash has the same molecular weight as non-glycosylated 
recombinant WFDC2 (~18 kDa) (Fig 3.19) which supports the theory that the positive bands 
accurately represent endogenous WFDC2 in bronchial secretions.   
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Figure 3.18. Western blot of WFDC2 expression in apical secretions from human bronchial cells. 
Two apical secretions from human bronchial cells grown at an air-liquid interface (1, 2) analysed by 
Western blotting against a control of recombinant human WFDC2 (3). Anti-WFDC2 polyclonal antibody 
used for detection of protein (N=2).  
 
 
Figure 3.19. Western blot of apical secretions from human bronchial cells digested with PNGase 
F compared to untreated secretions and recombinant WFDC2. An apical secretion of bronchial cells 
digested with PNGase F was analysed by Western blotting using anti-WFDC2 polyclonal antibody and 
compared to an untreated control and recombinant WFDC2. Lane numbers represent the following: 1 
– recombinant human WFDC2, 2 – untreated apical secretion, 3 – apical secretion digested with 
PNGase F (N=2).  
 
To quantify the concentration of WFDC2 in apical secretions from human bronchial cells, 
secretions from cells derived from 11 different donors were analysed using a WFDC2 ELISA 
(n=11). The mean concentration of WFDC2 in bronchial secretions was 86.4 nM with a range 
of 82.3 - 92.1 nM (Fig 3.20).  
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Figure 3.20. ELISA analysis of the concentration of WFDC2 in human lung ALI secretion. ELISA 
analysis was used to indicate the endogenous expression levels of WFDC2 in secretions from lung cells 
grown at an ALI (n=11). Samples were centrifuged to remove cells/debris and diluted according to the 
manufacturer’s recommendation prior to ELISA analysis. The mean ± SD of each data set are shown.  
 
3.7. Endogenous expression of murine Wfdc2 
To determine whether Wfdc2 is secreted from murine epithelial cells of the trachea (mTEC) 
and nasal cavity (mNEC), apical secretions from primary cells grown at an ALI were analysed 
by Western blotting. The results show that Wfdc2 is present in secretions from mTEC and 
mNEC cells grown at an ALI (Fig 3.21). The endogenous protein resolved slightly higher than 
that of recombinant Wfdc2, with a molecular weight of ~28-40 kDa compared to the 26-34 kDa 
recombinant protein.   
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Figure 3.21. Western blot of apical secretions from murine tracheal and nasal epithelial cells 
compared to recombinant Wfdc2. Apical secretions of murine tracheal epithelial cells (1) and nasal 
epithelial cells (2) analysed by Western blotting using anti-Wfdc2 polyclonal antibody, compared to 
recombinant murine Wfdc2 (N=2). 
 
3.8. Discussion 
Recombinant proteins are an effective resource for analysing protein function in vitro and are 
extensively used in research. To ensure that desired target proteins are produced to a high 
standard, cloning and expression systems should be carefully adapted with the end-product 
in mind. During this study, when synthesising WFDC2 orthologues for in vitro functional 
assays, the key considerations were that the recombinant proteins were correctly glycosylated 
and were also tagged with a marker to enable downstream purification. 
The vector utilised for WFDC2 production encoded a HCMV promoter and intron A upstream 
of the target gene insertion site to stimulate a high level of transcription (Chapman et al., 1991). 
A FLAG tag was incorporated into the reverse primer used for amplification of WFDC2 so that 
the tag was inserted immediately upstream of the stop codon. The inclusion of a FLAG tag, 
an eight-residue peptide (DYKDDDDK), was important for the downstream purification of 
WFDC2, as monoclonal antibodies raised against the FLAG epitope can be used for affinity 
purification using commercially available resins (Einhauer and Jungbauer, 2001). 
The most appropriate gene target for cloning of human WFDC2 was splice variant 0 (V0), 
often described as ‘full-length’ (FL) WFDC2. V0 is the only isoform that encodes both WFDC 
protein domains. Considering the potential for WFDC domains to establish distinct functions 
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within a single protein, as seen in SLPI (described in Section 1.3.2), it was important to 
produce a recombinant protein expressing both domains.  
Most of the expression analysis available in the literature utilises probes/antibodies that target 
FL WFDC2; consequently, very little is known about the expression profile of isoforms V1-V4 
(Bingle et al., 2002; Bingle et al., 2006; Drapkin et al., 2005; Kirchhoff et al., 1991). Preliminary 
RT-qPCR analysis using isoform-specific probes has shown that V0 is by far the most 
abundant isoform in the epididymis, breast, trachea and endometrium (Jiang et al., 2013). It 
is therefore likely that the lack of expression data pertaining to V1-V4 is due to their relative 
absence in comparison to V0. This data further supported the decision to discount V1-V4 as 
cloning targets.  
In the case of murine Wfdc2, very little is known about the expression of any of the splice 
variants. The limited data available in the literature and in unpublished data (Bingle, 
unpublished; Su et al., 2002; Kappler-Hanno and Kirchhoff, 2003) suggests that the FL murine 
Wfdc2 transcript (V0), encoding exons 1-5, is the most abundantly expressed variant (Section 
1.2.4). The fact that the rodent orthologue of Wfdc2 appears to have evolved an extra exon 
which serves to separate the two WFDC domains is interesting and could result in the protein 
exhibiting distinct functions to the human orthologue. Consequently, FL Wfdc2 was also 
targeted for protein synthesis.  
Following the successful insertion of both WFDC2 orthologues into vectors, the plasmids were 
utilised for transfection experiments. WFDC2 was initially transiently transfected into 
mammalian cells (HEK293) in a 24-well plate using two methods: FuGENE (a non-liposomal, 
lipid-based reagent) and calcium phosphate (a chemical method based on formation of a co-
precipitate between calcium phosphate and DNA). Western blot analysis showed that both 
transfection methods effectively induced expression of WFDC2 in the cell lysate. The band 
intensity was greater in lysate from cells transfected using FuGENE, suggesting that this 
method has a greater transfection efficiency and results in a greater protein yield (Fig 3.3). 
Nonetheless, the calcium phosphate method was also able to successfully induce production 
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of WFDC2 protein. Given the large yield of protein required for the intended downstream in 
vitro assays, the calcium phosphate method was taken forward as the chosen transfection 
method as it has been optimised for large scale experiments (Jordan et al., 1998) and is more 
cost-effective. The calcium phosphate transfection protocol was scaled-up for WFDC2 
production in T75 flasks. Co-transfection of the WFDC2 plasmid alongside a GFP-expressing 
vector gave a visual indication of the success/efficiency of the DNA delivery.  
The transient nature of the transfection method meant that WFDC2 secretion was finite, 
therefore an appropriate time-frame for protein collection was required. Conditioned media 
from the transfected cells was collected for 4 days and then analysed by Western blotting. The 
results demonstrated that human and murine WFDC2 secretion continued for 4 days of 
collection, although the band intensity was beginning to decrease by days 3-4 (Fig 3.5). By 
collecting the media and replacing it with fresh serum-free media, cells were maintained in 
nutrient-rich conditions and the protein was better protected from degradation by host-derived 
proteases due to daily harvesting. Serum-free media reduced the number of contaminating, 
undefined proteins in the conditioned media. 
HEK293 cells were chosen as the target cell line for transfection as mammalian cells are able 
to synthesise proteins with similar molecular structures to endogenous human/mouse 
proteins. The cells can produce complex glycosylated proteins, an important factor in the case 
of WFDC2 which has been shown to exhibit a complex glycan profile (Hua et al., 2014). 
Glycosylation can influence factors such as protein yield, clearance and stability, in addition 
to bioreactivity and immunogenicity (Moremen et al., 2012). HEK293 cells are used 
commercially to synthesise biotherapeutic proteins which demonstrates their suitability for 
production of recombinant peptides (Dumont et al., 2016). 
Recombinant WFDC2 was purified from the conditioned media of the transfected HEK293 
cells using an affinity resin with immobilised monoclonal antibody which binds to FLAG-tagged 
fusion proteins. The purified products were analysed by Western blotting using an anti-FLAG 
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monoclonal antibody for detection, and the results show a significant enrichment of WFDC2 
when compared to the original conditioned media (Fig 3.6).  
When the purified products were analysed using polyclonal antibodies raised against human 
and murine Wfdc2, a positive band of an identical molecular weight to that detected by anti-
FLAG antibody was visualised, supporting the identity of the recombinant protein.  
The molecular signature of Western blotted recombinant human WFDC2 showed two distinct 
bands, 18 kDa and 24 kDa in size, respectively (Fig 3.6c). The expected molecular weight of 
the protein is 13 kDa, however this discrepancy in size has already been reported in the 
literature (Drapkin et al., 2005; Hellström et al., 2003; Hua et al., 2014). It is hypothesised that 
the 24 kDa band results from the addition of N-glycans, predicted to be present at asparagine-
44. Human WFDC2 also has a predicted O-glycosylation site at threonine-33 and the presence 
of the FLAG peptide (1 kDa) would also increase the protein molecular weight above the 
predicted size. 
To confirm whether the 24 kDa band of human WFDC2 represented the presence of N-
glycans, the protein was subjected to digestion by PNGase F, an amidase enzyme capable of 
removing N-linked sugars from glycoproteins. Analysis of the cleaved product by Western 
blotting showed complete removal of the 24 kDa band, suggesting that it did indeed 
correspond to N-glycosylation. Although PNGase F treatment of WFDC2 has been carried out 
previously showing similar results (Drapkin et al., 2005), there is no finite evidence that the 
site of N-glycosylation is Asn-44, as is predicted using glycan predictor software. To confirm 
this theory, the human WFDC2 gene construct was targeted for site-directed mutagenesis 
(SDM), whereby the Asn-44 residue was converted to a Gln-44 amino acid. The substitution 
from one polar residue to another means it is unlikely that the protein folding of WFDC2 would 
be affected, while removal of the Asn residue prevents the post-translational addition of N-
linked sugars. When SDM-modified WFDC2 was analysed by Western blotting, the 24 kDa 
band was absent, thus showing that the upper band resulted from N-glycan linkages at Asn-
44 which add ~5 kDa to the molecular weight (Fig 3.10).  
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When PNGase F catalyses cleavage of N-glycans, the sugars that are cleaved away remain 
largely intact and this enables them to be further analysed. Analysis by Hua et al (2014) using 
mass spectrometry demonstrated that the N-linked sugars of recombinant human WFDC2 
consisted of complex biantennary structures with sialic acid residues present at the terminus 
of the sugar chains. To show that the protein produced in this study was correctly post-
translationally modified during synthesis, it was incubated with a sialidase enzyme (cloned 
from the Tannerella forsythia gene) which catalyses cleavage of sialic acid residues from the 
terminus of glycan chains. Western blot analysis demonstrated that the molecular weight of 
the protein was reduced following incubation with sialidase compared to the untreated control 
(Fig 3.11), suggesting that the protein is modified with complex oligosaccharides terminating 
with sialic acids, thus resembling its native structure. 
To further assess the quality of the protein, Western blot analysis was used to compare the 
recombinant protein with endogenous WFDC2. When whole saliva samples from healthy 
volunteers were analysed by Western blotting using an anti-WFDC2 polyclonal antibody, 
positive bands were present with a molecular weight of 24-32 kDa (Fig 3.14). The slightly 
higher molecular weight of salivary WFDC2 was hypothesised to represent differences in 
glycosylation, whereby endogenous WFDC2 exhibits more elaborate glycan structures than 
the recombinant protein. Similarly, when apical secretions derived from human bronchial cells 
cultured at an ALI were analysed by Western blotting, the same result was observed: positive 
bands were 24-30 kDa in size (Fig 3.16). 
To ensure that the ~30 kDa bands in saliva and ALI secretions represented WFDC2, the 
samples were digested with PNGase F and subjected to Western blot. The digested products 
resolved at the same molecular weight as the non-glycosylated (19 kDa) band of recombinant 
WFDC2 showing that the positive bands in saliva and ALI secretions did indeed represent 
WFDC2, albeit with a slightly more complex glycan profile.  
Interestingly, the saliva samples analysed by Western blotting were positive for WFDC2 at the 
expected molecular weight (~24 kDa) but also expressed an additional band that resolved at 
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a molecular weight of ~150 kDa (Fig 3.14). In contrast, when submandibular/sublingual 
(SMD/SL) and parotid secretions were analysed, a 24 kDa band was absent, but the SMD/SL 
secretions produced a positive band at 150 kDa. Given the abundance of mucins in saliva and 
their corresponding extensive molecular weight, it was hypothesised that the large band 
represented mucin 7, a secretory mucin abundant in saliva with a known molecular weight of 
~150 kDa. This theory was supported by the presence of the large band in SMD/SL secretions, 
which have a serous and mucinous component, whereas parotid serous secretions failed to 
express the large band. By probing the samples with an anti-MUC7 polyclonal antibody, a 
similar positive 150 kDa band was visible in all samples, aside from the parotid secretion which 
was negative for MUC7 (Fig 3.15).  
 It remains unclear whether the 150 kDa band in the WFDC2-probed blot resulted from 
WFDC2 binding to MUC7 or whether the anti-WFDC2 antibody simply bound non-specifically 
to MUC7 itself – further analysis would be required to elucidate any interactions between the 
two proteins. It should be noted, however, that there is evidence in the literature suggesting 
that WFDC2 forms interactions with mucins. During proteomic analysis of apical secretions 
from tracheobronchial epithelial (TBE) cells and induced sputum from healthy donors (Kesimer 
et al., 2009; Radicioni et al., 2016) WFDC2 was identified within the mucin-rich pool of proteins 
rather than in the protein-rich fraction of lower molecular weight proteins. Mucins are 
extensively glycosylated and have the capacity to bind to smaller glycosylated proteins even 
following treatment with strong denaturants (Radicioni et al., 2016). Other low molecular 
weight proteins with putative host defence functions were detected in the high-density fraction, 
including SLPI and BPI-fold containing family protein B1 (BPIFB1) (Radicioni et al., 2016). 
BPIFB1 is already known to co-localise with mucin 5B (MUC5B), which perhaps explains its 
presence in the high-density pool (Bingle et al., 2013; Bingle et al., 2012). It is hypothesised 
that these proteins associate with mucins to form an ‘interactome’, consequently altering the 
properties of the mucosal surface and enhancing the defensive properties of the mucosa 
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(Radicioni et al., 2016). It is feasible that WFDC2 interacts with mucins in order to contribute 
to mucosal properties.  
When recombinant murine Wfdc2 was analysed using the same Western blotting and enzyme 
digestion techniques, it resolved as a smeared band ranging from 26 kDa to ~34 kDa. The 
predicted molecular weight of murine Wfdc2 is 18 kDa, however this discrepancy can again 
be attributed to the presence of an abundance of glycans, identified using glycan predictor 
software. Wfdc2 has 17 predicted O-glycosylation sites, 15 of which are found within the exon 
3 encoded linker region found in rodents (see Appendix). No N-glycosylation sites were 
predicted. To confirm that the smeared band did indeed result from the presence of a multitude 
of sugars, the protein was subjected to sialidase digestion and was analysed by immunoblot. 
The digested protein showed a significant shift in molecular weight compared to the 
undigested control (Fig 3.13), suggesting that the recombinant protein is heavily glycosylated 
with complex O-glycans and that sialic acid residues are present at the termini of the sugar 
chains.  
Denatured murine Wfdc2 also shows a secondary band at ~50 kDa when analysed by Western 
blotting. Given that the molecular weight of murine Wfdc2 can be as low as ~24 kDa 
(presumably when in its deglycosylated form), it is possible that the protein is able to form a 
dimer. The recombinant protein was thus resolved on a native PAGE gel, which permits 
analysis of proteins in their natural conformation, avoiding disruption of protein complexes. 
The resultant immunoblot showed that murine Wfdc2 resolved at ~68 kDa, suggesting that the 
protein was capable of forming a dimer. Further analysis is required to determine whether this 
theory is correct. Human WFDC2 resolves on a native gel at ~26 kDa, suggesting that it does 
not form any protein complexes. Given that both proteins are extensively glycosylated, it 
seems unlikely that murine Wfdc2 resolves at a higher molecular weight due to the presence 
of oligosaccharides, as a similar result would be expected with human WFDC2. If murine 
Wfdc2 does indeed form a dimer, it is possible that the exon 3 linker is involved in the 
interaction, as this is the key difference between the structure of the two orthologues.  
110 
 
To more closely understand whether the recombinant murine protein resembles endogenous 
Wfdc2, Western blot analysis was performed using apical secretions derived from murine 
tracheal and nasal epithelial cells grown at an ALI. The immunoblot results showed that 
endogenous Wfdc2 resolved at a slightly higher molecular weight than recombinant protein, 
as was seen with human WFDC2. This analysis shows that recombinant proteins produced 
by HEK293 cells formed complex glycans with terminal sialic acids, however the glycan profile 
of endogenous proteins remained more extensive. 
The aim of synthesising human and murine WFDC2 protein was to use the recombinant 
protein in in vitro antimicrobial and anti-protease functional assays. In order to make the 
assays as biologically relevant as possible, it was important to identify a suitable concentration 
of protein to use. The literature is devoid of any quantitative analysis of WFDC2 levels at 
mucosal sites, aside from a study which tested the WFDC2 concentration in vaginal secretions 
from 18 healthy women. The ELISA analysis described a median WFDC2 concentration of 
108 nM (and a range of 2.6 to 429 nM). All remaining quantitative assessments of WFDC2 
are limited to serum levels in diseased patients, whereby WFDC2 serum concentrations tend 
to exist within the picomolar range.  
To enhance the understanding of WFDC2 expression in human mucosal secretions, ELISA 
analysis was used to quantify WFDC2 at sites hypothesised to express the protein. For 
instance, IHC has demonstrated that WFDC2 is abundantly produced in human salivary 
glands, where it is largely localised to the ducts (Fig 1.8). This ductular expression suggests 
that WFDC2 is secreted from salivary glands and is subsequently present in saliva – a theory 
that has been confirmed using Western blotting within this study (Fig 3.14). When analysed 
by ELISA, saliva samples contained a mean WFDC2 concentration of 139 nM, a level that is 
comparable to the concentration of SLPI detected in saliva as described in the literature (Lin 
et al., 2004; Shugars, 1999) 
IHC has also shown that WFDC2 is expressed in the airway epithelium and in submucosal 
glands, suggesting that the protein is secreted at the mucosal surface of the airways. In ALI 
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secretions from lung cells, a mean concentration of 86 nM of WFDC2 was identified. 
Quantification of WFDC2 in the airways and salivary glands was important for determining a 
biologically relevant concentration of recombinant protein to use in the downstream functional 
assays. 
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Chapter 4 
Investigating the putative host defence functions of WFDC2 
 
4.  
4.1. Introduction 
The antimicrobial and anti-protease activities of recombinant SLPI and elafin have been 
studied extensively in the literature using standard in vitro assays (Fernie-King et al., 2002; 
Gomez et al., 2009; Hiemstra et al., 1996; Si-Tahar et al., 2000; Wiedow et al., 1998). In 
comparison, WFDC2 has received very little attention, with only four functional analyses 
reported. The evidence so far suggests that neither recombinant human or murine WFDC2 
are incapable of exhibiting antibacterial activity, however, further analysis is required to 
substantiate this theory (Hua et al., 2014; Nishimura et al., 2008). The anti-protease activity of 
recombinant human WFDC2 has undergone limited analysis, which appears to show that the 
protein is capable of protease inhibition against serine proteases and matrix metalloproteases 
(LeBleu et al., 2013; Chhikara et al., 2012). However, the concentration of protein required to 
elicit such effects differs widely between studies and often reaches high micromolar levels that 
are not physiologically relevant. Consequently, the assays described in this chapter will be 
carried out using levels of WFDC2 that are considered to be biologically relevant. Finally, two 
reports have suggested that WFDC2 is not significantly upregulated in response to pro-
inflammatory mediators, as shown by RT-PCR (Bingle et al., 2006; Clauss et al., 2010). To 
verify these results, primary human salivary gland cells will be exposed to pro-inflammatory 
cytokines in the same way but changes in gene expression will instead be quantified using 
RT-qPCR, to improve the sensitivity of the assay.  
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4.2. Aims and objectives 
The aim of the work presented in this chapter was to identify whether WFDC2 is capable of 
significant antimicrobial and/or anti-protease activity, as hypothesised in the literature. 
Recombinant human and murine WFDC2 orthologues were used for in vitro assays to assess 
bacterial binding, killing and agglutination activity, as well as the capacity to inhibit biofilm 
formation or disrupt formed biofilms. The serine protease inhibitory activities of WFDC2 
orthologues were assessed using chromogenic substrates, while the effect of WFDC2 on 
MMP activity was measured by zymography. Additionally, RT-qPCR was used to quantify 
changes in WFDC2 expression in human primary cells when exposed to pro-inflammatory 
mediators. 
4.3. Materials and methods 
To access the relevant materials and methods utilised in this chapter, please refer to the 
sections below: 
• Protease inhibition assays were optimised as per Section 2.6. Serine protease assays 
and zymography analysis were performed as described in Section 2.6.2 and 2.6.3, 
respectively. 
• Bacteria were confirmed to be the expected strains as described in Section 2.7.1 via 
colony PCR and 16S sequencing (Section 2.7.3). Culture methods are defined in 
Section 2.7.2. Bacterial assays, including viability, binding, agglutination and biofilm 
assays are described in Section 2.7.4 to 2.7.11.  
• Culture conditions for propagation of primary salivary gland cells are defined in Section 
2.1.1. Cytokine exposure assays were performed as described in Section 2.8. 
Changes in gene expression were quantified using RT-qPCR, as outlined in Section 
2.2.5.  
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4.4. Analysis of protease inhibitory activity  
To establish whether WFDC2 is capable of inhibiting serine proteases, both WFDC2 
orthologues were incubated with trypsin and elastase. The effect on enzyme activity was 
monitored by measuring chromogenic substrate digestion via the subsequent accumulation of 
cleaved p-nitroanilide (p-NA).  
Firstly, trypsin and elastase were incubated with substrate alone (without WFDC2 or inhibitor 
controls) for 15 minutes at 37°C to ensure that the enzymes were active against their chosen 
chromogenic substrate. Different concentrations of enzyme (as used in(Erlanger et al., 1961 
and Gauthier et al., 1982) were tested against a fixed concentration of substrate to identify 
suitable reaction parameters. Enzyme concentrations that induced a change in absorbance of 
~0.3 were chosen for downstream protease inhibition experiments to allow scope for 
visualising any reduction in activity and so that the maximum substrate cleavage was a similar 
value for both trypsin and elastase experiments (Fig 4.1).  
 
Figure 4.1. Optimisation of enzyme concentration for use in protease inhibition assays. The rate 
of chromogenic substrate hydrolysis following exposure to increasing concentrations of trypsin (a) and 
elastase (b) was assessed by measuring the absorbance at 405 nm. The mean absorbance value of 
substrate alone (without enzyme) was subtracted from all other readings to account for background.  
Data represents the mean ± SD (n=3). 
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To assess the effect of WFDC2 on enzyme activity, WFDC2 protein (0, 100, 200, 500 and 
1000 nM) was pre-incubated with a fixed concentration of trypsin or elastase for 15 minutes 
to allow for binding between the potential inhibitor and enzyme substrate. Chromogenic 
substrate was added and the reaction was incubated for 15 minutes at 37°C. The reaction 
was quenched and the absorbance measured at 405 nm. Recombinant human SLPI (0, 100, 
200, 500 and 1000 nM) and a broad-spectrum protease inhibitor (PI) solution (added in 
sequentially increasing volumes) were used as controls for the assay.  
The results show that neither human or murine WFDC2 has any significant effect on trypsin 
activity at concentrations as high as 1000 nM (Fig 4.2a) (P=0.86 and P=0.2, respectively). The 
positive controls caused a significant reduction in trypsin activity, with SLPI causing a 50% 
decrease in enzyme activity at 500 nM (P=0.0003). The broad-spectrum PI solution induced 
an 80% reduction in trypsin activity even at a dilution 20-fold lower than the working 
concentration recommended by the manufacturer for total protease inhibition (see data point 
in line with 100 nM) (P=0.0001). Increasing the concentration of PI solution further had no 
greater inhibitory effect on trypsin. 
When incubated with elastase, the broad-spectrum PI solution appeared to cause a significant 
decrease in enzyme activity and, at the manufacturer’s recommended working concentration, 
elastase activity decreased by 60% (see data point in line with 1000 nM) (P=0.0001). On the 
other hand, human WFDC2, murine Wfdc2 and SLPI all failed to inhibit the activity of elastase. 
Instead, all three WFDC proteins appeared to cause an increase in substrate digestion (by 
21%, 28% and 13% respectively) compared to the no inhibitor control (Fig 4.2b). 
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Figure 4.2. Serine protease inhibitory activity of human and mouse WFDC2. The effect of WFDC2 
orthologues, SLPI and PI solution on trypsin (a) and elastase (b) activity were measured by monitoring 
changes in absorbance at 405 nm which represents chromogenic substrate hydrolysis. The mean 
absorbance of substrate alone was subtracted from all readings to account for background.  Results 
are expressed as a percentage reduction in enzyme activity with reactions without inhibitor representing 
100% enzyme activity. Data represents the mean ± SD (n=3). Significance value is calculated as activity 
compared to enzyme without inhibitor; ** P ≤ 0.01; *** ≤ 0.001; ≤ 0.0001.  1The PI solution was of an 
unknown concentration but was added in increasing volumes. Data point in line with 1000 nM 
represents the working concentration of PI solution recommended by the manufacturer.           
 
To determine whether WFDC2 orthologues are capable of gelatinase inhibition, increasing 
amounts of recombinant WFDC2 were incubated with fixed amounts of matrix 
metalloproteinases, MMP2 and MMP9, and subsequently analysed using zymography. MMP 
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activity was measured by analysing the bands of gelatin digestion which are visible following 
Coomassie staining of the gelatin gel.  
The results show that neither human or mouse WFDC2 were capable of significantly inhibiting 
MMP2 or MMP9 activity, even when an enzyme-to-WFDC2 ratio of 1:50 was explored i.e. 500 
ng of WFDC2 (Fig 4.3). No difference in band size resulting from gelatin digestion was visible 
at any WFDC2 concentration tested. 
 
Figure 4.3. Gelatinase inhibitory activity of human and mouse WFDC2. The effect of increasing 
amounts of human (a) and mouse (b) WFDC2 on the activity of MMP2 and MMP9 were measured using 
zymography. Gelatin digestion is visible as clear bands in the Coomassie-stained gelatin gel. MMP 
digestion is indicated (white arrows). Representative images shown (N=3).  
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4.5. Analysis of antimicrobial activity  
The antimicrobial properties of human and murine WFDC2 were assessed against 
Streptococcus mutans, Streptococcus gordonii, Streptococcus pneumoniae and Escherichia 
coli. Each bacterial strain cultured was confirmed to be the expected species by colony PCR 
followed by 16S rDNA sequencing. In all assays, FLAG peptide elution solution was used as 
a control.  
4.5.1. Binding assay 
The capacity of WFDC2 to bind to bacteria was measured using traditional pull down assays. 
Purified human and murine WFDC2 proteins were incubated with bacteria for 2 hours at 37°C 
and then cells were washed extensively to remove unbound protein. The bacterial pellet was 
analysed by Western blotting to determine whether any protein had bound to the bacteria.  
Human and murine WFDC2 appeared to be incapable of binding to the bacteria tested, as 
indicated by the absence of WFDC2 protein in the lysed bacterial pellet (Fig 4.4). Similarly, no 
binding was detected in the FLAG elution buffer control. The anti-FLAG monoclonal antibody 
appeared to bind non-specifically to S. gordonii, S. mutans and S. pneumoniae as bands of 
the incorrect size were present in lanes lacking WFDC2 protein.  
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Figure 4.4. Binding capacity of WFDC2 orthologues to bacteria. The capacity of WFDC2 to bind to 
E. coli (a), S. gordonii (b), S. mutans (c) and S. pneumoniae (d) was measured by pull down assay and 
subsequent Western blotting using anti-FLAG monoclonal antibody. Lane numbers in each blot 
represent the following: 1 – bacterial pellet with bound human WFDC2, 2 – unbound human WFDC2, 3 
– bacterial pellet with bound mouse Wfdc2, 4 – unbound mouse Wfdc2, 5 – bacterial pellet with bound 
FLAG elution buffer, 6 – unbound FLAG elution buffer. Representative images shown (N=3).  
 
4.5.2. Viability assays 
The effect of WFDC2 on bacterial viability was analysed using two methods. Firstly, a 
traditional method was used which involved incubating bacterial suspension with purified 
WFDC2 (0.5 and 1.0 µM). The bacterial suspension was incubated at 37°C for 3 hours and 
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then plated out via the Miles-Misra technique. The following day the number of colony forming 
units (CFU) in the original bacterial suspension were determined.  
The results show that incubation of human or mouse WFDC2 with any of the four bacteria 
strains tested had no effect on the bacterial viability either at 0.5 µM (data not shown) or at 1 
µM (Fig 4.5). There was no significant difference in the number of CFU per millilitre (CFU/ml) 
formed in the presence of WFDC2 compared to FLAG peptide or PBS negative controls.     
 
Figure 4.5. The effect of WFDC2 orthologues on bacterial viability analysed using the Miles-
Misra technique. Bacterial suspensions of E. coli (a), S. gordonii (b), S. mutans (c) and S. pneumoniae 
(d) were incubated with WFDC2 (1 µM) or controls and plated out using the Miles-Misra technique to 
determine the number of CFU/ml formed in the presence of WFDC2. Data represents the mean ± SEM 
(N=3; n=3). 
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The effect of WFDC2 on bacterial viability was also monitored by measuring changes in 
absorbance of bacterial suspension over time to produce a growth curve. Briefly, bacterial 
culture was inoculated with WFDC2 protein (1.0 µM) and seeded into a 96 well plate. The 
optical density of each well was measured at 600 nm every 30 minutes for 12 hours using a 
microplate reader.  
The results show that the addition of human or mouse WFDC2 to bacterial culture had no 
significant effect on bacterial growth when compared to untreated bacteria, or bacteria 
incubated with FLAG peptide elution buffer or PBS (Fig 4.6). Conversely, bacterial growth was 
significantly inhibited when cells were exposed to ampicillin (60 µg/ml). No change in 
absorbance was visible in wells loaded with sterile broth, showing that wells were not 
contaminated during incubation in the plate reader overnight.  
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Figure 4.6. The effect of WFDC2 orthologues (1 µM) on bacterial viability analysed using the 
growth curve technique. Suspensions of E. coli (a), S. gordonii (b), S. mutans (c) and S. pneumoniae 
(d) were incubated with WFDC2 protein overnight. Changes in suspension optical density at OD600 were 
measured every 30 minutes for 12 hours using a plate reader to produce a growth curve. Data 
represents the mean ± SD (n=3); * P ≤ 0.0001. 
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To determine whether bacteria were exposed to insufficient WFDC2 to induce a reduction in 
bacterial viability, the assay was repeated against S. gordonii and S. mutans with a greater 
concentration of WFDC2 (3 µM). The same controls were used as before but volumes were 
adjusted to account for the increased volume of WFDC2 added. 
The data shows that exposure of S. gordonii and S. mutans to a 3-fold higher concentration 
of the WFDC2 orthologues caused no change in bacterial growth (Fig 4.7) as no significant 
difference in bacterial viability was identified following exposure to WFDC2 or the negative 
controls. Incubation with ampicillin induced a significant reduction in bacterial viability.  
 
 
 Figure 4.7. Analysis of the effect of WFDC2 orthologues (3 µM) on bacterial viability using the 
growth curve technique. The growth curve viability assay was repeated using S. gordonii (a) and S. 
mutans (b) suspensions which were incubated with a 3-fold higher WFDC2 concentration (3 µM). Data 
represents the mean ± SD (n=3). * P ≤ 0.0001. 
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To determine whether recombinant WFDC2 was digested by bacteria during the 12-hour 
growth curve incubation, the protein was incubated with bacteria overnight at 37°C and then 
analysed by Western blotting to determine whether any obvious digestion had occurred.  
Overnight incubation with bacteria and WFDC2 appeared to induce some protein degradation 
(Fig 4.8). Glycan cleavage was identifiable in human WFDC2 incubated with S. gordonii and 
S. pneumoniae as evidenced by the reduction in band intensity of the upper glycosylated band 
of human WFDC2 (Fig 4.8a). The glycans of murine Wfdc2 also appeared to be cleaved when 
incubated with S. pneumoniae, as visualised by a reduction of the molecular weight of the 
smeared murine Wfdc2 band (Fig 4.8b).  
Protein degradation was analysed semi-quantitively using densitometry. The results show that 
the signal derived from human WFDC2 following incubation with S. gordonii and S. mutans 
was significantly reduced compared to WFDC2 that had been incubated with PBS only (Fig 
4.8c). All other bacteria failed to significantly reduce the signal, suggesting that the majority of 
the WFDC2 protein remained intact. The densitometry results for murine Wfdc2 show that 
overnight incubation with all four strains fails to produce a significant reduction in signal 
compared to the PBS control, suggesting that the protein is not degraded by the bacteria (Fig 
4.8d). 
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Figure 4.8. The degradative capacity of bacteria against WFDC2 proteins. Bacteria were incubated 
with both WFDC2 orthologues overnight at 37°C. The bacteria were pelleted and the human (a) and 
mouse (b) WFDC2 protein in the supernatant was analysed by Western blotting using anti-FLAG 
monoclonal antibody. Lane references represent the following: EC – WFDC2 incubated with E. coli, SG 
– WFDC2 incubated with S. gordonii, SM – WFDC2 incubated with S. mutans, SP – WFDC2 incubated 
with S pneumoniae, PBS – WFDC2 incubated with PBS (N=2; representative images shown). 
Densitometry values from Western blots of human (c) and mouse (d) WFDC2 are shown (mean ± SD, 
N=2); * P ≤ 0.05. 
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4.5.3. Agglutination assay 
The ability of WFDC2 to induce bacterial agglutination was measured by incubating purified 
WFDC2 with fluorescein isothiocyanate (FITC) labelled bacteria. In brief, optimised numbers 
of bacteria (see Appendix) were labelled with FITC, washed and resuspended with WFDC2 
(1 µM) overnight to test the capacity of WFDC2 to agglutinate bacteria. Saliva was used as a 
positive control for agglutination.  
The results show that the WFDC2 orthologues are unable to induce agglutination in the 
bacterial strains tested, as determined by the ‘pellet’ of non-agglutinated cells visible in each 
well (Fig 4.9). The saliva positive control induced agglutination in all four strains tested as 
indicated by the film of bacteria and lack of bacterial pellet. The negative controls also failed 
to induce agglutination. 
 
Figure 4.9. The agglutination capacity of WFDC2 orthologues. FITC-stained E. coli, S. gordonii, S. 
mutans and S. pneumoniae were incubated with human and mouse WFDC2 (1 µM) overnight to 
determine the capacity of WFDC2 to induce agglutination. Saliva was used as a positive control. FLAG 
peptide and PBS were used as negative controls (N=2, n=3; representative images shown).  
 
4.5.4. Biofilm formation and disruption assays 
The ability of WFDC2 to inhibit the formation of bacterial biofilms was tested by incubating 
recombinant WFDC2 (1 µM) with bacterial culture for 48 hours in a 96 well plate. The resultant 
biofilms were stained with 0.1% crystal violet and then solubilised in acetic acid, enabling the 
biofilms to be quantified using a microplate reader. Wells incubated with sterile broth were 
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stained and the absorbance reading was subtracted from all other values to account for 
background. 
The results show that human and mouse WFDC2 are incapable of significantly inhibiting the 
formation of biofilms in all bacteria tested compared to control wells containing untreated 
bacteria (Fig 4.10). Similarly, the FLAG peptide elution solution, saliva and PBS controls had 
no significant effect on biofilm formation. 
 
Figure 4.10. The effect of WFDC2 orthologues on bacterial biofilm formation. E. coli (a), S. gordonii 
(b), S. mutans (c) and S. pneumoniae (d) were exposed to human and mouse WFDC2 for 48 hours. 
The biofilms that formed in the presence of WFDC2 were stained and quantified. Statistical significance 
was calculated against untreated control. Data represents the mean ± SEM (N=3; n=3).  
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The capacity of WFDC2 to disrupt bacterial biofilms that are already established was also 
tested by adapting the method described above. Bacterial cultures were incubated in a 96 well 
plate for 24 hours, allowing time for biofilms to begin to form within the well. After 24 hours, 
recombinant WFDC2 (1 µM) was added to the bacteria and incubated for a further 24 hours. 
Adherent biofilms were then stained and quantified as before.  
The results show that the WFDC2 orthologues and controls are incapable of significantly 
disrupting biofilms in E. coli, S. gordonii and S. pneumoniae when compared to the wells 
containing bacteria alone (Fig 4.11). Interestingly, incubation of WFDC2 orthologues with S. 
mutans appears to significantly enhance the biofilms produced compared to the untreated 
control, however this enhancement is also evident when S. mutans is incubated with FLAG 
peptide and PBS controls. Saliva had no significant effect on the biofilms of S. mutans 
compared to the untreated control.  
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Figure 4.11. The effect of WFDC2 orthologues on bacterial biofilm disruption. E. coli (a), S. 
gordonii (b), S. mutans (c) and S. pneumoniae (d) biofilms that had grown over 24 hours were exposed 
to human and mouse WFDC2 and incubated with the protein for a further 24 hours. The resultant 
biofilms were stained and quantified to determine the effect of WFDC2 on biofilm disruption. Statistical 
significance was calculated against untreated control. Data represents the mean ± SEM (N=3; n=3); 
*PI≤ 0.05.  
 
4.6. WFDC2 expression in salivary gland cells  
To analyse the endogenous expression of all five WFDC2 splice variants using RT-PCR, 
primers were designed to span exon-exon boundaries and amplify individual isoforms. PCR 
conditions for the multiple primer pairs were optimised by testing three different annealing 
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temperatures (55°C, 60°C and 65°C) while the length of the annealing step and the number 
of cycles was kept constant (1 minute and 35 cycles, respectively). 
The results demonstrated that 60°C was the optimal annealing temperature as all bands were 
present at the expected size with minimal primer dimers forming (Fig 4.12). At an annealing 
temperature of 55°C and 65C, the V1 and V4 primers produce PCR products of the incorrect 
size. All subsequent splice variant RT-PCR reactions were carried out using an annealing 
temperature of 60C.  
 
Fig 4.12. Optimisation of PCR conditions for splice variant-specific primers. Different annealing 
temperatures for five primer pairs targeting WFDC2 splice variants were tested using PCR to identify 
optimal thermal cycling conditions. CAL27 cancer cell line cDNA was used as the template as it 
expresses high levels of WFDC2 (see Section 5.5). PCR products were resolved on a 2% agarose gel. 
Expected band sizes were V0: 105 bp; V1: 132 bp; V2: 97 bp; V3: 75 bp; V4: 85 bp. 
 
The endogenous WFDC2 expression in primary human sublingual gland (HuSL) cells derived 
from explanted human sublingual tissue was analysed by RT-PCR. Expression of all five splice 
variants was assessed semi-quantitatively using the aforementioned exon-spanning primers 
and the housekeeping gene, ornithine decarboxylase antizyme 1 (OAZ1), was used as the 
endogenous control. PCR products were resolved by agarose gel electrophoresis. 
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The RT-PCR results show that there is very low endogenous expression of V0, V1, V3 and 
V4 WFDC2 splice variants in HuSL cells when compared to the OAZ1 control (Fig 4.13).  
 
Fig 4.13. RT-PCR analysis of WFDC2 splice variant expression in HuSL cells. Primers specific to 
WFDC2 splice variants were used to probe primary human sublingual gland (HuSL) cell cDNA using 
RT-PCR to detect WFDC2 expression. PCR products were resolved on a 2% agarose gel. Expected 
band sizes were V0: 105 bp; V1: 132 bp; V2: 97 bp; V3: 75 bp; V4: 85 bp; OAZ1 endogenous control: 
164 bp (N=2).  
 
4.6.1. Cytokine exposure assay 
To determine whether the expression of WFDC2 in HuSL cells could be upregulated in 
response to inflammatory mediators, the cells were exposed to LPS (50 µg/ml), TNF-α (20 
ng/ml), IL-1ß (20 ng/ml) and IFN-γ (5 ng/ml) for 24 hours. RT-qPCR was then carried out to 
quantify WFDC2 expression and determine whether expression was affected following 
cytokine treatment when compared against the untreated control cells.   
The RT-qPCR analysis shows that when HuSL cells were exposed to LPS, TNF-α, IL-1ß and 
IFN-γ for 24 hours, no significant change in WFDC2 expression was seen when compared to 
the untreated controls (Fig 4.14).  
132 
 
 
Fig 4.14. RT-qPCR analysis of WFDC2 expression in HuSL cells following exposure to 
inflammatory mediators. WFDC2 expression in human primary sublingual gland (HuSL) cells was 
tested by RT-qPCR following exposure to inflammatory mediators: LPS (50 µg/ml), TNF-α (20 ng/ml), 
IL-1ß (20 ng/ml) and IFN-γ (5 ng/ml). WFDC2 expression is represented as the fold change in 
expression compared to the untreated HuSL cell controls. Data represents the mean ± SD (N=3; n=3).  
 
 
4.7. Discussion 
The aim of the work described in this chapter was to address the shortfalls in the literature 
regarding the putative anti-protease and antimicrobial functions of WFDC2. The development 
of recombinant human and murine WFDC2 protein, described in Chapter 3, provided tools to 
assess the biological activities of WFDC2 using in vitro functional assays.  
The experiments were performed using concentrations of WFDC2 that were determined to be 
biologically relevant. Assessment of endogenous protein levels present at sites with the 
highest predicted WFDC2 expression, namely the salivary glands and upper airways, 
exhibited mean concentrations of 139 nM and 86 nM respectively. These values were similar 
to the median level of WFDC2 detected in vaginal secretions, as reported by Orfanelli et al 
(2014). The highest recorded concentration of WFDC2 in secretions was that defined by 
Orfanelli in vaginal secretions of a patient where WFDC2 levels reached 429 nM. With these 
values in mind, the assays described in this chapter were largely performed using 1 µM of 
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WFDC2, which takes into account that the endogenous concentration may be elevated in 
response to factors such as pro-inflammatory mediators and infectious agents, or due to 
binding to mucosal/tooth surfaces where the protein may become enriched. The literature is 
lacking in quantitative expression data for WFDC2, aside from the serum concentrations of 
cancer patients (which are found at picomolar levels), which suggests that previous studies 
have utilised an arbitrary concentration of recombinant WFDC2 which may not be 
representative of the biological levels found in the body.  
Since its discovery in 1991, WFDC2 has been proposed to function as a host-derived serine 
protease inhibitor due to its possession of two WFDC domains which, in SLPI and elafin, have 
been shown to confer protease inhibitory properties (Kirchhoff et al., 1991). Within this study, 
recombinant WFDC2 was used in anti-trypsin and anti-elastase in vitro assays to determine 
whether it is indeed capable of inhibitory activity. 
Interestingly, the results from this study showed that WFDC2 orthologues had no significant 
effect on trypsin activity when compared to the activity of trypsin alone (without inhibitor). SLPI, 
on the other hand, was able to reduce the activity of trypsin by ~50% at a concentration of 500 
nM, an IC50 similar to that described in the literature (Masuda et al., 1995). At a concentration 
of 1 µM, SLPI was able to induce similar levels of trypsin inhibition to a broad-spectrum 
protease inhibitor solution (PI).  
Contrary to the anti-trypsin assay, analysis of elastase inhibition showed SLPI to have no 
inhibitory effect on elastase activity. It is unclear why SLPI failed to inhibit elastase within the 
parameters of this experiment, given its well documented potency as an elastase inhibitor 
(Masuda et al., 1995; Smith and Johnson, 1985; Ying et al., 1994; Ying and Simon, 1993). 
Two different sources of elastase were assayed, to discount the possibility that the problems 
resulted from an impure source of enzyme, but the same result was seen. Evidence in the 
literature suggests that SLPI is sensitive to oxidation, whereby exposure to oxidative agents 
can cause the inhibitor to be inactivated (Boudier and Bieth, 1994). Given that elastase and 
trypsin both bind to the same active site (Eisenberg et al., 1990), the discrepancy in SLPI 
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activity between the anti-trypsin and anti-elastase assays suggests that the problem resides 
specifically in the reaction conditions when using elastase, as a disrupted active site would 
affect trypsin inhibition too. It is possible that the buffer used in the elastase assay has affected 
SLPI activity as it contained 10% DMSO which was required for solubilisation of the substrate. 
DMSO may have induced oxidation of SLPI and inhibited its activity as a protease inhibitor.  
It is also unclear why the presence of SLPI and WFDC2 not only failed to inhibit elastase 
activity, but instead appeared to cause its activity to significantly increase. Interestingly, the PI 
control retained its capacity to inhibit elastase. The fact that the PI solution continued to elicit 
inhibitory activity within the experiment parameters adds complexity to the issue, as all 
potential inhibitors (PI, SLPI and WFDC2) were exposed to identical reaction conditions.  
When considering the results from the trypsin inhibitory assay, the disparity in activity between 
SLPI and WFDC2 can perhaps be explained by the differences in the structure of their WFDC 
domains. As described in Section 1.1.4 and 1.3.5, SLPI has a highly conserved pattern of 
cysteine residues within its C-terminal WFDC domain which confers protease inhibitory 
activity. This domain has an identical cysteine spacing to that seen in the WFDC motif of elafin, 
another proven protease inhibitor. No other members of the WFDC protein family have been 
shown to exhibit anti-protease activity as a result of their WFDC domain [although some 
members encode other domains which confer protease inhibition, such as eppin’s Kunitz 
domain (Wang et al., 2007)] and this corresponds with an absence of this cysteine pattern. 
Consequently, it has been suggested that the conserved domain structure of SLPI and elafin 
is an essential requirement for protease inhibition (Bingle and Vyakarnam, 2008). The fact that 
WFDC2 has an alternative, more closely aligned cysteine pattern suggests that the active site 
would not permit binding of a protease ligand.  
Murine Wfdc2 has a different structure to human WFDC2, with the aforementioned exon 3 
linker serving to separate the two WFDC domains (Section 1.2.4). This, however, does not 
appear to have sufficiently altered the structure in a way that permits the orthologue to exhibit 
anti-trypsin activity. This is perhaps because the cysteine-spacing within its domains is almost 
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identical to human WFDC2 and thus induces the same functional limitations (Bingle et al., 
unpublished). 
Analysis of WFDC2’s inhibitory capacity was extended to include matrix metalloproteases, 
MMP2 and MMP9, due to their prevalence in diseases also known to exhibit upregulated 
WFDC2, such as cancer and cystic fibrosis. When incubated with increasing concentrations 
of WFDC2, no significant reduction in MMP2 or MMP9 gelatin digestion was observed, 
suggesting that WFDC2 is not capable of gelatinase inhibition. It should be noted that SLPI is 
not reported to inhibit MMPs so was not an appropriate control for use in the zymography 
assays. 
The results from this study suggest that WFDC2 is incapable of trypsin and MMP inhibition; 
however, this is inconsistent with some data found in the literature, such as that described by 
Hua et al (2014), Chhikara et al (2012) and LeBleu et al (2013). Because of their conflicting 
results, the methods described in these studies were closely analysed and are discussed 
below. 
The protease inhibitory assay described by Hua et al (2014) utilises concentrations of protein 
that perhaps exceed levels that would be found in the human body, especially in the case of 
trypsin, which is exposed to a minimum concentration of 10.4 µM of WFDC2. If these 
concentrations cannot be achieved endogenously, then the biological relevance of the results 
should be called into question. Nonetheless, when 0.8 µM of WFDC2 was exposed to 
elastase, the enzyme activity did reduce by 15%, but it is unclear whether this result was 
statistically significant compared to negative controls as the P values were only shown for the 
highest WFDC2 concentration. The zymography results described in Hua et al (2014) also 
show WFDC2 inhibition of MMP9, however the concentration of WFDC2 protein required to 
produce this result is not described, which calls the reliability of the data into question. It is 
possible that a higher level of WFDC2 was used compared to the concentration used in this 
study which could, in part, explain the discrepancy in results. 
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In Chhikara et al (2012), the purified WFDC2 utilised for protease inhibition experiments was 
described as a 14 kDa glycosylated monomer which forms a 42 kDa trimer in native conditions. 
This result greatly contrasts with the molecular weight of recombinant and endogenous 
WFDC2 protein reported within this study and in the literature when analysed in denaturing 
and native conditions (Drapkin et al., 2005; Hellström et al., 2003; Hua et al., 2014). The 
authors attribute the difference in protein size to the fact that it was purified from seminal 
plasma and represents a different splice variant, yet tissues of the male reproductive tract are 
known to abundantly express WFDC2 V0 as shown by IHC (Uhlén et al., 2015), and V0 has 
been shown to be ~100-fold more abundantly expressed in the epididymis compared to V1-
V4 (Jiang et al., 2013). With this in mind, it seems unlikely that another isoform would be 
purified. These factors call the reliability of the results into question. 
The assays carried out by LeBleu et al (2013) appear to use a more appropriate concentration 
of WFDC2 and the human recombinant protein is closer to the expected size (~18 kDa). Their 
results show that human WFDC2 is able to inhibit the collagen digestion of MMPs and Prss 
enzymes, which contrasts with the results reported in this study (although their methods differ 
so results cannot be directly compared). The result also contrasts with that described by Hua 
et al (2014) as both MMP2 and MMP9 are shown to be inhibited by WFDC2. Evidently further 
experiments will be required to resolutely elucidate whether WFDC2 is capable of protease 
inhibition, given the ongoing inconsistencies in the data. 
During this study, the putative antibacterial functions of human and murine WFDC2 were also 
assessed. The functional assays were carried out using 1 µM of recombinant protein. FLAG 
peptide elution solution was used as a negative control as it is possible that, during the elution 
step of WFDC2 purification, some of the FLAG peptide used for elution could also be present 
in the purified WFDC2 product.  
The bacteria strains used within the in vitro assays were selected for various reasons. Firstly, 
Gram-positive and Gram-negative bacteria were desired as some antimicrobial agents are 
more effective against a particular Gram group, so Escherichia coli (Gram-negative) and 
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species of Streptococcus (Gram-positive) were chosen. Secondly, given that WFDC2 is 
abundantly expressed in the oral cavity and respiratory tract, and its concentration in 
secretions at these sites had been quantified, strains endogenous to the mouth and lungs 
were identified: S. gordonii and S. mutans which colonise the mouth, and S. pneumoniae 
which colonises the respiratory tract. Finally, the four chosen microbes represent different 
degrees of virulence. S. gordonii is commensal-like and represents the least harmful of the 
panel of bacteria chosen. S. mutans, though occurring naturally as part of the normal oral 
flora, is an opportunistic pathogen and a major cause of dental caries. The strain of E. coli 
used was derived from a clinical isolate of a patient with a urinary tract infection (UTI) therefore 
is likely to express virulence factors which enable urinary tract colonisation. UTIs can vary in 
severity, from mild bladder infection to potentially fatal renal failure and sepsis. Finally, S. 
pneumoniae is an invasive pathogen which can cause mild diseases such as otitis media and 
sinusitis or much more severe illnesses including pneumonia and meningitis. By using a 
variety of bacteria for the functional assays in this study, it is more likely that any antimicrobial 
activities of WFDC2 will be elucidated. 
When bacterial binding was tested using a traditional pull down assay, it was clear that neither 
WFDC2 orthologue was capable of binding to any of the four bacterial species. Due to the 
cationic nature of many WFDC family proteins, their putative mode of bactericidal activity is 
via cationic lysis. This ‘coating’ of bacteria and subsequent induction of membrane damage 
and lysis is known to occur with eppin and elafin, as described in Section 1.3.2. The fact that 
WFDC2 fails to interact with the bacteria strains tested suggests that, if it is capable of bacterial 
killing, it achieves lysis via a different route, without binding. This negative result is supported 
by data showing that incubation of murine Wfdc2 with Mycobacterium bovis fails to induce 
membrane permeabilization and killing, whereas murine Slpi is able to induce surface damage 
and bacterial killing when analysed in the same assay (Nishimura et al., 2008).  
Conversely, a positive interaction between WFDC2 and four different bacterial species 
(including S. aureus) has been reported in the literature, as determined by pull down assay 
138 
 
(Hua et al., 2014). Given that the recombinant WFDC2 used by Hua et al (2014) was an Fc-
fusion protein, the positive binding with S. aureus is probably due to the well documented 
binding interaction between the Fc domain of IgG and the S. aureus surface protein, Protein 
A. It is probable that the Fc-fusion changes the binding properties of WFDC2 to enhance its 
affinity with other bacterial surface proteins in addition to Protein A.     
The effect of WFDC2 on bacterial viability was tested using two different methods: a traditional 
assay which involved plating out WFDC2-exposed bacteria via Miles-Misra and counting the 
CFU, and a technique involving an overnight incubation of bacteria and protein, whereby 
absorbance of the suspension was monitored to analyse cell density. Both assays showed 
that WFDC2 orthologues had no effect on the viability of any of the four microbes tested. Even 
when the WFDC2 concentration was raised 3-fold higher, no bactericidal effects were seen. 
Data published by Hua et al (2014) also shows that incubation of recombinant WFDC2 with 
S. aureus has no significant effect on bacterial viability, even at a concentration as high as 
7.75 µM.  
This result supports the lack of interaction between WFDC2 and bacteria described in the pull-
down experiments: it seems unlikely that WFDC2 would elicit bacterial killing via an entirely 
different mechanism to that of its protein family members given their similar structure and its 
lack of other functional domains. It should also be noted that when the bacteria were incubated 
with WFDC2 overnight, the orthologues appeared to undergo protein degradation and glycan 
harvesting, as visualised by shifts in the Western blotting bands and quantified by 
densitometry. Glycosylation can affect protein stability, structure and activity, therefore it is 
possible that this cleavage of sugars by bacteria may negatively impact the biological function 
of WFDC2.    
Host defence roles of salivary glycoproteins also include agglutination and biofilm disruption. 
Agglutination is achieved by glycoproteins such as salivary agglutinin and mucins, which can 
induce bacterial aggregation, promote their clearance and prevent biofilm formation (Ericson 
and Rundegren, 1983). Although known agglutinins tend to be large proteins (>250 kDa) with 
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an abundance of glycosylation (Cross and Ruhl, 2018), other smaller glycoproteins have been 
shown to be involved in aggregation, such as members of the BPI fold containing family of 
proteins (Lunn, 2013). Like WFDC proteins, BPI fold containing family proteins are expressed 
in the oral cavity and upper respiratory tract, have putative innate immune functions and exhibit 
rapid molecular evolution (Bingle et al., 2009).  
To investigate whether WFDC2 is involved in such defence processes, the recombinant 
orthologues were used in agglutination and biofilm disruption assays. The results showed that 
WFDC2 orthologues were incapable of bacterial agglutination, with a clear pellet of bacteria 
forming in the well. In contrast, the saliva positive control clearly induced a film of bacteria to 
form.  
Biofilm formation and disruption assays were also carried out, which demonstrated that 
incubation with WFDC2 caused no significant disruption in the biofilms that formed, regardless 
of whether the protein was present while biofilms were still in the process of forming, or if 
protein was added to an already established biofilm. Host proteins with proposed anti-biofilm 
activity tend to elicit their effects by binding to bacteria; for example, salivary IgA binds to 
bacterial adhesins to prevent their initial attachment to oral surfaces and subsequent biofilm 
formation (Childers et al., 2006; Smith and Taubman, 1996). As WFDC2 appears unable to 
bind to bacteria, this perhaps explains their inability to affect biofilms. It should, however, be 
noted that tissue culture plastic (TCP) is not representative of the tooth surface/enamel 
pellicle, therefore it is possible that this method of analysing biofilm formation could prevent 
endogenous anti-biofilm functions of WFDC2 to be recognised e.g. if bacteria have a greater 
propensity to bind to TCP than the tooth. Nonetheless, these preliminary investigations 
suggest that WFDC2 is incapable of compromising the biofilms or inducing agglutination to 
contribute to bacterial clearance. 
To augment the functional assay data collected using recombinant protein, endogenous 
WFDC2 expression was also examined using RT-qPCR. Changes in WFDC2 expression in 
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primary sublingual gland (HuSL) cells were measured in response to exposure to pro-
inflammatory mediators. 
The endogenous WFDC2 expression in HuSL cells was low, as shown by RT-PCR and gel 
electrophoresis. The difference in expression between whole sublingual glands (Fig 1.8) and 
the primary cells was most likely due to the explanted cells being grown as a monolayer and 
in a defined cell culture medium, which affects the cell phenotype. Monolayer cells are devoid 
of complex structures such as acini and ducts, therefore the primary sites known to abundantly 
express WFDC2 were absent, which was reflected in the RT-PCR result.  
When the primary cells were exposed to pro-inflammatory mediators for 24 hours, there was 
no significant change in WFDC2 gene expression when measured by RT-qPCR and 
compared against the untreated control. This result is interesting as it corroborates the 
functional assay data which appears to show that WFDC2 is incapable of anti-protease or 
antimicrobial activity. If WFDC2 was capable of protease inhibition, its expression would most 
likely be upregulated in response to pro-inflammatory cytokines such as IL-1β and TNF-α, 
which are produced at sites of inflammation resulting from excessive protease activity. This is 
the case for both SLPI and elafin, which are largely upregulated in response to cytokines and 
proteases themselves (see Section 1.3.4). As a result, SLPI and elafin are frequently 
upregulated in diseases characterised by inflammation and dysregulated protease activity 
such as emphysema and psoriasis (Alkemade et al., 1994; Betsuyaku et al., 2002). If WFDC2 
was capable of antimicrobial activity, WFDC2 gene expression levels would be expected to 
become upregulated in response to pro-inflammatory cytokines and bacterial PAMPs such as 
LPS.  
These results suggest that the correlation between bacterial colonisation and WFDC2 
upregulation, described in Section 1.3.3, is not due to conventional upregulation of WFDC2 
expression in response to common alarm signals such as IL-1β, TNF-α and LPS.  
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It should also be noted that within the scope of this study, two oral-derived cancer cell lines 
with moderate to high endogenous WFDC2 expression were used in a similar exposure assay, 
as described in Chapter 5. The cancer cell lines also showed no significant change in gene 
expression in response to IL-1β and TNF-α, supporting the results seen when monitoring 
HuSL cellular responses. Exposure assays published in the literature using ovarian cancer 
cells also showed that IL-1β and TNF-α had no observable effect on WFDC2 expression, 
whereas elafin was upregulated by both cytokines (Clauss et al., 2010; described in Section 
1.3.4.). 
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Chapter 5 
Determining the role of WFDC2 in tumorigenesis 
 
5.  
5.1. Introduction 
Although an abundance of histological evidence is available in the literature to show WFDC2 
expression in gynaecological and lung tumours (Bingle et al., 2006; Georgakopoulos et al., 
2012; Uhlen et al., 2017), there is limited information regarding expression of WFDC2 in 
tumours of the oral cavity (Galgano et al., 2006). To address this, two different subtypes of 
oral tumour will be analysed by immunohistochemistry (IHC) to elucidate the WFDC2 staining 
pattern.  
The overexpression of WFDC2 in cancer is well documented, however, it is unclear whether 
WFDC2 plays an active role in tumorigenesis and the literature remains conflicted. Many 
attempts have been made to knock-down WFDC2 expression in cancer cell lines using small 
interfering RNA (siRNA), with varying success (Gao et al., 2011; Guo et al., 2015; Lu et al., 
2012; Zhu et al., 2016), yet CRISPR gene editing has not been used to assess the effect of 
WFDC2 silencing on cell behaviour. To address this, an appropriate cancer cell line with high 
endogenous WFDC2 expression will be targeted for CRISPR gene editing, and the assays 
described in this chapter will be the first experiments to use CRISPR cells to assess the effects 
of WFDC2 on cell behaviour. Finally, cancer cell lines will also be used to observe changes in 
WFDC2 expression in response to pro-inflammatory mediators, to expand upon the exposure 
assays described in the literature (Clauss et al., 2010). 
5.2. Aims and objectives 
The aim of the research presented in this chapter was to further elucidate the expression 
profile of WFDC2 in oral cancer and to determine whether its expression affects cancer cell 
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behaviour. Immunohistochemistry was used to analyse WFDC2 expression in oral tumours. 
Analysis of WFDC2 expression in oral and lung cancer cell lines was used to determine the 
level of gene expression and any subsequent secretion of WFDC2 protein into conditioned 
media. The effect of pro-inflammatory mediators on WFDC2 expression in oral cancer cell 
lines was assessed using RT-qPCR. Finally, an oral cancer cell line identified to express high 
levels of endogenous WFDC2 was targeted for CRISPR/Cas9 gene editing. Successful gene 
silencing was evidenced by the absence of WFDC2 protein in the conditioned media when 
analysed by Western blotting and ELISA. The downstream effect of WFDC2 silencing on 
cancer cell behaviour was monitored using standard functional assays.   
5.3. Materials and methods 
To access the relevant materials and methods utilised in this chapter, please refer to the 
sections below: 
• The expression of WFDC2 protein in oral cancers was assessed using 
immunohistochemistry as described in Section 2.11. 
• Oral- and lung-derived cancer cell lines were cultured as outlined in Section 2.1.1. The 
endogenous WFDC2 gene expression in cancer cell lines was analysed by RT-PCR 
and RT-qPCR as described in Section 2.2.2 to 2.2.5. The secretion of endogenous 
WFDC2 protein from the cancer cell lines was analysed by Western blotting and 
ELISA, as described in Section 2.3.3 and 2.3.7, respectively. 
• Cancer cell lines were exposed to pro-inflammatory mediators and the changes in 
WFDC2 gene expression were monitored by RT-qPCR, as described in Section 2.8.  
• CRISPR gene editing was performed as per the methods in Section 2.9. Successful 
gene editing was confirmed by RT-PCR, RT-qPCR, Western blotting and ELISA, as 
outlined in Section 2.9.12.  
• The CRISPR edited cells were subjected to conventional cell behaviour assays as 
described in Section 2.10.   
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5.4. Expression of WFDC2 in oral tumours  
To assess whether WFDC2 protein is produced in tumours of the oral cavity, five cases of 
squamous cell carcinoma (SCC) of the tongue and a single case of lymph node metastasis 
were analysed by immunohistochemistry (IHC) using a monoclonal antibody raised against 
human WFDC2. 
Positive WFDC2 staining was found to be exclusively localised to phenotypically normal minor 
salivary glands present within the tongue, with intense positivity being visible in the epithelium 
of the ducts (Fig 5.1). All other cell types present in the sections, particularly tumour cells, 
were negative for WFDC2 expression, suggesting that the protein is not expressed in oral 
SCC. A single case of SCC lymph node metastasis was also analysed and was negative for 
WFDC2 staining (data not shown).   
The expression of WFDC2 in mucoepidermoid carcinoma (MEC), the most common type of 
salivary gland tumour, was also assessed by IHC. In contrast to SCC, many MEC sections 
exhibited positive, focal WFDC2 expression (21/58 sections were positive). Staining was 
notably abundant in mucin-producing cells, with intense staining also visible in cystic spaces 
(Fig 5.2a-f). WFDC2 staining was largely absent in sites of normal mucous acini within the 
MEC tissue (Fig 5.2g and Fig 5.2h).   
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Fig 5.1. Localisation of WFDC2 in human squamous cell carcinoma of the tongue. Sections of 
squamous cell carcinoma (SCC) of the tongue were stained for WFDC2 by IHC. Cancer cells were 
negative for WFDC2, while minor salivary glands were positive for WFDC2 (a-g). Healthy parotid gland 
tissue was used as a control for positive staining (h). Original magnification of the images was 10X.   
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Fig 5.2. Localisation of WFDC2 in human mucoepidermoid carcinoma. Sections of 
mucoepidermoid carcinoma (MEC) were stained for WFDC2 by IHC (a-h). Positive staining was seen 
in mucous-producing cells and cystic ductal spaces (a-f). Normal mucous acini were mostly negative 
for WFDC2 (g, h). Original magnification of the images was 4X. Staining performed by Debora Pereira 
(visiting student from the University of Campinas, Brazil). 
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5.5. Expression profile of WFDC2 in cancer cell lines 
Data in the literature has shown that cancer cell lines derived from lung and ovarian tumours 
endogenously express WFDC2 (Bingle et al., 2006; Drapkin et al., 2005), thus providing a 
valuable tool for knockdown studies. To further analyse the expression profile of WFDC2 in 
cancer cell lines, four oral cancer cell lines and six lung cancer cell lines (see Table 2.1) were 
analysed by RT-PCR and RT-qPCR to identify and quantify positive gene expression. 
Downstream protein secretion into culture media was also analysed using Western blotting 
and ELISA.  
To semi-quantitatively assess whether all five splice variants of WFDC2 are expressed by the 
ten cell lines in question, primers for PCR were designed to target individual splice variants. 
OAZ1 was used as an endogenous control. Resultant PCR products were resolved on a 2% 
agarose gel.  
The results appear to show that all five splice variants are expressed in CAL27, H357, NCI-
H292, NCI-H441 and NCI-H358 cell lines. CAL27 and NCI-H441 cells appeared to express 
the highest level of WFDC2 variants when compared to the band intensity of the endogenous 
control, OAZ1 (Fig 5.3). FaDu, D20 and NCI-H647 cell lines expressed low levels of WFDC2 
and failed to express variant 2 and/or variant 4. NCI-H322 and NCI-H226 lacked expression 
of all five splice variants.  
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Fig 5.3. Differential expression of WFDC2 splice variants analysed by RT-PCR. Primers specific 
to WFDC2 splice variants (V0-V4) were used to probe 10 cancer cell line target cDNAs using RT-PCR 
to detect splice variant expression. PCR products were resolved on a 2% agarose gel. Expected band 
sizes were V0: 105 bp; V1: 132 bp; V2: 97 bp; V3: 75 bp; V4: 85 bp; OAZ1 endogenous control: 164 bp 
(N=3).  
 
RT-qPCR was utilised to quantify expression of WFDC2 using TaqMan primers that detected 
isoform V1. Expression was determined as the fold-change compared to the B2M endogenous 
control. The results show that expression of WFDC2 in CAL27 cells, a cell line derived from a 
squamous cell carcinoma of the tongue, was significantly higher than in all other cancer cell 
lines tested (P=<0.0001) (Fig 5.4). NCI-H441 cells, derived from a papillary adenocarcinoma 
of the lung, were the second most highly expressing cells. This supports the semi-quantitative 
RT-PCR analysis of the cell lines seen in Fig 5.3.     
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Fig 5.4. RT-qPCR quantification of WFDC2 gene expression in 10 cancer cell lines. WFDC2 
expression in 4 oral-derived and 6 lung-derived cancer cell lines was tested using RT-qPCR. WFDC2 
expression is represented as the fold change in expression compared to the B2M endogenous control. 
NCI-H441 is significantly more highly expressed than all cell lines (P=<0.0001) apart from CAL27. The 
CT values are presented in the Appendix. Data represents the mean ± SD (N=3; n=3). **** P ≤ 0.0001.  
 
To further analyse the expression levels of WFDC2 in cancer cell lines, the presence of 
WFDC2 protein in conditioned media was analysed by Western blotting. Serum-free 
conditioned media from all 10 cancer cell lines was collected, concentrated and analysed by 
BCA to determine total protein concentration. The protein content was standardised and 45 
µg of total protein was subjected to Western blot analysis.  
The Western blotting result shows that WFDC2 is only detectable in media derived from 
CAL27 cells (Fig 5.5). All other cancer cell lines failed to express detectable levels of WFDC2. 
The molecular weight of the positive band is ~25 kDa.  
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Fig 5.5. Western blot analysis of WFDC2 protein secretion in 10 cancer cell lines. The presence 
of WFDC2 protein in concentrated conditioned media from four oral-derived and six lung-derived cancer 
cell lines was analysed by Western blotting using an anti-WFDC2 monoclonal antibody. Lane numbers 
represent the following: 1 – CAL27, 2 – FaDu, 3 – H357, 4 – D20, 5 – NCI-H647, 6 – NCI-H292, 7 – 
NCI-H441, 8 – NCI-H226, 9 – NCI-H358, 10 – NCI-H322, 11 – recombinant human WFDC2 (N=2). 
 
To quantify the endogenous concentration of WFDC2 secreted by cancer cell lines, 
conditioned media from the ten cancer cell lines was analysed using a WFDC2 ELISA. An 
equal concentration of total protein was analysed for each sample which was subsequently 
diluted according to the manufacturer’s recommendation.  
CAL27 cells secreted significantly more WFDC2 protein than all other cell lines tested 
(P=<0.0001) with a mean concentration of 147.5 nM in the conditioned media (Fig 5.6). This 
result supports both the RT-qPCR and Western blot analysis. NCI-H441 cells exhibited the 
second most abundant level of WFDC2 of protein (16.1 nM), followed by H357 (10.5 nM). All 
other cell lines secreted less than 3 nM of WFDC2. It should be noted that although the 
expression levels were extremely low for many cell lines, concentrations of WFDC2 were still 
detectable (>0 nM).  
151 
 
 
Fig 5.6. ELISA quantification of WFDC2 protein production in 10 cancer cell lines. WFDC2 
production in 4 oral-derived and 6 lung-derived cancer cell lines was tested using ELISA. Data is 
presented as WFDC2 concentration (nM), with the mean ± SD shown (n=3) **** P ≤ 0.0001.  
 
5.6. Cytokine exposure assay 
To determine whether WFDC2 gene expression in cancer cell lines could be upregulated in 
response to inflammatory mediators, two oral-derived cancer cell lines (CAL27 and H357) 
were exposed to TNF-α (20 ng/ml), IL-1ß (20 ng/ml) and IFN-γ (5 ng/ml) for 24 hours. RT-
qPCR was carried out to quantify WFDC2 expression levels in the cytokine-exposed cells and 
determine whether expression was affected following treatment when compared to untreated 
control cells.     
The RT-qPCR analysis shows that exposure of CAL27 cells to IL-1ß and TNF-α for 24 hours 
had no significant effect on WFDC2 gene expression compared to the untreated control 
(P=0.997 and P=0.998 respectively). Interestingly, IFN-γ appeared to significantly reduce 
WFDC2 expression by approximately 0.5-fold (P=0.027) (Fig 5.7a). 
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Similarly, when H357 cells were exposed to IFN-γ they displayed a significant 0.7-fold 
reduction in WFDC2 expression (P=0.008). Treatment with IL-1ß and TNF-α caused no 
statistically significant change in WFDC2 expression compared to the untreated H357 cells, 
(P=0.830 and P=0.168 respectively) although TNF-α did cause an ~1.5-fold increase in 
WFDC2 expression (Fig 5.7b).       
 
Fig 5.7. RT-qPCR analysis of WFDC2 expression in CAL27 and H357 cells following exposure to 
inflammatory mediators. WFDC2 expression in CAL27 (a) and H357 (b) cells was tested by RT-qPCR 
following exposure to inflammatory mediators: LPS (50 µg/ml), TNF-α (20 ng/ml), IL-1ß (20 ng/ml) and 
IFN-γ (5 ng/ml). WFDC2 expression is represented as the fold change in expression compared to the 
untreated cell control. Data represents the mean ± SD (N=3; n=3); ** P ≤ 0.01, * P ≤ 0.05. 
 
5.7. CRISPR/Cas9 gene editing of WFDC2 in an oral cancer cell line 
CRISPR/Cas9 gene editing was utilised to knock-out the expression of WFDC2 in CAL27 cells 
which exhibit high endogenous WFDC2 expression. The editing event was carried out using 
a plasmid encoding a guide RNA and Cas9 endonuclease, in addition to GFP which was used 
for downstream selection of transfected mammalian cells. Extensive tests were carried out to 
confirm that a successful gene silencing event had occurred. The CRISPR edited cells were 
subsequently used for downstream functional assays. 
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5.7.1. CRISPR editing 
In order to recruit a Cas9 nuclease to the gene of interest and induce silencing, a single guide 
RNA (sgRNA) must be synthesised: the sgRNA is a 20 nucleotide DNA sequence 
complementary to the target gene.  
To silence WFDC2, two different sgRNAs were designed and synthesised, each targeting the 
5’ end of exon 2 (Fig 5.8). Each sgRNA (sgRNA1 and sgRNA2) was ligated into a pX458 
target vector and was subsequently transformed into competent E. coli cells. The pX458-
sgRNA1 and pX458-sgRNA2 plasmids were isolated from ampicillin-resistant transformants. 
A sample of each plasmid was subjected to restriction digestion to confirm the presence of the 
vector, however at this stage the presence or absence of the ligated sgRNA cannot be 
confirmed due to its small size (~20 bp) which cannot be visualised on an agarose gel. 
 
Fig 5.8. The CRISPR target site. A schematic diagram depicting the CRISPR target site within exon 2 
of human WFDC2 isoform V0 (a). The exact target site of the two sgRNAs within exon 2 are shown (b). 
 
Target CAL27 cells were seeded into a 6-well plate and co-transfected with pX458-sgRNA1 
(1 µg) and pX458-sgRNA2 (1 µg) plasmids using JetPrime transfection reagent in order to 
induce a dual cleavage by Cas9 and remove ~40 nucleotides from exon 2 of WFDC2 (i.e. both 
sgRNA1 and sgRNA2 targets).  
Transfected cells were sorted via fluorescence activated cell sorting (FACS) according to the 
GFP expression of positive transformants. Negative transformants were also collected to be 
used as a negative control in downstream assays. Following FACS sorting, cells were serially 
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diluted in a 96-well plate for clonal isolation, with the aim of growing colonies of cells derived 
from a single progenitor cell.  
Colonies were expanded and genomic DNA (gDNA) was extracted and analysed by PCR 
using two primer pairs which were designed to be 50-100 bp upstream/downstream of the 
sgRNA target. PCR products were used to identify populations of clones with the desired 
CRISPR knockout mutation. Genomic DNA derived from CAL27 cells that were not 
successfully transfected with the pX458 vector (i.e. FACS sorted but GFP negative) was 
included in the PCR to act as a negative control. 
PCR products derived from gDNA of 12 different clonal colonies were resolved on an agarose 
gel. The results showed that colony 11 had a visible shift in expected band size (Fig 5.9) with 
both primer pairs which suggested that a deletion resulting from a successful gene editing 
event had occurred.  
 
Fig 5.9. Resolution of PCR products derived from gDNA of potential gene edited CAL27 colonies. 
Primer pairs flanking the sgRNA target within gDNA of CRISPR gene edited CAL27 cell colonies were 
used for PCR. Products were resolved on a 2% agarose gel.  In the absence of CRISPR-induced 
deletions, expected band sizes were 226 bp for primer pair 1 and 223 bp for primer pair 2. Lanes 1-12 
represent different potential gene edited colonies (N=1).  
 
The PCR product from colony 11 and the negative control were subjected to a PCR clean-up 
and resolved for longer on a 2% agarose gel to identify whether multiple products were 
present. More extensive resolution demonstrated that three separate bands were present 
within the PCR product from colony 11, although all three bands appeared to be smaller than 
the 223 bp control (Fig 5.10).   
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Fig 5.10. Higher resolution of the PCR product from colony 11. The PCR product visualised in Fig 
5.9 was purified and resolved further on a 2% agarose gel against the negative control PCR product to 
identify the presence of multiple bands. The expected band size for the negative control was 223 bp. 
Lane numbers represent the following: 1 – colony 11 PCR product, 2 – negative control (N=1).  
 
The three bands present within the PCR product of colony 11 were extracted from the gel and 
sent for Sanger sequencing. A sample of the resultant gel extracted, purified products was 
also analysed by gel electrophoresis to ensure the targeted bands had been successfully 
isolated (Fig 5.11).  
 
Fig 5.11. Resolution of three gel extracted bands from colony 11. The PCR product visualised in 
Fig 5.10 was subjected to a gel extraction to separate individual products from the same sample. 
Extracted products were resolved on a 2% agarose gel to ensure they had been successfully isolated. 
Lane labels represent the following: 1 – colony 11 fragment 1, 2 – colony 11 fragment 2, 3 – colony 11 
fragment 3, 4 – unseparated bands of colony 11 PCR product, 5 – PCR clean-up of negative control, 6 
– original negative control PCR product (N=1).  
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The sequencing results showed that fragment 1 i.e. the smallest band (Fig 5.11, lane 1) had 
been successfully gene edited, as a 46 bp deletion in the gDNA was identifiable (see 
schematic Fig 5.12). Approximately 25 bp of exon 2 was excised inducing a premature stop 
codon (Fig 5.13), in addition to 21 bp at the 3’ end of intron 1. The deletion of 3’ intronic DNA 
included the conserved 3’ AG splice site.  
The sequences derived from fragment 2 and 3 i.e. the intermediate and largest bands (Fig 
5.11, lane 2 and 3) also showed that a deletion event had occurred, with 5 and 2 nucleotides 
being removed from the 3’ terminus of intron 1, respectively (see schematic Fig 5.12). As a 
result, both transcripts lacked the 3’ AG splice site. When the sequence identity between 
fragments 2 and 3 compared to WT disappeared, the remaining sequence showed no 
sequence similarity with WFDC2; in fact, when the sequence was inputted into BLAST 
software (NCBI blastn Suite), no sequence identity with any known sequence could be 
identified. This suggests that the additional nonsense sequence is an artefact of the PCR 
reaction and is due to the random assignment of nucleotides to the nascent PCR product. 
Fig 5.12. Schematic diagram of sequencing results of CRISPR edited colony 11 cells. Sequencing 
results of individual PCR products derived from colony 11 are summarised in a schematic diagram. 
Fragment 1-3 represent the individual bands shown in Fig 5.11, Lane 1-3, and the WT and control 
sequences are included. Sizes of relevant sections of the DNA in question are shown (bp).  
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Fig 5.13. Schematic diagram to show the truncation of exon 2 in fragment 1. The sequencing result 
of the fragment 1 PCR product derived from colony 11 was inputted into ExPASy translate tool 
(https://web.expasy.org/translate/) to identify the effect of the DNA truncation on the peptide sequence. 
WT peptide sequence is shown for reference.  
 
The sequencing results derived from the CRISPR negative control showed that the gDNA was 
identical to that of wild-type WFDC2, thus showing that no mutations were present in WFDC2 
of the negative control CAL27s.  
 
5.7.2. WFDC2 expression in CRISPR edited cells 
The CRISPR gene edited CAL27 cells were subjected to a number of assays to determine 
whether the deletions that occurred in intron 1 and exon 2 caused silencing of the WFDC2 
gene.  By carrying out RT-PCR using a forward primer targeting exon 1 and a reverse primer 
in exon 5, three different PCR products can potentially be amplified (V0, V1 and V2) depending 
on the cDNA profile derived from the CRISPR edited cells. 
The PCR products derived from the CRISPR edited cells showed a ~150 bp shift in band size 
compared to WT and negative control cells (Fig 5.14). The band present in WT and control 
cells is consistent with the expected product for V0 (450 bp), whereas the band in CRISPR 
edited cells is similar to the expected band for V2 (306 bp).  
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Fig 5.14. RT-PCR analysis of splice variants in CRISPR edited cells. Primers spanning the full-
length of WFDC2 were used to probe cDNA derived from CRISPR edited cells and controls using RT-
PCR. PCR products were resolved on a 1% agarose gel. Lanes represent the following: 1 – WT CAL27, 
2 – CRISPR negative control cells, 3 – CRISPR edited cells. Splice variants that can be amplified by 
the primer pair include V0 (450 bp), V1 (579 bp) and V2 (306 bp) (N=3).  
 
RT-PCR was also performed using primers specific to splice variant V0 and V2. OAZ1 was 
used as an endogenous control. The PCR products show that there is higher V0 expression 
in the WT and negative control compared to CRISPR cells (Fig 5.15). There appears to be 
greater expression of V2 in CRISPR cells, although positive expression of V2 is also visible in 
the control cells (Fig 5.15). 
 
Fig 5.15. V0 and V2 expression in CRISPR edited cells by RT-PCR. Primers specific to splice 
variants V0 and V2 were used to probe cDNA from CRISPR edited cells and controls using RT-PCR. 
Products were resolved on a 2% agarose gel. Lanes represent the following: 1 – WT CAL27, 2 – 
CRISPR negative control cells, 3 – CRISPR edited cells. Band sizes were as follows: V0 – 105 bp, V2 
– 97 bp, OAZ1 – 164 bp (N=3).  
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When WFDC2 expression was analysed by RT-qPCR using TaqMan primers against splice 
variant V1, the CRISPR gene edited cells were shown to express significantly less WFDC2 
compared to both the CRISPR negative control (P=0.0137) and the WT CAL27 cells (P=0.002) 
evidencing that a considerable knockdown had been induced (Fig 5.16).  
 
Fig 5.16. RT-qPCR quantification of WFDC2 gene expression in CRISPR gene edited CAL27 cells. 
WFDC2 expression in CRISPR gene edited cells compared to the negative control and WT CAL27 cells 
was analysed by RT-qPCR. WFDC2 expression is represented as the fold change in expression 
compared to the B2M endogenous control. Data represents the mean ± SD (N=3; n=3); ** P ≤ 0.01, * 
P ≤ 0.05.  
 
Conditioned media derived from CRISPR gene edited cells was analysed by Western blotting 
and ELISA to determine whether the cells were still capable of successfully secreting WFDC2 
protein. The serum-free conditioned media from gene edited, negative control and WT cells 
was concentrated, analysed by BCA and then protein content was standardised so that the 
same amount of total protein was analysed per cell phenotype.  
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The Western blot results demonstrated that the WT and CRISPR control cells were capable 
of producing WFDC2 protein, while the CRISPR gene edited cells were unable to secrete a 
detectable level of WFDC2 protein into the conditioned media (Fig 5.17).  
The ELISA results showed that CRISPR edited CAL27 cells secreted no detectable WFDC2 
protein into the conditioned media and therefore express significantly less protein than the WT 
and negative controls (P=0.007 and P=0.002, respectively) (Fig 5.18). There was no 
significant difference in protein production between the WT and negative control cells.  
 
Fig 5.17. Western blot analysis of WFDC2 protein production in CRISPR gene edited CAL27 cells. 
Expression levels of WFDC2 in concentrated conditioned media from CRISPR gene edited cells 
compared to control cells were analysed by Western blotting using an anti-WFDC2 monoclonal antibody 
(N=2). Lane numbers represent the following: 1 – WT CAL27 conditioned media; 2 – CRISPR negative 
control conditioned media, 3 - CRISPR edited cell conditioned media, 4 – recombinant human WFDC2 
control.  
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Fig 5.18. ELISA quantification of WFDC2 protein production in CRISPR gene edited CAL27 cells. 
WFDC2 production in conditioned media from CRISPR gene edited cells compared to WT and CRISPR 
negative control cells was analysed using an ELISA. Protein production is shown as the concentration 
of WFDC2 (nM), with the mean ± SD (N=3, n=2). ** P ≤ 0.01. 
 
5.8. CRISPR cell functional assays  
The CRISPR gene edited CAL27 cells were subsequently used for a number of functional 
assays, including proliferation, adhesion, migration and invasion assays, to determine whether 
the CRISPR edited cells behaved differently to the CRISPR negative control and WT cells.  
5.8.1. Cell morphology  
The cells were visually assessed to determine whether the CRISPR editing had affected the 
morphology of the cells. Comparison of the three cell phenotypes showed that there was no 
striking difference in the cell appearance (Fig 5.19). The majority of cells in each group had a 
rounded morphology and grew as colonies, while some cells showed a stellate morphology 
and appeared to bridge gaps between colonies. 
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Figure 5.19. Phase-contrast microscopy images of CRISPR edited cell morphology versus 
controls. The morphology of CRISPR edited cells was analysed via phase-contrast microscopy and 
compared to WT and CRISPR negative controls.  WT (a, b), CRISPR negative (c, d) and positive 
CRISPR edited cells (e, f) were imaged at an original magnification of 10X (N=3, n=4 fields of view, 
representative images shown). 
 
5.8.2. Viability assays 
To determine whether the CRISPR cells were less viable then the control cells, an MTS assay 
was performed. Cells were seeded into a 96-well plate at a density of 5,000 cells per well and 
cultured for 72 hours. MTS solution was then added and the linear relationship between the 
absorbance value and metabolic activity meant cell viability could be assessed.  
The results show that significantly more viable WT cells were present in culture compared with 
the negative control cells, which showed an average reduction in absorbance of 24% 
(P=0.020) (Fig 5.20). There was no significant difference in absorbance between CRISPR 
edited cells and WT (P=0.064), or CRISPR edited cells and negative controls (P=0.61). 
CRISPR cells had an absorbance value that was 17% lower than the WT cells.   
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Fig 5.20. Viability assay using CRISPR gene edited CAL27 cells. The viability of CRISPR gene 
edited cells compared to WT and CRISPR negative control cells was analysed using an MTS assay. 
Absorbance correlates with the number of viable cells. Results show the mean ± SEM (N=3; n=3) * P ≤ 
0.05.  
 
To support the results determined from the MTS assay, cells were also manually counted. 
Cells were seeded into a 6-well plate at a density of 3 x 105 cells and incubated for 48 hours. 
The total number of cells were then counted using a haemocytometer. The results show that 
after 48 hours, significantly more WT cells were counted compared to the negative control 
(P=0.036). There was no significant difference in the number of CRISPR cells and either WT 
or negative control cells (P=0.0667 and P=0.876, respectively) (Fig 5.21). 
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Fig 5.21. Manual counting of CRISPR gene edited CAL27 cells. The proliferation of CRISPR gene 
edited cells compared to WT and CRISPR negative control cells was analysed by counting the total cell 
number using a haemocytometers. The number of cells per ml are shown and results represent the 
mean ± SEM (N=3) * P ≤ 0.05.  
 
5.8.3. Adhesion assay 
The adhesive capacity of CRISPR edited cells was also tested by coating a 96-well plate with 
extracellular matrix (ECM) components, fibronectin and collagen I. Adherent cells that 
remained bound to the plate following a PBS wash were quantified using MTS reagent to 
determine the number of viable cells remaining in culture.  
The results show that CRISPR edited cells exhibit no significant difference in their adhesive 
capacities compared to the WT and negative control (Fig 5.22). Both the CRISPR edited and 
CRISPR negative control cells appear to be slightly less adherent to the ECM components 
tested than their WT counterpart, however this difference is not significant. 
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Fig 5.22. Adherence assay using CRISPR gene edited CAL27 cells. The adherence of CRISPR 
gene edited cells compared to WT and CRISPR negative control cells was analysed using collagen I 
(a) and fibronectin (b) coated 96-well plates. The number of adherent cells was measured via MTS 
assay. Absorbance correlates with the number of remaining (i.e. adhered) viable cells following a PBS 
wash. Results show the mean ± SEM (N=3; n=3). 
 
5.8.4. Migration assay 
The CRISPR edited cells were also assessed for any changes in migratory behaviour using 
Transwell assays. Cells were seeded into 8 µm pore Transwells and allowed to migrate for 7 
hours toward serum-containing media beneath the Transwell which acted as a 
chemoattractant. Non-migrated cells were swabbed away and the cells that had migrated 
through the membrane were stained with crystal violet and manually counted.  
The CRISPR negative control cells showed the highest level of migration, with significantly 
more cells per field of view compared to WT cells (P=0.011) and the positive CRISPR edited 
cells (P=0.0012) (Fig 5.23). Although the CRISPR edited cells appeared to show some 
reduction in migration compared to WT, this difference was not significant (P=0.114).  
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Fig 5.23. Migration assay using CRISPR gene edited CAL27 cells. The migration of CRISPR gene 
edited cells compared to WT and CRISPR negative control cells was analysed using Transwells, 
whereby migrated cells were stained and counted. The results are shown as the mean number of cells 
present per field of view taken from a total of 7 fields of view. Results show the mean ± SEM; (N=3; 
n=3) * P ≤ 0.05; *** P ≤ 0.001.  
 
5.8.5. Invasion assays 
To analyse the invasive capacity of the cells, 8 µm pore Transwells were coated with Matrigel, 
a basement membrane matrix, and cells were left to invade towards serum-containing media 
in the well below for 24 and 48 hours. Non-invaded cells were swabbed away and invaded 
cells were stained with crystal violet and then solubilised. The solubilised stain was measured 
via a microplate reader, the absorbance value represents the number of stained cells per 
insert.  
The results show that the CRISPR edited cells had a slightly reduced invasive capacity after 
24 hours compared to WT (P=0.660) and negative CRISPR control cells (P=0.364) but this 
difference was not significant (Fig 5.24a). After 48 hours, the CRISPR edited cells showed 
significantly reduced invasion compared to WT (P=0.0011) and negative control (P=0.0002) 
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cells (Fig 5.24b). The mean percentage reduction in invasion after 24 hours between CRISPR 
edited cells and WT or negative control cells was 13% and 17%, respectively.  
  
Fig 5.24. Invasion assay using CRISPR gene edited CAL27 cells. The invasion of CRISPR gene 
edited cells compared to WT and CRISPR negative control cells was analysed using Matrigel-filled 
Transwells, whereby cells were left to invade for 24 (a) or 48 (b) hours. Cells were then stained with 
crystal violet and solubilized. The absorbance of the solubilized cells was measured using a plate 
reader. Results show the mean ± SEM (N=3; n=3).  
 
5.9. Discussion  
The primary reason that WFDC2 is of interest to the scientific community is that its expression 
becomes exacerbated in ovarian cancer in addition to other malignancies including those of 
the lung and endometrium (see Section 1.4). When analysed histologically, the majority of 
tissues derived from gynaecological and pulmonary cancers show intense positive WFDC2 
staining throughout the tumour. Some tissues exhibit more focal staining and, in these cases, 
positivity almost always aligns with abnormal ductular tissue (see Fig 1.11 and 1.12). Ovarian 
malignancies have been extensively analysed for WFDC2 expression, both in terms of 
quantifying serum levels and by histopathology, since the early 2000s. The expression of 
WFDC2 in other malignancies has drawn attention more recently, as serum levels of the 
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protein were also found to be elevated in lung cancer, calling into question the value of WFDC2 
as a biomarker for non-gynaecological diseases.  
WFDC2 expression in oral cancers is yet to be substantially defined in the literature. Within 
this study, IHC was used to analyse tissue sections of squamous cell carcinoma (SCC) of the 
tongue and mucoepidermoid carcinoma (MEC), with the aim of contributing to the 
understanding of WFDC2 expression in non-gynaecological malignancies. Oral SCCs make 
up 90% of the tumours of the oral cavity and the tongue is one of the most common sites, 
while MEC is the most common salivary gland malignancy in young adults and is most 
commonly found in the parotid gland (El-Naggar et al., 2017).  
When analysed histologically, SCC of the tongue tissue was negative for WFDC2, with islands 
of tumour cells appearing entirely devoid of staining (Fig 5.1). The only sites of positive 
WFDC2 expression were the minor glands of the tongue, which appeared to have a normal 
ductal structure and most likely represented untransformed healthy regions of tissue. The SCC 
analysis suggests that transition from a healthy phenotype to a malignant one does not 
necessarily correlate with an upregulation of WFDC2. On the other hand, when WFDC2 
expression in SCC of the lung was analysed by Bingle et al (2006) the results showed that 
many sections exhibited focal positive staining (18/60 cases), although the majority of cases 
(41/60) were negative. The comparison of SCC of the tongue and lung suggests that the 
presence of WFDC2 in SCC is site specific. 
When MEC tissue was analysed in the same way, positive WFDC2 staining was identified in 
36% of the tumour sections. Positivity was particularly abundant in mucous-secreting cells and 
in cystic spaces. Regions of phenotypically normal acini were identifiable and found to be 
mostly negative for WFDC2 which supports the evidence in the literature (Bingle et al., 2006). 
It is of interest to note that another salivary gland tumour that is characterised by cystic spaces 
and abundant mucous-producing cells, known as mucinous adenocarcinoma (MAC), 
experiences frequent amplification of the locus 20q13, upon which WFDC2 is expressed 
(Uchida et al., 2010; Wyszyńska-Pawelec et al., 2013). It is possible that the upregulation of 
169 
 
WFDC2 that occurs in MEC results from a similar amplification of the WFDC locus on 
chromosome 20.  
It is interesting that healthy mucous cells within salivary glands are negative for WFDC2 (with 
positivity instead being almost entirely ductular) but following neoplastic transformation, the 
MEC tumour cells with a mucous-like phenotype express abundant WFDC2. Nevertheless, 
not all mucous-rich tumours exhibit high levels of WFDC2; for example, mucinous ovarian 
tumour sections exhibit negative or low focal WFDC2 staining and subsequently release 
comparatively low levels of WFDC2 into serum compared to other ovarian cancer types 
(Drapkin et al., 2005; Hertlein et al., 2012; Galgano et al., 2006).  
The histological analysis carried out in this study has contributed to the understanding of 
WFDC2 expression in oral cancers but has also shown that the extent of WFDC2 positivity in 
cancer largely depends on the tumour site and not necessarily the phenotype of the tumour 
itself. The differences in WFDC2 expression between SCC of the tongue versus the lung, or 
mucinous tumours of the salivary gland versus the ovary, support this theory.  
Within this study, analysis of WFDC2 expression was extended to investigate expression in a 
panel of ten cancer cell lines derived from the lung and oral cavity. Cancer cell lines are well 
established tools for analysis of cancer in vitro and are ideal targets for genome modifications 
given their homogeneity and indefinite replicative capacity. Cell lines derived from a number 
of tumour types, including ovarian, pancreatic and endometrial cancers, have been utilised for 
making WFDC2-overexpression and knockdown clones (see Section 1.4.5). Neither oral- or 
lung-derived cancer cell lines have been used as tools to analyse WFDC2 function prior to 
this study. 
When analysed by traditional RT-PCR, the V0 splice variant showed the most abundant 
expression in CAL27, H357, NCI-H292 and NCI-H441 cell lines. A similar trend was found 
when analysing splice variants, where the aforementioned cell lines expressed the highest 
levels of V1-V4. Cell lines with low V0 expression, such as FaDu and NCI-H647, also exhibited 
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lower expression of the V1-V4 isoforms, with some variants such as V2 being absent 
altogether. In the case of cell lines that failed to express V0, such as NCI-H226 and NCI-H322, 
no other variants were expressed either. These results support data described by Jiang et al 
(2013) who report that V0 is significantly more abundant in human tissues samples (trachea, 
epididymis, breast and endometrium) than the other four isoforms (Section 1.2.2).  
When RT-qPCR was used to quantify WFDC2 expression in the cancer cell line panel, CAL27 
cells were found to express the gene most abundantly, with NCI-H441 cells exhibiting the 
second highest levels. When conditioned media was analysed by ELISA, CAL27 cells were 
shown to secrete significantly more WFDC2 than all other cells, secreting ~10-fold more 
WFDC2 than NCI-H441s. This result was supported by Western blot analysis, whereby 
WFDC2 was only detectable in the conditioned media of CAL27 cells. 
The CAL27 cell line was established in 1982 from a squamous cell carcinoma of the tongue 
but has since been reclassified as an adenosquamous carcinoma following histopathological 
analysis and xenograft studies (Jiang et al., 2009). Adenosquamous carcinomas are 
characterised by their high invasive and metastatic capacity, with a worse prognosis than other 
types of SCC (El-Naggar et al., 2017).  
There is no obvious correlation between WFDC2 expression levels and the cell line tissue 
origin. CAL27 and H357 cells are both derived from SCC of the tongue but exhibit disparate 
WFDC2 expression. NCI-H441 (the second highest WFDC2-expressing cell line) is derived 
from a papillary adenocarcinoma of the lung, a tumour which is characterised by early lymph 
node metastasis, so is similar to CAL27 in its enhanced capacity for invasion/migration (Aida 
et al., 2004; Miyoshi et al., 2003). NCI-H358, which expressed the third highest amount of 
WFDC2, is derived from bronchioalveolar carcinoma of the lung, which, unlike CAL27 and 
NCI-H441, exhibits a good prognosis and overall survival (Okubo et al., 1999). Cancer cell 
lines lose the original characteristics of their tumour source due to their growth as a clonal 
population in defined culture media without influencing factors from the tumour 
microenvironment (Wilding and Bodmer, 2014); this means that cell lines often have an altered 
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expression profile and behave differently to the original tissue. This factor most likely explains 
why CAL27 cells exhibit high WFDC2 expression when SCC of the tongue tissue sections are 
devoid of WFDC2 protein when analysed by IHC. Similarly, it may explain why two different 
cell lines derived from the same subtype of tumour (CAL27 and H357) express such different 
levels of WFDC2.  
Cytokines are frequently implicated in the development of cancer as inappropriate cytokine 
expression can lead to chronic inflammation which can subsequently induce malignant 
transformation of cells (Hussain and Harris, 2007). Cytokines have also been implicated in the 
progression of cancer, whereby certain inflammatory mediators appear to mediate pro-tumour 
effects (Dranoff, 2004). When CAL27 and H357 were exposed to TNF-α and IL-1β, there was 
no significant effect on WFDC2 expression. This result supports the cytokine exposure assay 
described in Chapter 4 using HuSL cells and may suggest that WFDC2 is not significantly 
upregulated in response to inflammation; however, it is possible that CAL27 cells cannot 
exhibit any further upregulation due to having reached a maximal possible expression of 
WFDC2. TNF-α and IL-1β are known to mediate pro-cancer effects that are involved in 
processes such as metastasis and angiogenesis, therefore, if WFDC2 expression is not 
upregulated in response to cytokines, this suggests that the protein is not involved in such 
tumorigenic effects (Kim et al., 2009; Orosz et al., 1995; Voronov et al., 2003). 
Interestingly, both H357 and CAL27 cells exhibited a significant downregulation of WFDC2 in 
response to IFN-γ. This result did not appear to be caused by IFN-γ-induced cell death, as the 
cellular B2M expression levels, which approximately correlate with cell number, were not 
decreased compared to untreated cells (see Appendix for CT values of B2M). IFN-γ is more 
of a mediator of immune responses compared to TNF-α and IL-1β (which are pro-
inflammatory) and is involved in key immune processes such as activation of NK cells and 
macrophages and induction of antigen presentation via the major histocompatibility complex 
(Boehm et al., 1997). In cancer, IFN-γ has been shown to elicit anti-tumour activity by being 
pro-apoptotic, anti-proliferative and by enabling tumour surveillance due to its capacity for 
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stimulating antigen presentation (Dunn et al., 2004; Miller et al., 2009). Indeed, IFN-γ knockout 
mice are reported to be more susceptible to developing carcinogen-induced tumours (Osawa 
et al., 2006).  
The correlation of high serum WFDC2 levels with poor prognosis in ovarian cancer patients, 
as well as reports that show increased proliferative and invasive capacities of WFDC2 
overexpressing clones (reviewed in Section 1.4), suggest that WFDC2 is pro-tumorigenic. It 
is possible that IFN-γ downregulates WFDC2 in cancer (and subsequently in cancer cell lines) 
as an anti-tumour response.  
It is also worthy of noting that a down-regulation of SLPI in response to IFN-γ has been 
observed in macrophages (Jin et al., 1997). The authors suggest that this is due to SLPI being 
upregulated in response to LPS where it can suppress the LPS-induced activation of NF-κB 
and its downstream pro-inflammatory pathways, meaning that a downregulation of SLPI by 
IFN-γ reinstates the defensive responses of macrophages. This is supported by literature 
showing that Slpi knockout mice are more susceptible to septic shock, suggesting that Slpi is 
involved in dampening excessive inflammation (Nakamura et al., 2003). It seems unlikely that 
WFDC2 would be downregulated for the same reason as SLPI as the evidence described in 
Chapter 4 suggests that the proteins do not elicit the same functions. It is more likely that 
WFDC2 plays a role in tumorigenesis and is thus downregulated in cancer cell lines by IFN-γ 
in an attempt to suppress tumour growth and invasion.  
The main aim of the work described in this chapter was to identify the role of WFDC2 in 
influencing cancer cell behaviour. To do so, a cancer cell line with high endogenous WFDC2 
expression, namely CAL27, was selected as a target for CRISPR gene editing and then used 
for downstream functional assays. Although siRNA knockdown WFDC2 clones have 
previously been described in the literature, WFDC2 CRISPR knockout cancer cells have not 
yet been used to study cancer cell behaviour. CRISPR has the potential to induce complete 
gene silencing, whereas a knockdown will only partially silence expression.  
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The CRISPR sgRNAs were designed to recruit the Cas9 nuclease to exon 2 of WFDC2, which 
would thus silence three out of five WFDC2 splice variants, including the most prevalent 
isoform, V0. Exon 2 encodes the N-terminal WFDC domain and also includes the site of N-
glycosylation (Asn-44). The presence of a deletion in colony 11 was visualised on a gel where 
it exhibited a smaller size than the control colonies and was subsequently analysed by 
sequencing.  
The three PCR products derived from colony 11 gDNA showed that all sequences lacked the 
3’AG splice site of intron 1. The 3’AG is a requirement for splicing, therefore its deletion 
prevents the excision of intron 1 which subsequently excludes exon 2 from the resultant 
mature mRNA. The deletion of residues within exon 2 in PCR fragment 1 (see Fig 5.11 and 
5.12) meant that a premature stop codon was also introduced, further supporting the notion 
that no WFDC2 isoforms containing exon 2 could form. As a result, the synthesis of mature 
mRNA encoding protein isoforms V0, V1 and V4 was unfeasible but successful splicing could 
still occur between exon 1 and 4 to form isoform V2, and exon 4 and 5 to produce isoform V3.  
To further determine whether the CRISPR editing had been successful in silencing WFDC2, 
RT-PCR was carried out using cDNA derived from the CRISPR cells and controls. The primers 
spanned the whole gene transcript (targeting exon 1 and 5), meaning that they could amplify 
V0, as well as V1 and V2. The results showed that in the two controls, V0 was by far the most 
abundantly expressed isoform (450 bp). A faint second band was also visible at ~300 bp which 
most likely represents V2 (306 bp). Interestingly, the CRISPR PCR product showed a single 
intense band at ~300 bp, with no other visible bands at 450 bp or 579 bp, suggesting that the 
CRISPR cells were no longer able to express V0 or V1 and instead directed all pre-mRNA into 
synthesising V2. When primers specific to V2 were utilised, the CRISPR cells expressed more 
V2 than the controls, suggesting that V2 expression is indeed exacerbated due to the silencing 
of exon 2-containing isoforms.  
When specific primers designed to target V0 were used for RT-PCR the results showed that, 
although V0 expression was significantly more abundant in WT and control cells, some V0 
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expression was also detectable in the CRISPR cells. This result suggests that a mixed 
population of cells remained within the CRISPR colony despite every effort to expand the 
colony from a single mutant cell. Nonetheless, the low band intensity shows that successfully 
edited cells (which lack expression of V0, V1 and V4) predominate in the mixed population. 
This hypothesis is also supported by RT-qPCR data which shows a significant reduction of V1 
expression in CRISPR cells compared to the controls, with CRISPR cells expressing 1% of 
the WFDC2 expression found in controls. 
When WFDC2 expression was analysed at the protein level, the results were conclusive. 
Western blotting showed that when 45 µg of total protein was analysed, CRISPR cells 
secreted no detectable WFDC2 in their conditioned media, whereas the negative control cells 
continued to express protein. Similarly, when the concentration was analysed by ELISA, the 
CRISPR cells had no detectable WFDC2 in their conditioned media, whereas the controls had 
an abundance of WFDC2. The absence of protein is particularly interesting when compared 
to the expression of WFDC2 in the different WT cancer cell lines (Fig 5.6), as even the lowest 
expressing cell lines still secreted detectable levels of protein (the lowest concentration being 
452 pM, secreted by NCI-H322 cells). Although the RT-PCR analysis suggested that some 
V0 expression may remain in the CRISPR cells, protein analysis appeared to show that the 
mRNA detected was not translated into protein. For this reason, the cells were subsequently 
used for downstream functional analyses. Behavioural assays were used to compare the 
growth characteristics of the CRISPR and control cells, with the aim of determining the role of 
WFDC2 in influencing cancer cell behaviour.  
When the metabolic activity and proliferative capacity of the cells was assayed using MTS 
reagent and cell counting, both the negative control and CRISPR cells exhibited reduced 
proliferation compared to WT. This is most likely due to both groups having undergone 
transfection, FACS sorting and single cell expansion, all of which are harsh treatments that 
may affect cell viability. This evidence suggests that, contrary to the data published in the 
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literature, WFDC2 does not increase cell proliferation and thus it is unlikely to propagate 
tumour growth directly.  
The effect of WFDC2 on cell adhesion was tested against collagen I and fibronectin, two main 
components of the ECM, and no significant difference in adhesion was identified between the 
CRISPR cells and controls. Given that adhesion molecules, e.g. integrins, are key to 
influencing migration and invasion, if WFDC2 was capable of inducing changes to cell motility 
its effects would be unlikely to be mediated by adhesive mechanisms. The disparity in the 
number of adhered WT cells versus the negative control and CRISPR cells most likely arises 
from the reduced viability of the latter groups.  
The CRISPR cells were further analysed for changes in cell motility. The WFDC2-knockout 
cells appeared to show a reduced capacity for migration, although the difference compared to 
the WT control was not statistically significant. Interestingly, when analysed for changes in 
invasive capacity, the CRISPR edited cells showed a statistically significant reduction in 
invasion compared to the control cells; a mean reduction of 13-17%. Given the aggressive 
and infiltrative phenotype of CAL27 cells, the fact that WFDC2-silencing has an inhibitory 
effect on their ability to migrate and invade may suggest that the gene exhibits pro-metastatic 
activity. It is feasible that if a less invasive cell line was used for the CRISPR studies, the effect 
on cell motility may have been more pronounced.  
The lack of extensive behavioural changes identified from the CRIPSR cell analysis was 
surprising, especially given the WFDC2-mediated effects reported in the literature using 
siRNA knockdown clones, which express considerably more WFDC2 compared to the 
CRISPR cells engineered in this study. The siRNA clones are reported to exhibit significantly 
reduced proliferation, migration and invasion rates (Guo et al., 2015; Lu et al., 2012; Zhu et 
al., 2016); indeed, the siRNA knockdowns induced ~50-60% reduction in invasion compared 
to controls (Lu et al., 2012; Guo et al., 2015). While the CRISPR cells in this study did show 
changes in migratory and invasive activities, the key difference between the CRISPR cells and 
the siRNA clones described in the literature is their disparate proliferation rates.  
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When considered more closely, some of the assays reported in the literature show only 
moderate differences between clones with modified WFDC2 expression and their controls. 
For example, Zhu et al (2016) uses both WFDC2-overexpressing and WFDC2-knockdown 
clones to analyse changes in viability using an MTT assay. Although there is a statistically 
significant difference in absorbance readings between groups (overexpressing cells have a 
higher proliferation rate than the mock control and knockdown cells have a lower proliferation 
rate), the error bars overlap and mean OD readings are close together, suggesting that the 
result is not biologically significant. Li et al (2012) describes significantly higher proliferation in 
WFDC2-overexpressing cells compared to mock cells, yet their MTS assay results are plotted 
as ‘a ratio of DNA content’ and no error bars are shown. The unconventional expression of 
this data perhaps calls its reliability into question. Data described in Gao et al (2011) and Lu 
et al (2012) support the findings in this study, as they describe no significant changes in cell 
viability/proliferation of WFDC2-overexpressing cells when assessed against controls.  
Discrepancies in the literature are also notable in xenograft studies. WFDC2-overexpressing 
ovarian cancer cells have been used to induce tumour development via subcutaneous 
injection in two separate reports; however, the resultant tumours were significantly larger than 
controls when isolated and measured in the work of Zhu et al (2016), whereas Gao et al (2011) 
describe the opposite, with the cells giving rise to significantly smaller tumours than controls. 
Both studies used the same ovarian cancer cell line to synthesise overexpression clones. 
Further investigations will be required to more resolutely determine the role of WFDC2 in 
influencing cancer cell behaviour. The evidence discussed in this study suggests that by 
knocking out the expression of WFDC2, the cells have reduced invasive and migratory 
capacities. To further examine this hypothesis, it would be of interest to additionally edit the 
exon 2-knockout CAL27 cell line to cause silencing of exon 4. This would silence all 5 WFDC2 
splice variants and could subsequently be used as a complete WFDC2-knockout cell line.  
The fact that the CRISPR cells produced in this study still produce V2 mRNA means that it is 
entirely probable that some functional V2 isoforms were expressed by the CRISPR cells. The 
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hypothesised upregulation of V2 (shown in Fig 5.15) may have had an effect on the CRISPR 
phenotype, meaning that, although the cells could not secrete V0 protein, they expressed a 
compensatory level of V2 – an isoform expressing a WFDC domain. Unfortunately, this theory 
cannot be tested as, thus far, no antibody has been raised against V2. If the function of the C-
terminal and N-terminal domain are the same, then the C-terminal domain in V2 may act in a 
compensatory fashion when V0 is silenced. In conclusion, the effects on cell behaviour 
mediated by the V0-knockout were moderate, with cells appearing to show some reduction in 
invasion and migration. The limited behavioural changes may be due to the compensatory 
activity of V2. It should also be noted that in all of the WFDC2-knockdown models described 
in the literature, no reference is made to the fact that WFDC2 can be alternatively spliced and 
therefore the prospect of four isoforms continuing to be produced at normal, or indeed 
elevated, levels is not discussed.  
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Chapter 6 
Analysis of the Wfdc2-knockout mouse phenotype 
 
6.  
6.1. Introduction 
Multiple in vitro and xenograft studies have been described in the literature with the overall 
aim of elucidating the function of WFDC2 (Gao et al., 2011; Li et al., 2013; Lu et al., 2012; Zhu 
et al., 2016), yet little has been gleaned from these studies regarding the role of WFDC2 in 
healthy tissues. One research tool yet to be utilised is the generation of Wfdc2-knockout mice. 
The analysis described in this chapter will compare the histopathological phenotype of tissues 
derived from heterozygous knockout and WT adult mice. The phenotype of homozygous 
knockout mouse embryos will also be studied to determine whether Wfdc2 plays a role in 
embryonic development. These studies will fill a gap in the literature, providing a novel 
perspective to the discussion surrounding the function of Wfdc2 in mice. 
6.2. Aims and objectives 
The aim of the work described in this chapter was to compare the histological phenotype of 
heterozygous Wfdc2-knockout and wild-type (WT) mouse tissues. Organs from WT and 
heterozygote adult mice were studied, firstly by analysing their tissue architecture by H&E 
staining, and secondly by assessing the extent of Wfdc2 expression within the tissues to 
determine whether the mutant phenotype resulted in a concomitant reduction in Wfdc2 protein 
production. Analysis of Wfdc2 staining in WT mice was important as no IHC data is available 
in the literature regarding murine Wfdc2 expression. The expression of Slpi, a closely related 
WFDC protein, was also quantified to determine whether its expression was upregulated in 
heterozygotes to compensate for any reduction in Wfdc2 expression. To assess the phenotype 
of homozygote Wfdc2-knockout mice, embryos were analysed by micro-computed 
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tomography (micro-CT) at the MRC Harwell Institute to identify any distinct structural defects 
in homozygotes, to establish a biological function for Wfdc2 in development.  
6.3. Materials and methods 
To access the relevant materials and methods utilised in this chapter, please refer to the 
sections below: 
• Knockout mice tissues were processed as per the methods in Section 2.11.1 to 2.11.3.  
• H&E staining was carried out as described in Section 2.11.5. 
• Immunohistochemistry was performed by Jessica-Leigh Tallis (a Sheffield 
Undergraduate Research Experience scheme student, supervised by Hannah Armes) 
using the method described in Section 2.11.6. 
• The antibodies used are summarised in Table 2.13 and positive staining was quantified 
using the method outlined in Section 2.11.8. 
• Micro-CT analysis of homozygous embryos was performed by researchers at the MRC 
Harwell Institute. 
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6.4. Wfdc2-knockout mice 
Wfdc2-knockout mice were established at the MRC Harwell Institute and were generated via 
CRISPR-induced mutation. A 2431 nucleotide region spanning intron 2 to intron 4 was deleted, 
thus removing two essential exons (namely exons 3 and 4) to induce a null allele. The 
homozygote knockout animals exhibited a lethal phenotype, whereby the animals died shortly 
after birth and prior to weaning, while heterozygote animals were viable.  
6.5. Analysis of heterozygotes 
6.5.1. Tissue architecture  
Tissues derived from WT and heterozygous adult mice were processed, sectioned and then 
stained with haematoxylin and eosin (H&E) to visually analyse the structure of the tissues. 
Salivary gland, trachea, lung, stomach, gastrointestinal tract, kidney, testis, epididymis and 
ovary derived from six WT animals (three male, three female) and six heterozygotes (three 
male, three female) were analysed. The tissues were visually inspected for any apparent 
architectural differences or anomalies between phenotypes, in addition to looking for any 
fibrosis or ulceration, lymphocyte infiltration or reductions in specific cell types likely to express 
Wfdc2 e.g. secretory cells. The airways were studied for any thickening of alveolar/bronchial 
walls or any reduction in alveoli. Tissues of the gastrointestinal system were analysed for loss 
of villi or reduction in mucous-secreting cells.  
Visual analysis of the WT and heterozygote tissues showed no discernible structural 
differences between the two phenotypes in any of the tissues studied. Figures 6.1 to 6.3 show 
representative images of H&E stained tissues derived from WT and heterozygote mice.  
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Fig 6.1. H&E stained tissues of murine salivary glands and respiratory tract. Tissue sections show 
H&E staining in WT (left panel) and heterozygote (right panel) murine salivary gland (10X 
magnification), trachea (20X), mucosal glands (20X) and lung (4X).  
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Fig 6.2. H&E stained tissues of murine gastrointestinal tract and kidney. Tissue sections show 
H&E staining in WT (left panel) and heterozygote (right panel) murine stomach (10X), small intestine 
(10X), large intestine (10X) and kidney (10X).  
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Fig 6.3. H&E stained tissues of murine reproductive tracts. Tissue sections show H&E staining in 
WT (left panel) and heterozygote (right panel) murine epididymis (10X), testis (4X), fallopian tube (20X) 
and ovary (10X).  
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6.5.2. Wfdc2 expression  
Immunohistochemistry (IHC) was used to determine the localisation of Wfdc2 protein in 
numerous murine tissues. A polyclonal antibody raised against murine Wfdc2 was used to 
detect the protein. Due to the absence of data in the literature regarding murine Wfdc2 protein 
localisation, WT tissues were carefully analysed for positive Wfdc2 staining and compared to 
the array data available online (Su et al., 2002). Negative controls are shown in the Appendix. 
Analysis of positive staining showed that the localisation of Wfdc2 protein is largely consistent 
with the gene expression data published on the BioGPS portal (see Fig 1.10 in Section 1.2.4). 
Salivary gland, trachea, lung, stomach, intestines, kidney, fallopian tube and testis all stained 
positively for Wfdc2 while epididymis and ovary were largely negative. 
Wfdc2 was present in all major salivary glands. In the parotid gland, the protein was localised 
to the acinar cells and was notably absent in the ducts (Fig 6.4a). Conversely, in the sublingual 
gland (Fig 6.4b and Fig 6.4d) Wfdc2 was localised almost entirely to the ducts, although some 
positivity was visible in the serous demilunes. Staining was also predominantly found in the 
ducts of the submandibular gland (Fig 6.4c and Fig 6.4d). When positivity was quantified using 
Aperio ImageScope software and presented as a percentage of positively stained pixels, 
Wfdc2 was shown to be most abundant within the parotid gland, followed by the 
submandibular gland (Fig 6.5). 
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Fig 6.4. Localisation of Wfdc2 in murine salivary glands. Tissue sections show WT murine salivary 
gland tissue stained for murine Wfdc2 by IHC. Positive staining was identified in parotid (a), sublingual 
(b, d) and submandibular (c, d) glands. Fig 6.4d shows both sublingual (right) and submandibular gland 
(left) tissue. Original magnification of the images was 40X (a, b), 20X (c) and 10X (d).   
 
 
Fig 6.5. Quantification of Wfdc2 staining in murine salivary glands. Quantification of positive Wfdc2 
staining of murine salivary gland tissue analysed by IHC. Quantification was based on the percentage 
of positively stained pixels from total pixels present determined using Aperio ImageScope software. 
Mean ± SD are shown, with data points representing individual Wfdc2 expression for each animal. 
Staining of negative controls were subtracted to account for background.  
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In the airways, intense Wfdc2 staining was found in the tracheal epithelium (Fig 6.6a and Fig 
6.6b). Submucosal glands in the upper airways were also positive, with staining largely being 
localised to serous cells within the glands (Fig 6.6b). Positive staining continued down the 
trachea and into the large airways, with staining visible in the epithelium of bronchi and 
bronchioles (Fig 6.6c, Fig 6.6d). Epithelia of the alveoli were largely negative for Wfdc2, 
although some individual cells within the alveolar epithelium were Wfdc2-positive (Fig 6.6d).  
 
Fig 6.6. Localisation of Wfdc2 in murine airways. Tissue sections show WT murine trachea and lung 
tissue stained for murine Wfdc2 by IHC. Positive staining was identified in the trachea (a, b), 
submucosal glands (b) and bronchioles (c, d). Alveoli were largely negative for Wfdc2 (c, d). Original 
magnification of the images was 20X (a, b, d) and 10X (c).   
 
When analysed more closely, positive Wfdc2 staining within the tracheal epithelium appears 
to co-localise with non-ciliated cells (Fig 6.7). The cilia project outwards into the lumen of the 
trachea while Wfdc2-expressing non-ciliated cells tend to be shorter. 
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Fig 6.7. Localisation of Wfdc2 in the tracheal epithelium. Tissue sections show the WT murine 
tracheal epithelium (a, b) which has been stained for murine Wfdc2 by IHC. Positive staining was 
identified in non-ciliated cells (marked with a black arrow) while ciliated cells appear to be negative for 
Wfdc2 (marked with blue arrow). Original magnification of the images was 40X (a) and 20X (b).   
 
Wfdc2 staining was abundant throughout the digestive tract. In the stomach, positive staining 
was seen within the gastric pits of the mucosa which open into the stomach lumen (Fig 6.8a, 
traverse section visible in Fig 6.8b). When moving laterally through the mucosa, from the 
lumen towards the submucosa, the centre of the mucosal tissue was largely negative for 
Wfdc2 staining; however, at the base of the mucosa Wfdc2 appeared to localise to chief cells 
(Fig 6.8a, Fig 6.8c). 
In the small intestine, the brush border of enterocytes of the villi were moderately stained, 
while the internal lamina propria remained negative for Wfdc2 (Fig 6.8d-f). Interestingly, 
individual goblet cells scattered between the columnar enterocytes were intensely stained (as 
highlighted in the expanded area in Fig 6.8e). Crypts present at the base of the villi also 
appeared to exhibit moderate staining, again displaying marked staining of goblet cells (Fig 
6.8d-f).  
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Wfdc2 staining was abundant within the mucosa of the large intestine, with positive staining 
visible throughout the tubular glands and crypts of the mucosa (Fig 6.8g-h). Goblet cells were 
intensely stained, a factor consistent with the small intestine. Positivity appeared to be most 
abundant at the base of the mucosal glands (Fig 6.8h). Traverse sections through the mucosa 
reiterate the abundance of positive mucous cell staining (Fig 6.8i).  
 
Fig 6.8. Localisation of Wfdc2 in murine gastrointestinal tract. Tissue sections show WT murine 
gastrointestinal tissue stained for murine Wfdc2 by IHC. Positive staining was identified in the stomach 
mucosa (a, b, c), small intestine (d, e, f) and large intestine (g, h, i). A magnified section of a villus in 
the small intestine is shown (e) so that individual goblet cells are visible. Original magnification of the 
images was 40X (b, h, i), 20X (a, c, e, f) and 10X (d, g).   
 
 
 
 
189 
 
Wfdc2 was moderately expressed within the kidney. Staining was visible throughout the 
convoluted tubules of the cortex (Fig 6.9a) and could be found within the lumen of the tubules 
(see magnified section in Fig 6.9c). The glomeruli were negative (Fig 6.9a) and the collecting 
tubules of the medullary ray were only weakly positive (Fig 6.9b).  
Fig 6.9. Localisation of Wfdc2 in murine kidney. Tissue sections show WT renal tissue stained for 
murine Wfdc2 by IHC. Positive staining was identified in the renal cortex (a, c) and moderate staining 
found in the medullary ray (b). Glomeruli were negative for Wfdc2 (a, c). A section of the renal cortex is 
magnified (c) to show the lumen of a convoluted tubule. Original magnification of the images was 40X 
(c) and 20X (a, b).   
 
In the male reproductive tract, Wfdc2 expression was variable. In the testis, positive staining 
was abundant within the germ cells, although the late stage germ cells found in the lumen 
appeared to stain more intensely than the early stage germ cells seen at the basal layer (Fig 
6.10a-b). The interstitial tissue, seminiferous epithelium and Sertoli cells were all negative for 
Wfdc2. Similarly, the epididymis appeared to lack Wfdc2 staining, although there was some 
faint positivity visible in the brush border of the columnar epithelium (Fig 6.10c-d). 
In the female reproductive tract, Wfdc2 staining was also mostly negative. In the ovary there 
was some minor staining visible within follicles of different stages, but no staining was seen in 
the remainder of the tissue (Fig 6.11a-b). Conversely, significant staining was found in the 
columnar epithelium of the fallopian tube (Fig 6.11c).  
190 
 
 
Fig 6.10. Localisation of Wfdc2 in murine male reproductive tract. Tissue sections show WT 
reproductive tract tissue stained for murine Wfdc2 by IHC. Positive staining was identified in the testis 
(a, b). The epididymis was largely negative for Wfdc2 (c, d). Original magnification of the images was 
20X (b) and 10X (a, c, d).   
 
Fig 6.11. Localisation of Wfdc2 in murine female reproductive tract. Tissue sections show WT 
reproductive tract tissue stained for murine Wfdc2 by IHC. The ovary was largely negative for Wfdc2 
(a, b). Positive staining was identified in the fallopian tube (c). Original magnification of the images was 
20X (b, c) and 10X (a).   
 
 
Wfdc2 staining within mouse gastrointestinal tissues appeared to frequently co-localise with 
mucous or mucous-producing cells. When tissues of the gastrointestinal tract were stained 
with alcian blue, a dye which stains acid mucins, a similar staining pattern to that of Wfdc2 
emerged. In the small intestine, mucous-secreting goblet cells stained positively for alcian blue 
within the epithelia of villi and in the crypts at the base of the villi (Fig 6.12a-b). In the large 
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intestine, positive blue staining was profuse due to the abundance of large goblet cells 
spanning the crypts of the mucosa (Fig 6.12c-d). This staining pattern correlates with Wfdc2 
staining in the intestines (see Fig 6.8). 
 
Fig 6.12. Alcian blue staining of murine gastrointestinal tract. Tissue sections show WT murine 
gastrointestinal tissue stained with alcian blue. Positive staining was identified in the goblet cells of the 
small intestine (a, b) and large intestine (c, d). Magnified sections of a villus within the small intestine 
(b) and of a tubular mucosal gland of the large intestine (d) are shown so that individual cells are visible. 
Original magnification of all images was 20X.   
 
Although a trend of co-localisation between alcian blue and Wfdc2 was observed in tissues of 
the gastrointestinal tract, a similar trend was not seen in the respiratory tract or oral cavity. For 
instance, Wfdc2 was found to be present within the submandibular and sublingual glands (see 
Fig 6.4) but its pattern of expression was distinct to that of salivary mucins (Fig 6.13). Wfdc2 
was specifically found in the ducts of the submandibular and sublingual glands, whereas alcian 
blue staining was notably absent from the ducts, instead positivity was seen in the mucous 
acini (Fig 6.13a and 6.13c).  When submandibular glands were analysed for mucin 5B 
(MUC5B) expression using IHC, the protein was abundant within the mucous cells (Fig 16.3d).  
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In submucosal glands of the upper respiratory tract, both alcian blue and MUC5B localised to 
mucous within the glands (Fig 6.13e-f). The staining pattern appeared to be distinct to Wfdc2 
staining, which showed positivity in smaller serous glands rather than the obviously mucous-
filled ducts (Fig 6.6b).   
 
Fig 6.13. Mucous staining of murine salivary glands and submucosal glands. Tissue sections 
show WT murine salivary glands (a-d) and airway submucosal glands (e-f) stained with alcian blue (a, 
c, e) and stained for MUC5B (b, d, f). Positive alcian blue staining was identified in the mucous cells of 
the sublingual gland (a) and submandibular gland (b). Positive MUC5B staining was seen in the 
sublingual gland (c) but was absent in the submandibular gland (d). Both alcian blue and MUC5B 
localised to mucous cells of the submucosal glands (e, f). Original magnification of images was 40X (a-
d) and 20X (e-f).   
 
Wfdc2 is expressed in non-mucous secreting cells such as club cells, as evidenced by the co-
localisation of Wfdc2 with club cell secretory protein (CCSP), which is the predominant 
secretory protein of club cells (Fig 6.14). Club cells are present within the tracheal and 
bronchial epithelium.  
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Fig 6.14. Localisation of CCSP in murine airways. Tissue sections show WT murine tracheal and 
lung tissue stained for murine CCSP by IHC. Positive staining was identified in the trachea (a) and 
bronchi (b). Original magnification of the images was 40X (a) and 20X (b).   
 
6.5.3. Slpi expression  
Given the frequent parallels drawn between the human orthologues of WFDC2 and SLPI, the 
expression profile of murine Slpi was studied via IHC to determine whether it co-localises with 
Wfdc2. The results showed that Slpi and Wfdc2 have a similar yet distinct pattern of 
expression. 
In the respiratory tract, Slpi staining was present within the tracheal and bronchial epithelium 
(Fig 6.15a-b) and was largely absent in the peripheral lung. Likewise, in the oral cavity, Slpi 
staining was similar to Wfdc2 in the major salivary glands, with staining in the acinar cells of 
the parotid gland and in the ducts and serous demilunes of the sublingual glands (Fig 6.15d-
e). In contrast to Wfdc2, the submandibular gland stained positively for Slpi in the acini as well 
as the ducts (Fig 6.15f).  
Slpi staining within the stomach presented a similar pattern of staining to Wfdc2, with positivity 
at the surface of the mucosa within the gastric pits, in addition to staining within chief cells at 
the base of the gastric glands (Fig 6.15g). Interestingly, in the intestines, Slpi localisation was 
distinct to Wfdc2, largely due to its notable absence in goblet cells. In the small intestine 
staining was present within the brush border of the columnar epithelium of the villi and within 
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the intestinal crypts, while goblet cells within the crypts and villi were negative (Fig 6.15h).  
Minor Slpi staining was found in the large intestine, particularly at the mucosal surface 
epithelium. The crypts were largely negative for Slpi and goblet cells were negative (Fig 6.15i-
j). 
In the kidney, weak Slpi staining was visible throughout the convoluted tubules of the cortex 
and the glomeruli were negative (Fig 6.15k). In the male reproductive tract, Slpi was abundant 
in the brush border of the columnar epithelium of the epididymis. Staining was strongest at the 
initial segment and caput of the epididymis but weaker towards the cauda (Fig 6.15l-m). Slpi 
staining was absent in the testis (Fig 6.15n) and in the female reproductive tract, Slpi was also 
largely absent within the ovary and the fallopian tube (Fig 6.15o). 
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Fig 6.15. Localisation of Slpi in murine tissues. Tissue sections show WT tissues stained for murine 
Slpi by IHC. Positive staining was identified in the trachea (a, b), bronchi (c), parotid gland (d), sublingual 
gland (e), submandibular gland (f), stomach (g), small intestine (h), large intestine (i, j), kidney (k) and 
epididymis (l, m). Testis (n) and ovary (o) were negative for Slpi. Original magnification of the images 
was 40X (d, i, k), 20X (a, b, c, e, f, g, h, j) and 10X (l, m, n, o).    
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6.6. Comparison of heterozygote and wild-type protein expression 
To determine whether the heterozygous knockout mice, which by definition have a single copy 
of the Wfdc2 gene and thus theoretically express a 50% reduction in gene expression, 
resultantly produce less Wfdc2 protein, the heterozygous and WT tissues were analysed by 
IHC. Tissue sections from each animal were stained for Wfdc2 protein using a polyclonal 
antibody and then positive DAB staining was quantified using Aperio ImageScope software. 
Positive staining was presented as a percentage of positively stained pixels.  
Quantification of positive staining demonstrated that there was no significant difference in 
Wfdc2 protein production between phenotypes (Fig 6.16), except for the large intestine which 
showed significantly higher staining in tissue derived from heterozygote animals. The 
percentage of positive staining was extensively variable between animals, regardless of 
phenotype. Higher mean percentages of positive staining were frequently seen in 
heterozygote tissues, including the submandibular gland, intestines and male and female 
reproductive tissues, although this difference was not significant.  
197 
 
 
Fig 6.16. Quantification of positive Wfdc2 immunostaining in WT and heterozygote mouse 
tissues. Positive staining was quantified and presented as a percentage of positively stained pixels per 
tissue. Graphs show positive staining in WT and heterozygotes for each tissue analysed (a-l) and 
individual data points represent each animal. The control shows background when tissues were 
incubated with secondary antibody only. Data represents the mean ± SD; * P ≤ 0.05. 
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The expression of Slpi was also analysed to determine whether heterozygote animals produce 
more Slpi protein than WT animals to compensate for the effect of Wfdc2 silencing. IHC was 
carried out using a polyclonal antibody raised against Slpi and positive DAB staining was 
quantified using Aperio ImageScope as previously described. As testis, ovary and kidney 
tissues from both phenotypes were largely negative for Slpi, this staining was not quantified.  
Quantification of positive Slpi staining demonstrated that there was no significant difference in 
Slpi protein production between tissues from WT and heterozygous animals (Fig 6.17). In the 
parotid gland staining was significantly higher in WT animals than heterozygotes, however the 
number of parotid tissue samples derived from heterozygotes was low (n=2) so the results are 
most likely due to the low sample number. Extensive variability in the percentage of positivity 
was visible between animals regardless of phenotype, particularly in the submandibular gland, 
trachea, intestines and epididymis. 
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Fig 6.17. Quantification of positive Slpi immunostaining in WT and heterozygote mouse tissues. 
Positive Slpi staining was quantified in WT and heterozygotes for each tissue analysed (a-i). Individual 
data points represent each animal. The control shows background when tissues were incubated with 
secondary antibody only. Data represents the mean ± SD; * P ≤ 0.05. 
 
To determine whether heterozygote animals displayed a greater propensity for fibrosis, tissues 
were analysed using Picrosirius red – an anionic dye which associates with collagen networks. 
Representative images of Picrosirius staining are shown in Fig 6.18. The Picrosirius red 
staining of lung sections from WT and heterozygotes was compared and quantified. A slight 
increase in the amount of positive staining in the heterozygote was identified, although the 
difference was not statistically significant (Fig 6.19a). When kidneys were subjected to the 
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same analysis, the results also showed no significant difference in positively stained pixels 
between the two phenotypes (Fig 6.19b).  
 
Fig 6.18. Picrosirius staining of murine lung and kidney tissue. Tissue sections show WT murine 
lung (a, b) and kidney (c, d) tissue stained with Picrosirius stain. Staining was visible around the bronchi 
but was absent in the alveoli (a, b). Staining was diffuse throughout the kidneys (c, d). Original 
magnification of images was 10X (a, c, d) and 20X (b). 
 
Fig 6.19. Quantification of Picrosirius red staining in WT and heterozygote mouse lungs and 
kidneys. Positive Picrosirius staining was quantified in WT and heterozygote lungs (a) and kidneys (b). 
Individual data points represent each animal. Data represents the mean ± SD. 
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6.7. Analysis of homozygous embryos  
Homozygous Wfdc2-knockout animals were viable at embryonic day E18.5 but the phenotype 
was lethal by weaning. The embryonic phenotype was studied at the MRC Harwell Institute 
and all results described in Section 6.7 are those communicated from researchers at MRC 
Harwell. 
Embryos at E14.5 and E18.5 were analysed by micro computed tomography (micro-CT) to 
give 3D assessments of the embryos. Relative embryo size was measured by deriving embryo 
volume and crown-to-rump length from the micro-CT images. 
When WT (N=2) and homozygote (N=4) embryos were compared, there was no difference in 
the volume or length of the embryos at E14.5 or E18.5 (Fig 6.20). The homozygote embryo 
volumes showed a greater spread of data at both embryonic days. Although there was no 
difference in the size of the embryos between phenotypes, at E18.5 two homozygote animals 
did exhibit a 20% larger volume than the mean of the WT embryos (Fig 6.21).  
 
Fig 6.20. Assessment of WT and homozygote embryo size. Embryo size was analysed at E14.5 
and E18.5 by measuring embryo volume (mm3) and crown-to-rump length (mm). Individual data points 
represent each embryo and the mean is shown.  
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Fig 6.21. Micro-CT images of WT and homozygote embryo size. Representative images of WT and 
homozygote embryo size at E18.5 when analysed by micro-CT. Homozygote individuals that were 20% 
larger than the mean WT embryo size are marked with an asterisk (*).  
 
Tissues/organs visualised by micro-CT were manually annotated and any morphological 
anomalies in the homozygote embryos were stated as a ratio (embryos with anomalies/total 
embryos analysed). At E14.5 and E18.5, the trachea and main bronchi were consistently found 
to exhibit structural differences compared to the WT animals in all four homozygotes analysed 
at both developmental time points. Other tissues including the fusion soft palate – nasal 
septum (E14.5), testis (E18.5) and ventricles (E18.5) had anomalies that were found in one 
out of four homozygotes. Two out of four animals also exhibited oedema at E18.5. Full details 
of the tissues and organs analysed and the number of annotations given are shown in Table 
6.1.   
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Table 6.1. Analysis of morphological defects in homozygote embryos. Homozygote embryos 
imaged using micro-CT at E14.5 and E18.5 were manually annotated and compared to WT. Any 
morphological defects in tissues or organs were catalogued. 
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The micro-CT analysis of homozygote animals listed that all four homozygote embryos at 
embryonic day E14.5 and 18.5 exhibited structural defects in the trachea and main bronchus. 
When the micro-CT images from E14.5 were studied, the tracheal lumen in all homozygotes 
was significantly constricted or completely absent, while WT animals had a visible space down 
the centre of their tracheas (Fig 6.22 and 6.23). Similarly, the main bronchi of the homozygotes 
appeared to lack a lumen, while the WT embryos had a clear luminal space within each 
bronchus (Fig 6.24 and 6.25). 
 
Fig 6.22. Micro-CT images of WT and homozygote tracheas (E14.5). Representative images of WT 
(N=2) and homozygote (N=4) embryo tracheas at E14.5, analysed by micro-CT. Tracheas are indicated 
with a white arrow.  
205 
 
 
Fig 6.23. Expanded view of micro-CT images of tracheas (E14.5). Micro-CT images shown in Fig 
6.22 are expanded 200X to visualise the trachea (indicated with an arrow). 
 
 
Fig 6.24. Micro-CT images of WT and homozygote main bronchi (E14.5). Representative images 
of WT (N=2) and homozygote (N=4) embryo main bronchi at E14.5, analysed by micro-CT. Bronchi are 
indicated with a white arrow.  
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Fig 6.25. Expanded view of micro-CT images of main bronchi (E14.5). Micro-CT images shown in 
Fig 6.24 are expanded 250X to visualise the bronchi (indicated with arrows).  
 
By E18.5, a visible tracheal lumen had developed in the homozygote animals; however, the 
lumen appeared to be narrower in the homozygotes compared to the WT (Fig 6.26 and 6.27). 
When measured, the trachea diameter was found to be 37% narrower in homozygotes 
compared to WT after being normalised to embryo size (crown-to-rump length) suggesting 
that the homozygote tracheas were significantly constricted (Fig 6.28). The main bronchi also 
showed a similar trend: by E18.5, the homozygotes had developed luminal spaces in the 
bronchi but the lumina appeared to be narrowed in comparison to WT (Fig 6.29 and 6.30). 
The diameter of the bronchial lumen was not measured but visual analysis appeared to 
suggest that constriction had occurred in the homozygote bronchi.  
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Fig 6.26. Micro-CT images of WT and homozygote tracheas (E18.5). Representative images of WT 
(N=2) and homozygote (N=4) embryo tracheas at E18.5, analysed by micro-CT. Tracheas are indicated 
with a white arrow.  
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Fig 6.27. Expanded view of micro-CT images of tracheas (E18.5). Micro-CT images shown in Fig 
6.26 are expanded 200X to visualise the trachea (indicated with an arrow). 
 
 
Fig 6.28. Assessment of WT and homozygote trachea diameter. The trachea diameter of WT (N=2) 
and homozygote (N=4) animals at E18.5 were measured from micro-CT images. Data is expressed as 
a percentage of the embryo (normalised to embryo size). Individual data points represent each embryo 
and the mean is shown. 
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Fig 6.29. Micro-CT images of WT and homozygote main bronchi (E18.5). Representative images 
of WT (N=2) and homozygote (N=4) embryo main bronchi at E18.5, analysed by micro-CT. Bronchi are 
indicated with a white arrow.  
 
 
Fig 6.30. Expanded view of micro-CT images of main bronchi (E18.5). Micro-CT images shown in 
Fig 6.29 are expanded 250X to visualise the bronchi (indicated with arrows).  
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6.8. Discussion  
Although the function of WFDC2 has previously been analysed using in vitro and xenograft 
studies, the results are conflicted and its biological role is yet to be firmly established. One 
investigative method that has not yet been employed is the use of knockout mice models. The 
recent establishment of Wfdc2-knockout mice at the MRC Harwell Institute provided a novel 
tool for investigating Wfdc2 function. The work described in this chapter aimed to use WT 
animals to establish the expression profile of Wfdc2 in mice, in addition to using knockout 
animals to identify any phenotypic changes that resulted from Wfdc2 silencing. The overall 
aim was to further elucidate the function of Wfdc2 in health and disease. 
Histological analysis of WT mouse tissues was important for furthering the understanding of 
Wfdc2 expression; thus far, no IHC data has been published in the literature establishing the 
localisation of Wfdc2 in mice. IHC carried out during this study showed that positive Wfdc2 
expression largely correlated with the high throughput sequencing data available in the 
literature (see Fig 1.10); for instance, according to BioGPS, the lung, large intestine, salivary 
gland and stomach all express Wfdc2 (Su et al., 2002). The level of gene expression described 
by Su et al (2002) appears to correlate with the amount of positive IHC staining identified in 
this study, for instance, array data shows that in the gastrointestinal system Wfdc2 is most 
abundant in the large intestine, followed by the stomach, with the small intestine expressing 
the least Wfdc2. This fits the same trend as that visualised by IHC.  
The IHC analysis also demonstrated that murine Wfdc2 exhibits a similar staining pattern to 
its human counterpart, with both orthologues positively staining the bronchi, salivary glands, 
large intestine, fallopian tube, kidney and testis (Uhlén et al., 2015). WFDC2 expression tends 
to be localised to ductal/secretory cell types in human and mouse; for instance, in the salivary 
glands WFDC2 orthologues are localised to the ducts, in the large airways their expression is 
limited to the respiratory epithelium and underlying submucosal glands, while the large 
intestine shows WFDC2 positivity in the tubular glands and their associated goblet cells 
(Bingle et al., 2006; Uhlén et al., 2015).  
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The staining pattern of Wfdc2 in the airways suggests that it is most commonly the product of 
serous cells. For instance, Wfdc2 expression in the airways closely correlates with that of club 
cells (see Fig 6.6), which are non-ciliated, serous cells found exclusively in the bronchiolar 
epithelium (Rokicki et al., 2016). Although Wfdc2 co-localises with club cells in the bronchiolar 
epithelium it is also abundant in the large airways where club cells are largely absent, 
suggesting that it is expressed by other subtypes of epithelial cell.  Positive staining was also 
seen in what appear to be serous acini of submucosal glands (Fig 6.6). This expression pattern 
is similar to other antimicrobial factors such as lysozyme, β-defensins, lactotransferrin and 
SLPI, which tend to be produced by serous cells of the respiratory tract e.g. club cells/ciliated 
cells of the epithelium and serous-type submucosal glands (Bingle et al., 2006; Bowes et al., 
1981; Dohrman et al., 1994; Grubor et al., 2006; Uhlén et al., 2015). To further support the 
theory that Wfdc2 is expressed by serous cells, airway tissue was stained for markers of 
mucous, such as alcian blue and MUC5B (see Fig 6.13e-f). The staining pattern for mucins 
was distinct to Wfdc2, with no visible co-localisation of Wfdc2 with alcian blue or MUC5B.  
In the oral cavity, Wfdc2 also appears to be expressed by serous cells rather than mucous 
cells. For example, positive staining was identified in serous acini of the parotid gland, whereas 
mucous acini of the submandibular and sublingual glands were devoid of Wfdc2 as shown by 
the distinct localisation to MUC5B and alcian blue. In the mixed glands, Wfdc2 is found 
exclusively in ducts and serous demilunes. The ductal expression of Wfdc2 suggests that the 
protein is supplemented into the viscous saliva produced by mixed glands as it is excreted 
from ducts rather than being initially exuded into saliva from acinar cells. This ductal staining 
is also seen in other host defence proteins such as lysozyme, SLPI and lactotransferrin, but, 
unlike Wfdc2, this is often coupled with positive expression in acini of mixed glands (Bingle et 
al., 2006; Korsrud and Brandtzaeg, 1982; Uhlén et al., 2015).  
Curiously, the converse is true in the gastrointestinal tract, where Wfdc2 appears to exhibit 
mucous-associated secretion. In the small intestine, anti-microbial peptides e.g. α-defensins 
and lysozyme are secreted from Paneth cells at the base of intestinal crypts (Cunliffe et al., 
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2001; Erlandsen et al., 1974), therefore, given the similar staining patterns of such factors in 
the airways and the shared putative defence functions, Wfdc2 would perhaps be expected to 
be co-expressed at the same site. Instead, Wfdc2 is almost exclusively linked to mucous cells, 
namely in goblet cells of the small and large intestine and mucous cells of the gastric pits of 
the stomach. Intestinal goblet cells are specialised for mucin production (largely of MUC2), 
carrying out a lubricating/protective function and serving to facilitate stool transit (Johansson 
et al., 2009). The mucous cells at the surface of the stomach mucosa secrete high levels of 
MUC5AC (Rodríguez-Piñeiro et al., 2013). Wfdc2 expression does not appear to correlate 
with expression of specific mucins, in as much that its expression is most abundant in the 
stomach and large intestine whereas MUC2 is most abundant in the large intestine, and least 
expressed in the stomach and MUC5AC shows the converse (Rodríguez-Piñeiro et al., 2013).  
The presence of Wfdc2 in chief cells is also atypical for anti-microbial proteins. Chief cells are 
present at the base of gastric glands, where they secrete pepsin (a proteolytic enzyme). The 
role of Wfdc2 in these cells is unknown, however the expression has been shown to be 
upregulated 30-fold during the metaplastic transition of chief cells to spasmolytic polypeptide-
expressing metaplasia (SPEM) cells (Weis et al., 2014). In fact, Wfdc2 has been proposed to 
act as a novel marker of SPEM cells (Nozaki et al., 2008; Weis et al., 2014). 
To summarise, the IHC analysis of murine tissues shows that Wfdc2 is a secretory protein that 
is expressed by serous cells of the oral cavity and airways where it may contribute to the 
biological function of mucous secretions such as saliva and airway surface lining fluid. It is 
absent at sites where mucous is lacking, such as the alveoli of the lung. Its expression in 
mucous-secreting cells of the stomach and intestines, as well as the glandular epithelium of 
the fallopian tubes, also links Wfdc2 expression to secretory mucosal surfaces. These sites of 
expression suggest that Wfdc2 is involved in contributing to the composition and function of 
mucosal surface lining fluids, a theory which continues to propagate the view that Wfdc2 is 
involved in host defence in some way. However, it is possible that secretion at these sites may 
play a different and, as yet, unidentified role.  
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When the histology of WT tissues was compared to those of heterozygote animals no 
structural defects or significant differences in tissue architecture were identifiable. This was 
most likely owing to the lack of change in Wfdc2 protein expression between WT and 
heterozygotes: when positive staining was quantified, there appeared to be no significant 
reduction in Wfdc2 protein in heterozygotes. In fact, many heterozygote tissues showed a 
higher mean percentage of positive staining compared to WT, including the large intestine 
where the difference was statistically significant.  
The ‘normal’ level of Wfdc2 protein production in heterozygotes suggests that the single 
functional Wfdc2 allele undergoes a compensatory upregulation in expression in response to 
the knockout event. Such genetic adaptive responses have been reported in the literature; for 
instance, DNA lesions have been shown to induce reorganisation of chromatin whereby 
epigenetic changes make compensatory genes more accessible and result in increased 
expression (Ziv et al., 2006). It has been proposed that dosage compensation systems, that 
were originally thought to be sex-chromosome-specific, play an important role in buffering the 
harmful phenotypes resulting from genetic alterations in autosomes (El-Brolosy and Stainier, 
2017; Valsecchi et al., 2018). Monoallelic expression of Wfdc2 in heterozygotes most likely 
results in dosage compensation due to the fact that Wfdc2 is essential for embryonic 
development, as determined by the lethal phenotype observed in homozygotes.  
Genetic knockouts may also induce upregulation of paralogous genes with redundant 
functions; therefore, the heterozygous tissues were assessed to determine whether they also 
exhibited a compensatory increase in Slpi protein. Quantification of Slpi showed that there 
was no significant difference in protein levels between phenotypes. This may be due to two 
factors. Firstly, it may result from the dosage compensation of Wfdc2 in heterozygotes, 
meaning that the animals did not exhibit any loss of Wfdc2 function that could be rectified by 
an increase in Slpi. Secondly, it may be due to the fact that, despite their shared possession 
of WFDC domains, Slpi and Wfdc2 elicit entirely different biological functions. A lack of 
functional redundancy would explain why Slpi is not upregulated in heterozygotes.  
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Heterozygotes and WT animals were additionally analysed for any observable differences in 
collagen networks due to the fact that WFDC2 has been implicated in human fibrotic diseases 
such as cystic fibrosis and renal fibrosis (see Section 1.5): in fact, it is hypothesized to be 
involved in the process of collagen turnover in renal fibrosis (LeBleu et al., 2013). When lung 
and kidney heterozygous tissues were studied using Picrosirius red stain, there was no 
significant difference in the percentage of positive staining. Similarly, no changes in collagen 
thickness or accumulation were observed between phenotypes. Again, it is difficult to 
speculate the significance of this due to the ‘normal’ Wfdc2 production in the heterozygotes 
and the potential absence of a mutant phenotype.  
 Although the heterozygous tissues elucidated little about the function of Wfdc2, the 
homozygous knockouts provided compelling insights into its role in development. Most 
interestingly, the phenotype was lethal: homozygote animals died shortly after birth at some 
point prior to weaning. Lethality after birth is suggestive of a respiratory phenotype as, prior to 
birth, gas exchange occurs via the placenta, meaning that successful respiration after birth 
will only occur if the airways have developed correctly during embryogenesis. In corroboration 
with this theory, the trachea and main bronchi of homozygote embryos at embryonic day 14.5 
and 18.5 were visibly constricted compared to WT. When measured at E18.5, the trachea 
diameters were found to be significantly narrower in homozygotes.  
An understanding of the genetic factors involved in mammalian embryonic airway 
development has steadily progressed over the last 20 years and transgenic mouse models 
have been a valuable resource to comprehend the complex interplay of regulatory signals 
involved. Many factors have been implicated in the process of airway organogenesis due to 
the revealing phenotypes of transgenic mice. For instance, Wnt5a homozygous mutants 
exhibit significantly truncated trachea and over-branching of the distal airways (Li et al., 2002). 
Traf4 mutants have a constriction in the upper trachea at the junction between the trachea 
and pharynx (Shiels et al., 2000) and Hoxa-5 homozygous mutants experience tracheal 
occlusion as a result of narrowing of the tracheal lumen, as well as having reduced lung 
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branching (Aubin et al., 1997).  The phenotype of Wfdc2 homozygous mutant embryos 
suggests that Wfdc2 is also involved in development of the trachea and main bronchi, however 
its exact function is unclear. 
A number of different tissue components are involved in the multistage process of tracheal 
morphogenesis, including cartilage rings, smooth muscle and pseudostratified columnar 
epithelial cells. In the mouse embryo, tracheal and lung development is initiated at E9. At 
E11.5, mesenchymal cells begin to differentiate into smooth muscle and by E14.5 
chondrogenesis is underway. From E14.5 onwards the epithelium changes to form a 
pseudostratified epithelium and at E18.5 the trachea is considered mature. Careful analysis 
of this developmental process performed by Kishimoto et al (2018) has provided important 
insights into the factors involved in driving tracheal growth and expansion. Although tracheal 
elongation is largely facilitated by a specific smooth muscle cell alignment (mediated by Wnt5a 
signalling), luminal expansion is regulated by two distinct factors: cartilage formation and 
epithelial organisation (Kishimoto et al., 2018).  
Between E10.5 to E14.5 the external diameter of the murine trachea is unchanged, but from 
E14.5 onwards it continually expands. One of the factors affecting tracheal diameter is the 
cartilage, which begins to develop from E14.5 forming C-shaped rings around the trachea to 
prevent it from collapsing (Kishimoto et al., 2018). To determine the role of cartilage in luminal 
growth, Sox9 transgenic mice were used; Sox9 mutants lack cartilage progenitor cells and 
therefore their trachea develop without cartilage. When the lumen of Sox9 mutants were 
measured, the animals showed a 50% reduction in the total luminal surface area, while its 
length was not significantly altered (Kishimoto et al., 2018). Although this finding may, at a 
glance, suggest that Wfdc2 influences chondrogenesis, on further inspection the phenotypes 
of the two mutants appear distinct. Sox9 mutants show a collapsed trachea at E18.5 with no 
visible lumen and the external diameter of the trachea remains unchanged between E14.5 
and E18.5 (Kishimoto et al., 2018; Turcatel et al., 2013). Wfdc2 mutants, however, have a 
visible lumen along the entire length of the trachea which is narrowed compared to the WT 
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(Fig 6.23 and 6.27) and, in contrast to Sox9, the external diameter of Wfdc2 mutant tracheas 
between E14.5 and E18.5 does appear to be increased (although this has not been quantified 
from the micro-CT images). The fact that there is no evidence in humans or mice that Wfdc2 
is expressed in cartilage or that its expression in tissues correlates with a proximity to cartilage 
furthers the notion that Wfdc2 does not affect chondrogenesis.  
The second important factor to influence tracheal diameter is the luminal epithelium. Although 
it may be supposed that epithelial cells can only instigate luminal growth by proliferating, they 
actually perform a more complex role in tracheal expansion. Mesenchymal and epithelial cells 
proliferate rapidly from E12.5 to E14.5 (at which the proliferation rate peaks) and the degree 
of cell growth is consistent with the fold-change in luminal surface area. However, from E14.5 
onwards, the cell proliferation rate decreases while the luminal surface continues to grow. By 
analysing the lumen using confocal microscopy, Kishimoto et al (2018) determined that the 
additional factor affecting luminal diameter was the ‘reshaping’ of the epithelium. The group 
showed that the proportion of luminal cells with an exposed apical surface increased over time 
and that, once the cells were present at the lumen, their apical surfaces expanded. The 
morphological changes at the lumen surface were quantified to demonstrate the extent of the 
rearrangement: between E14.5 to E16.5, 60% of tracheal cells had an apical surface exposed 
and 40% were contained at the basal side; by E18.5 the number of apical surface cells had 
increased to 80% due to further migration/expansion from the basal side to the apical surface. 
As a result of the remodelling of the epithelium, the tracheal lumen increased in surface area 
independently of proliferation (Kishimoto et al., 2018).  
The Wfdc2 mutant phenotype showed differences in luminal expansion at E14.5 and E18.5 
compared to WT and these differences could be attributed to failed epithelial organisation or 
reduced proliferation. The fact that the homozygotes showed a tracheal phenotype at E14.5 
may suggest that Wfdc2 is involved in influencing epithelial proliferation, as tracheal growth at 
this stage is largely due to cell number expansion (Kishimoto et al., 2018); however, by E14.5 
60% of tracheal epithelial cells had acquired an apical surface so it is also possible that without 
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Wfdc2 expression, the epithelium had failed to enlarge due to an absence of apical surface 
enlargement and emergence. At E18.5, the mutant trachea had expanded somewhat, but still 
exhibited a 37% reduced lumen diameter compared to WT. The expansion that occurred 
between E14.5 and E18.5 independently of Wfdc2 may be due to continued Sox9-mediated 
cartilage growth. The differences in luminal diameter between WT and Wfdc2 knockout 
animals could be attributable to either a reduction in epithelial cell proliferation or due to failed 
epithelial reorganisation. These theories will be discussed in more detail in Chapter 7. 
The change in diameter of the main bronchi is probably attributable to the same Wfdc2-
mediated developmental limitations as the trachea, as the bronchi are continuous with the 
trachea and are structurally similar i.e. are both are reinforced with cartilage and lined with a 
pseudostratified columnar epithelium.   
Given the well documented expression of Wfdc2 in the epithelium of murine and human 
tissues including the large airways, it is feasible that its developmental role would impact 
epithelial cell behaviour rather than that of chondrocytes or smooth muscle cells. Nonetheless, 
extensive analysis is required to fully understand how Wfdc2 affects tracheal and bronchial 
development. The continued and abundant expression of Wfdc2 in tissues of the adult airway 
suggests that the protein continues to play a functional role outside of development. 
In addition to the trachea and bronchi, other tissues/organs were listed to exhibit structural 
defects in the Wfdc2 mutants compared to WT. The annotations with regard to the palatal 
shelf, nasal septum, thyroid, ventricles, interventricular septum, kidney and testis all occurred 
in 1/4 homozygotes, and were only found in one of the two timepoints (E14.5 or E18.5). The 
inconsistency in the annotations mean it is difficult to draw substantial conclusions from the 
data or attribute the changes to an actual phenotypic change resulting from Wfdc2 silencing, 
therefore they will not be discussed in more detail.  
 
218 
 
Chapter 7 
Final discussion  
 
7.  
7.1. Discussion 
The overarching aim of the work described in this thesis was to determine the function of 
WFDC2, with the primary objective of understanding whether it is involved in tumorigenesis. 
A multifaceted approach was adopted using recombinant WFDC2 protein, a WFDC2-knockout 
oral cancer-derived cell line and Wfdc2-knockout mice as tools to elucidate its function.  
Although WFDC2 is hypothesised to be involved in mucosal defence, the recombinant human 
and murine WFDC2 orthologues synthesised in this study were found to exhibit no 
antibacterial effects against the four species of bacteria tested, nor anti-protease activity 
against trypsin or MMPs. Although these results contradicted a widely held hypothesis, when 
considered more closely, the potential reasoning behind the negative data became apparent.  
WFDC2 is largely hypothesised to exhibit antimicrobial and anti-protease activity due to its 
homology to SLPI and elafin. However, aside from their shared possession of WFDC domains, 
there are a number of key differences between the proteins. Firstly, SLPI and elafin are 
cationic at physiological pH (pI 9.11 and 9.14, respectively), meaning it is probable that they 
exhibit their moderate antimicrobial effects via membrane disruption (as discussed in Section 
1.3.2), whereas human and murine WFDC2 are negatively charged at physiological pH (pI 
4.69 and 5.21, respectively) and would be unable to induce membrane effects in the same 
way (pI values determined using ExPASy tool; Section 2.12). Secondly, WFDC2 is abundantly 
glycosylated whereas SLPI and elafin are devoid of glycan modifications; AMPs 
characteristically lack post-translational modifications (Wiesner and Vilcinskas, 2010). Thirdly, 
as extensively discussed in Sections 1.1.4 and 1.3.5, WFDC2 has an alternative cysteine 
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spacing to the conserved alignment found in SLPI and elafin that facilitates protease inhibition; 
without this cysteine spacing, the would-be active site of WFDC2 is, in all probability, too small 
to permit binding of a protease ligand. 
Perhaps the most compelling evidence to indicate that WFDC2 and SLPI exhibit different 
functions are the phenotypes of the resultant knockout mice which differ greatly in their 
severity. Slpi-knockout mice develop normally to adulthood and the homozygote phenotype 
only becomes apparent following experimental treatments; for instance, the mice are more 
susceptible to Mycobacteria infection (Nishimura et al., 2008) and experience exacerbated 
disease when infected with Leishmania (McCartney-Francis et al., 2014). They also have a 
heightened susceptibility to septic shock following exposure to LPS (Nakamura et al., 2003). 
In stark contrast, we found that Wfdc2-knockout mice exhibited a lethal phenotype, where the 
pups died shortly after birth, prior to weaning. The premature death of the mice appeared to 
result from respiratory defects as the lumen of the trachea and bronchi were constricted, thus 
respiration was obstructed. 
The phenotype of the Wfdc2 knockout mice analysed in this study led to the hypothesis that 
Wfdc2 was involved in the process of tubulogenesis of the trachea and bronchi, most likely by 
regulating the reorganisation of the luminal epithelium to enable expansion of its apical surface 
(as discussed in Section 6.8). A protein involved in luminal development in Drosophila 
melanogaster known as Crumbs (Crb) presents an interesting example of an embryonic 
regulator of epithelial organisation. Crb localises to the epithelial plasma membrane where it 
mediates epithelial cell polarity and apical membrane growth (Pellikka et al., 2002; Wodarz et 
al., 1995). Uncontrolled expression of Crb results in expansion of the luminal apical membrane 
of the trachea during late stage Drosophila embryogenesis (Laprise et al., 2010). Similarly, 
overexpression of Crb causes salivary gland lumina to expand while loss of Crb function leads 
to defects in salivary gland formation, including constriction of the lumen, as a result of 
changes in apical membrane growth (Myat and Andrew, 2002).  
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It is possible, given the phenotypic effects described in this study, that Wfdc2 plays a similar 
role to Crb in reorganising the luminal epithelial surface of mammalian glands and tubes. 
Although the Drosophila Crb gene provides a viable example of how luminal defects such as 
those found in Wfdc2-knockout mice may arise, the evolutionary distance between mice and 
fruitflies limits its relevance somewhat.  
A Crb orthologue that exists in mammals, Crumbs 3 (CRB3), appears to perform similar 
activities to its orthologue in Drosophila, for instance, in vitro it has been reported to be 
involved in regulating epithelial apicobasal polarity (Szymaniak et al., 2015). Interestingly, 
when Crb3-deficient mice are analysed, they exhibit a number of phenotypic defects that are 
similar to those of Wfdc2-knockout mice. The Crb3-homozygote mice die perinatally as a result 
of respiratory distress, while the heterozygotes are viable and show no obvious defects. When 
homozygote embryos at E18.5 are analysed, lung defects including ‘atrophy of luminal 
spaces’, and ‘airways filled with ectopic debris’ are evident. The kidneys also exhibit defects 
in polarisation which cause the formation of cysts and the accumulation of fibrotic tissue. 
Additionally, the intestinal villi are irregular and frequently fused together (Charrier et al., 2015; 
Whiteman et al., 2014).  
The Crb3 knockout mice are relevant to this study as they demonstrate how proteins which 
regulate epithelial development can cause defects in lung organogenesis when their 
expression is silenced, as well as defects that extend far beyond the airways to sites such as 
the kidney and intestines. Although the analysis of Wfdc2-knockout mice reported in this study 
only showed defects in the large airway lumen, the level of detail that could be visualised using 
micro-CT imaging was limited. It is entirely possible that other architectural defects are present 
in the embryos, and these defects will only be discernible upon further histopathological 
inspection. If other sites do exhibit phenotypic changes, it is most probable that they will be 
found in ducts and tubules that are positive for Wfdc2 in adult mice, such as salivary glands, 
intestinal crypts, the fallopian tube, renal tubules and seminiferous tubules of the testis.  
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Clearly Wfdc2 is important for development of the airways, yet its role in adult tissues remains 
unclear. The fact that tracheal and bronchial WFDC2 expression continues into adulthood 
suggests that it continues to serve a purpose in these tissues. Indeed, expression of genes 
involved in embryonic development are often sustained in adult tissues where they frequently 
play roles in maintenance and repair. For instance, Sox9, a key protein required for tracheal 
development (see Section 6.8), is expressed in a subpopulation of adult pulmonary basal cells 
where it is reported to be involved in regeneration of damaged lung tissue in response to injury 
signals (Ma et al., 2018). Crb3, however, appears to be involved in maintenance of contact 
inhibition and regulation of tight/adherens junctions, as determined by in vitro analysis of 
immortalised mammalian cell lines (Karp et al., 2008; Mao et al., 2017). It is possible that 
Wfdc2 regulates epithelial surface dimensions and morphology in adulthood in a similar way 
to its hypothesised role in the embryo.  
With this in mind, it is wholly understandable how dysregulation of proteins that are involved 
in maintaining the organisation of epithelia could lead to tumour formation. If such processes 
become uncontrolled, they can promote activities such as cell migration and metastasis. There 
are many examples of this, for instance, Twist (a transcription factor that controls embryonic 
epithelial-mesenchymal transition; EMT) has been shown to play an essential role in 
promoting metastasis in breast cancer (Yang et al., 2004). Loss of polarity, loss of cell-to-cell 
contacts and increased cell migration are characteristic of EMT, however these processes are 
also key to tumorigenesis. As a result, proteins involved in embryonic EMT are frequently 
implicated in cancer. Other cell polarity proteins, such as Par3 and Crb3 are also implicated 
in tumorigenesis. Loss of Par3, a scaffolding protein localised to tight junctions, can enhance 
cell invasion and metastasis due to downstream effects on actin remodelling and cell-ECM 
interactions (McCaffrey et al., 2012). Similarly, loss of Crb3 expression can have detrimental 
effects on cell polarity and cell-cell junctions resulting in increased cell migration (Karp et al., 
2008).  
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If WFDC2 plays a role in regulating epithelial organisation, this explains why the protein is so 
frequently upregulated in diseases characterised by epithelial remodelling and destruction, 
such as cystic and renal fibrosis. It would also explain how the frequent upregulation of 
WFDC2 that occurs in cancer could lead to tumour-enhancing effects. 
This theory corroborates the results presented in Chapter 5, whereby the CRISPR gene edited 
cells were shown to exhibit significantly reduced cell invasion as a result of WFDC2 silencing. 
If WFDC2 is indeed involved in promoting cell migration and metastasis it would explain why 
WFDC2 serum levels frequently correlate with poor prognosis and increasing disease stage 
(see Section 1.4.1). Although heightened WFDC2 expression occurs in ovarian cancer as a 
result of the frequent amplification of the WFDC2-encoding locus, 20q13 (Section 1.4.3), it is 
also possible that WFDC2 is selectively upregulated by the cancer cells as a result of its pro-
tumour effects.  
A multitude of evidence has shown that WFDC2 expression becomes amplified in cancer, yet 
there is no data in the literature describing loss-of-function WFDC2 mutations. By analysing 
exome/genome sequencing datasets such as The Genome Aggregation Database (gnomAD), 
the frequency of single nucleotide variants (SNVs) in the general population can be assessed. 
The data from gnomAD suggests that WFDC2 has a strong selective pressure against loss-
of-function variants, as shown by the absence of any homozygous loss-of-function mutations 
in the population analysed. This supports the phenotype of the homozygous knockout mice, 
suggesting that total silencing of WFDC2 expression is not viable in humans either.  
Two missense homozygous mutations are recorded, but neither of them target the conserved 
cysteine residues, therefore it is possible that the mutations do not drastically alter the 
secondary structure of the protein enough to affect its function, or that the mutations only affect 
one WFDC domain lobe and therefore the other domain remains functional. The phenotype of 
the heterozygous knockout mice appear to show that a single functional copy of Wfdc2 is 
sufficient to enable normal development to adulthood, therefore it is feasible that the various 
missense/nonsense heterozygous SNVs reported in gnomAD are not deleterious to the host, 
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as a single allele is able to preserve a healthy phenotype. It is also possible that the different 
WFDC2 splice variants exist in order to maintain expression of the gene if V0 expression 
becomes disrupted. 
Given that the RT-PCR analysis described in Section 5.7.2 suggested that the CRISPR cells 
directed their transcriptional machinery towards synthesis of isoform V2 as a consequence of 
V0 silencing (Fig 5.14 and 5.15), it is possible that isoforms V1-V4 are functionally redundant 
to V0. With this in mind, it is likely that the downstream effect of silencing all five WFDC2 
isoforms would induce much greater changes to cell behaviour than identified in this study.  
Limitations of the study and future work  
The assessment of antimicrobial activity performed in this study used a small panel of bacteria 
which were chosen due to their capacity to colonise sites proven to secrete WFDC2. In the 
interest of further clarity, it may be useful to expand the range of bacteria tested. Bacteria 
strains that have been reported to correlate with elevated WFDC2 levels would be interesting 
strains to analyse, including Gardnerella vaginalis (Orfanelli et al., 2014) and colonisers of 
cystic fibrosis lung such as Pseudomonas aeruginosa (Nagy et al., 2016). Generation of a 
dose-response curve may serve as a more appropriate means of resolutely showing whether 
WFDC2 can inhibit bacterial growth, although it is important to avoid concentrations that 
cannot occur naturally. Further analysis of WFDC2 levels in human secretions including 
epithelial secretions of the trachea, intestine and male and female reproductive tracts would 
ensure that the biological concentration of WFDC2 is well established. In the interest of 
consistency, it may also be more reliable to assess the concentration of WFDC2 in 
endogenous samples using the recombinant protein derived from this study as the standard 
when quantifying the WFDC2 concentration by ELISA.  
One of the difficulties in assessing the activity of recombinant WFDC2 is that its biological 
activity is unknown; as a result, no WFDC2 control exists to show that the recombinant protein 
produced in this study was active under the defined test conditions. SLPI is a good control for 
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anti-protease activity as it has well-documented inhibitory activity against trypsin and elastase; 
this information only serves to add to the perplexity regarding the unusual elastase inhibition 
assay results (Section 4.4). Contrary to its potent anti-protease activity, SLPI only has 
moderate antibacterial activity and at a concentration of 1 µM it is unable to significantly reduce 
the number of colony forming units in any of the assays referenced in Table 1.1. This would 
therefore make it a poor candidate to use as a control in the bacterial assays described in 
Section 4.5. 
The studies analysing the effect of cytokine exposure on cellular WFDC2 expression 
described in Sections 4.6.1. and 5.6. have only limited value, as they lack an appropriate 
positive control (such as IL-8) to show that the cytokines are actively capable of inducing 
downstream changes to gene expression. Additionally, the lack of change in WFDC2 
expression shown by CAL27 cells following exposure to cytokines may be due to the cells 
reaching a limit in the amount of WFDC2 they are capable of secreting – CAL27 cells 
endogenously express very high levels of WFDC2 without the presence of stimuli.  
Within the scope of this study CRISPR edited cancer cells were generated, with the aim of 
silencing expression of the predominant WFDC2 splice variant, V0. Although V0 protein 
production was successfully abolished via CRISPR editing, the expression of splice variant 
V2 appeared to become upregulated in place of V0 in the CRISPR cells, which may therefore 
have reinstated some WFDC2 function as a result of genetic redundancy. In the interest of 
clarity, it would be valuable to perform further gene editing to silence the remaining splice 
variants in the CAL27 cells and then repeat the cell behaviour assays. This would determine 
whether a complete knockout of all WFDC2 isoforms induces a more significant effect upon 
the cell phenotype and, in turn, would provide evidence as to the redundancy of V0 and V2 
isoforms. It would also certainly be of interest to further analyse the differences between the 
CRISPR knockout and control cells by comparing their transcriptome using RNA-seq. 
Finally, although the micro-CT analysis of homozygous Wfdc2 knockout mice was illuminating 
in demonstrating that the large airways of the mice were constricted, unfortunately, only limited 
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conclusions could be drawn from the data. It would be extremely interesting to histologically 
analyse the E14.5 and E18.5 embryos. Firstly, H&E staining could be used to show the cellular 
morphology of the tracheal and bronchial lumen, providing information as to how the tissue 
architecture was malformed. Secondly, immunohistochemistry could be used to visualise the 
presence of adherens junctions (via E-cadherin staining) and tight junctions (via ZO-1) to study 
any changes to the apical surface of the lumen. It would also be interesting to analyse whether 
any changes in tissue architecture occurred outside of the airways, for instance in the major 
salivary glands, large and small intestine, kidney and reproductive tracts, given the abundance 
of Wfdc2 identified at these sites in adult mice.  
The potential studies that could be carried out using the knockout mouse embryos are 
extensive. One of the most crucial investigations would be to perform RNA-seq to compare 
the transcriptome of different tissues between knockout and WT embryos, to try to elucidate 
pathways affected by Wfdc2 silencing and to further determine its role in development. It would 
also be very interesting to isolate tracheal epithelial cells from conditional mutant mice and 
culture them in vitro to observe differences in growth characteristics and morphology between 
the WT and mutant cell populations.  
7.2. Final conclusions and clinical relevance  
The work described in this thesis suggests that WFDC2 is not simply an innocent bystander 
that becomes upregulated during tumorigenesis as a result of amplification of the 20q13 locus. 
Instead, WFDC2 appears to promote tumour progression by promoting cancer cell invasion, 
which could explain the correlation between WFDC2 levels and disease severity. Further 
rigorous investigations will be required to determine the exact mechanisms through which 
WFDC2 is able to induce cell invasion; however, it is possible that the protein may provide an 
interesting therapeutic target for inhibition of metastasis in the future.  
Another factor worthy of further study is the WFDC2-encoding locus, 20q13, which is reported 
to undergo frequent amplifications. Assuming that this genetic event induces an upregulation 
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of WFDC2 expression (thus promoting its hypothesised pro-malignant effects), then it may 
provide an interesting marker to identify patients at risk of developing an ovarian malignancy. 
It would certainly be of clinical interest to study the frequency of 20q13 locus amplifications 
more closely in ovarian cancer patients, as the locus has the potential to act as a useful 
screening tool to identify both sporadic and familial cases of disease. Patients identified to be 
at higher cancer risk due to amplification of 20q13 would benefit from routine tests to give the 
greatest likelihood of an early cancer diagnosis.  
Finally, evidence presented within this study has shown that WFDC2 splice variants have the 
potential to undergo compensatory upregulation when V0 expression is downregulated. This 
compensatory expression suggests that the isoforms exhibit redundant functions. With this in 
mind, it is possible that WFDC2 serum levels may be incorrectly quantified in the clinic via the 
use of the FDA-approved ELISA kit, which is only able to detect V0. If the V1-V4 splice variants 
are overexpressed in cancer patients without a concomitant upregulation in V0, the serum 
levels of a patient may be identified as being normal and the affected individual would go 
undiagnosed.  
To conclude, this study has shown that WFDC2 is not capable of antimicrobial or anti-protease 
activity as is frequently hypothesised. Instead WFDC2 appears to play an, as yet, unidentified 
role in the development of the trachea and bronchi. Its effects on tissue morphology extend 
beyond the confines of embryonic development, as WFDC2 appears to affect cancer cell 
behaviour by promoting invasion. This suggests that WFDC2 is involved in the process of 
tumorigenesis, and as such, its overexpression in cancer is indicative of poor prognosis.  
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Appendices 
 
Supplementary methods and reagents 
DNA agarose gel electrophoresis 
For a 1% gel, 1 g of agarose was added to 100 ml 1X Tris-acetate-EDTA (TAE), heated and 
supplemented with 0.2 µg/ml ethidium bromide. Colourless DNA samples were mixed with 1 
µl of loading dye prior to loading. PCR Ranger 100 bp DNA ladder (Norgen Biotek) and 
GeneRuler 1 kb DNA ladder (ThermoFisher Scientific) were used as reference ladders. TAE 
buffer was made as 50X stock solution (242 g of Tris base, 57.1 ml of glacial acetic acid, 100 
ml of 0.5 M pH 8.0 EDTA, made to 1 L with H2O). The stock solution was diluted in water to 
give a 1X TAE working solution. 
Polyacrylamide gel electrophoresis and Western blotting  
Lower Tris buffer for SDS-PAGE 
Lower Tris buffer was made with 18.17 g of Tris (ThermoFisher Scientific), 0.4 g of SDS pellets 
(ThermoFisher Scientific) and made to 100 ml with H2O. The pH of the solution was adjusted 
to pH 8.8. 
Upper Tris buffer for SDS-PAGE 
Upper Tris buffer was made with 6.06 g of Tris (ThermoFisher Scientific), 0.4 g of SDS 
(ThermoFisher Scientific) and made up to 100 ml with H2O. The pH of the solution was 
adjusted to pH 6.8. 
SDS-PAGE 12% acrylamide gel 
To make the resolving gel for a 1.5 mm 12% gel, 3 ml of 40% acrylamide (ThermoFisher 
Scientific) and 2.5 ml of Lower Tris were added to 4.3 ml of H2O. Prior to pouring between the 
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glass plates, 350 μl of 10% ammonium persulfate (APS; Acros Organics) and 5 μl of TEMED 
(AppliChem) were added to the gel solution to induce crosslinking. The gel was protected from 
drying out by layering isopropanol on top of the resolving gel which was removed prior to 
addition of the stacking gel.  
For the stacking gel, 2.1 ml of Upper Tris and 975 μl of 40% acrylamide were added to 4.725 
ml of H2O. Prior to pouring, 100 μl of 10% APS and 17 μl of TEMED were added to the solution. 
A comb was added between the plates to form lanes for protein loading. 
2X SDS loading buffer 
Samples for analysis by Western blotting were lysed in 2X SDS lysis buffer, made by adding 
1 protease inhibitor tablet (Roche) to 1 ml of 1 M DTT (ThermoFisher Scientific), 1 ml of 20% 
SDS (ThermoFisher Scientific), 2 ml of glycerol (ThermoFisher Scientific), 1.25 ml of 0.5 M pH 
6.8 Tris-HCl (ThermoFisher Scientific), 0.2 ml of 0.02% bromophenol blue (Sigma-Aldrich) and 
4.55 ml of H2O. 
SDS-PAGE running buffer 
SDS-PAGE running buffer was made as a 10X stock solution using 10 g of SDS pellets 
(ThermoFisher Scientific), 188 g of glycine (ThermoFisher Scientific) and 30.2 g of Tris base 
(ThermoFisher Scientific) made up to 1 L with H2O. This stock solution was diluted in water to 
give a 1X working solution. 
Semi-dry transfer buffer 
Semi-dry transfer buffer was made using 5.8 g of Tris base, 2.9 g of glycine, 0.37 g of SDS 
and 200 ml of methanol, made up to 1 L with H2O. 
Lower Tris buffer for native PAGE 
Lower Tris buffer was made by adding 54.5 g of Tris base (ThermoFisher Scientific) to 300 ml 
of H2O, with the solution adjusted to pH 8.8. 
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Upper Tris buffer for native PAGE 
Upper Tris buffer was made by adding 6 g of Tris (ThermoFisher Scientific) to 100 ml of H2O 
with the solution adjusted to pH 6.8. 
Native PAGE 10% acrylamide gel 
To make the resolving gel for a 1.5 mm 10% native gel, 3.33 ml of 40% acrylamide 
(ThermoFisher Scientific) and 2.5 ml of Lower Tris were added to 4.17 ml of H2O. Prior to 
pouring between the plates, 50 μl of 10% APS (Acros Organics) and 5 μl of TEMED 
(AppliChem) were added to the gel solution to cause crosslinking. To make the stacking gel, 
2.5 ml of Upper Tris and 3.33 μl of 40% acrylamide were added to 4.17 ml of H2O. Prior to 
pouring, 50 μl of 10% APS and 10 μl of TEMED were added to the solution and a comb was 
added between the plates to form lanes for protein loading. 
Native PAGE sample buffer 
Native PAGE sample buffer was made using 4.8 ml of H2O, 1 ml of 0.5 M pH 6.8 Tris-HCl 
(ThermoFisher Scientific), 2 ml of glycerol (ThermoFisher Scientific) and 0.2 ml of 0.5% (w/v) 
bromophenol blue (Sigma-Aldrich). 
Native PAGE running buffer 
Native PAGE running buffer was made with 30.3 g of Tris base (ThermoFisher Scientific) and 
144 g of glycine (ThermoFisher Scientific), made up to 1 L with H2O. The pH was adjusted to 
pH 8.3. 
10X TBS 
A 10X Tris buffered saline (TBS) solution was made with 80 g of NaCl (ThermoFisher 
Scientific), 2 g of KCl (BDH Chemicals) and 30 g of Tris base (ThermoFisher Scientific), made 
up to 1 L with H2O. The pH was adjusted to pH 7.6. This stock solution was diluted to a 1X 
working solution. 
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1X TBS-Tween 
TBS-Tween wash buffer was made by adding 1 ml of Tween-20 (VWR Chemicals) to 1 L of 
1X TBS. 
Zymography 
5X non-reducing sample buffer  
Non-reducing sample buffer was made with 10 g of SDS, 50 ml of glycerol, 25 mg of 
bromophenol blue and 4.91 g of Tris, made up to 250 ml with H2O. 
7.5% acrylamide gel with gelatin 
To make the resolving gel for a 1.0 mm 7.5% gel, 1.5 ml of 40% acrylamide (ThermoFisher 
Scientific), 2 ml of 1.5 M Tris (pH 8.8), 40 µl of 20% SDS and 2 ml of gelatin (4 mg/ml) were 
added to 2.5 ml of H2O. Prior to pouring between the glass plates, 80 μl of 10% APS (Acros 
Organics) and 10 μl of TEMED (AppliChem) were added to the gel solution to induce 
crosslinking. The gel was protected from drying out by layering isopropanol on top of the 
resolving gel which was removed prior to addition of the stacking gel.  
For the stacking gel, 1.25 ml of 0.5 M Tris (pH 6.8), 0.5 ml of 40% acrylamide and 25 µl of 
20% SDS were added to 3.245 ml of H2O. Prior to pouring, 50 μl of 10% APS and 10 μl of 
TEMED were added to the solution and a comb was added between the plates to form lanes 
for protein loading. 
Zymography washing buffer 
Washing buffer was made with 6.25 ml of Triton-X 100, 12.5 ml of 1 M Tris HCl (pH 7.5), 625 
µl of 2 M CaCl2 and 2.5 µl of 0.1 M ZnCl2, made up to 250 ml with H2O. 
Zymography incubation buffer 
Incubation buffer was made with 2.5 ml of Triton-X 100, 12.5 ml of 1 M Tris HCl (pH 7.5), 625 
µl of 2 M CaCl2 and 2.5 µl of 0.1 M ZnCl2, made up to 250 ml with H2O. 
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Additional results 
Glycosylation site prediction 
Online NetNGlyc 1.0 and NetOGlyc 4.0 Server prediction results for human and mouse 
WFDC2 are shown in the figures below. The positions of predicted N- or O-glycans are 
indicated.  
 
NetNGlyc 1.0 Server prediction results for human WFDC2. 
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NetOGlyc 4.0 Server prediction results for human WFDC2. 
 
NetNGlyc 1.0 Server prediction results for murine Wfdc2. 
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NetOGlyc 4.0 Server prediction results for murine Wfdc2. 
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Bacterial count at OD600 of 1.0 
The number of bacterial cells per cm3 in cell suspensions at an OD600 of 1.0 was counted using 
a Helber bacterial 1 cell counter (Thoma). The results shown in the table below represent the 
mean ± SD. 
Bacterial strain Mean number of cells per cm3 ± SD 
E. coli 1.95 x 109 ± 7.50 x 107 
S. gordonii 3.70 x 109 ± 2.75 x 108 
S. mutans 6.52 x 109 ± 6.38 x 108 
S. pneumoniae 2.70 x 109 ± 5.00 x 107 
 
Bacterial count at OD600 of 1.0. Mean ± SD cells per cm3 at OD600 of 1.0 are summarised for each 
species (N=3). 
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Optimisation of agglutination assay 
To determine the appropriate number of cells to be used in the agglutination assay, different 
volumes of bacterial suspension (at an OD600 of 1.0) were pelleted, washed in PBS and then 
labelled with FITC.  Excess FITC was removed by repeated washes and then bacteria were 
resuspended in 1 ml of PBS which acted as a non-agglutinating negative control. One hundred 
microlitres of suspension was added to each well and incubated overnight in a U-bottomed 
96-well plate. When analysed the following day via a UV box imaging system, wells that had 
visible ‘pellets’ of bacteria were identified as having an appropriate number of cells seeded for 
downstream experiments. 
The results showed that the following volumes of bacterial suspension should be used for 
downstream agglutination assays: 0.5 ml of E. coli, 0.9 ml of S. gordonii, 0.9 ml of S. mutans 
and 0.7 ml of S. pneumoniae.  
 
Optimisation of the volume of bacterial suspension required for agglutination assays. Different 
volumes of bacterial suspension (at OD600 of 1.0) were tested to determine the optimal volume required 
to give downstream visible ‘pellets’ of bacteria in wells where no agglutination had occurred. Each tested 
volume of cells was pelleted, resuspended in 1 ml of PBS and stained with FITC. The FITC-stained 
bacteria were resuspended in 1 ml of PBS and 100 µl were loaded into wells of a U-bottomed 96-well 
plate (n=2).  
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Expression of WFDC2 in salivary gland organoids 
Organoids were developed by Zulaiha Rahman (School of Clinical Dentistry, University of 
Sheffield) from biopsy samples of normal human sublingual gland tissue. Cells were cultured 
in a basement membrane matrix (i.e. Matrigel) in an enriched media at an air-liquid interface 
(ALI). Signalling pathway inhibitors were added to the enriched media to study their effect on 
cell differentiation within the organoid. A summary of the inhibitors used and their functions 
are described in the table below. 
 
A summary of the inhibitors used for differentiation studies of salivary organoids.  
 
WFDC2 expression in salivary gland organoids was analysed using RT-qPCR. RNA derived 
from organoids, kindly donated by Zulaiha Rahman, was used to synthesise cDNA as 
described in Section 2.2.2 and the cDNA was used for qPCR analysis as described in Section 
2.2.5.  
HuSL cells have very low endogenous WFDC2 expression (see Fig 4.13) which is potentially 
due to the lack of highly differentiated cells such as ductular cells and mucous-secreting cells. 
The HuSL cells were exposed to retinoic acid (RA; 50 nM) for 24 hours and the response in 
WFDC2 expression was measured via RT-qPCR. RA is a factor important for differentiation 
of mucous cells (Lechner et al., 1982) so it was hypothesised that exposure to RA would 
induce an upregulation in WFDC2 expression. The results show that a moderate upregulation 
in WFDC2 expression did occur in the HuSL cells but this change was not statistically 
significant due to the variation between biological repeats.  
Inhibitor Function 
Reference 
SR7826 
LIM kinase inhibitor, inhibits cofilin phosphorylation, 
inhibits cell migration and invasion  
(Ray et al., 2014) 
A8301 
Transforming growth factor beta (TGFβ) type I receptor 
superfamily activin-like kinase (ALK5) inhibitor, inhibits 
epithelial to mesenchymal transition by TGFβ signaling  
(Gurung et al., 2015)  
DMH1 Bone morphogenic protein (BMP) inhibitor  
(Ao et al., 2012) 
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RT-qPCR analysis of WFDC2 expression in HuSL cells following exposure to retinoic acid. 
WFDC2 expression in human primary sublingual gland (HuSL) cells was tested by RT-qPCR following 
exposure to retinoic acid. WFDC2 expression is represented as the fold change in expression compared 
to the untreated HuSL cell controls. Data represents the mean ± SD (N=3; n=3).  
 
HuSL cells can be grown in complex three-dimensional culture systems using extracellular 
matrices such as Matrigel to form salivary gland organoids. The organoids can develop 
branches, positively express markers for acinar cells and secrete active amylase, and thus 
provide a novel in vitro system for studying salivary glands and salivary gland diseases. 
To determine whether organoids grown from HuSL cells expressed more WFDC2 than the 
cells grown at a monolayer, RT-qPCR was used to quantify gene expression from these 
tissues.  
The RT-qPCR results show that although WFDC2 expression can be upregulated up to ~150 
fold in organoids compared to monolayer cultures, there is a huge amount of variation in 
WFDC2 expression in the organoids, meaning that the difference between monolayer and 
organoid culture systems is not significant. The variation of WFDC2 expression in organoids 
may be due to the variation in formation of structures such as ducts, where WFDC2 would be 
most abundant.  
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RT-qPCR analysis of WFDC2 expression in HuSL monolayers and organoids. HuSL cells grown 
as a monolayer and HuSL cells grown in complex 3D culture to form an organoid were analysed by RT-
qPCR to quantify WFDC2 expression, which is represented as the fold change in expression compared 
to the monolayer cells. Data represents the mean ± SD (N=3; n=3).  
 
During development of the organoid culture system, various signalling pathway inhibitors were 
included in the culture medium in order to prevent spontaneous differentiation of progenitor 
cells and control the differentiation process. Inhibitors were also used to influence the 
morphology of the organoids by limiting the progenitor population of cells’ capacity for invasion 
and migration.  
To establish whether WFDC2 expression within the HuSL organoids was affected when the 
tissues were exposed to different inhibitors, WFDC2 expression in the organoids was 
quantified using RT-qPCR.  
The results show that there was no significant difference in WFDC2 expression between 
organoids that were exposed to signalling pathway inhibitors compared to untreated HuSL 
cells cultured as a monolayer.  
Organoids treated with SR7826, a LIM-kinase inhibitor known to supress cell migration and 
invasion, showed extensive upregulation in WFDC2 expression in some organoids, however 
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others exhibited a less drastic upregulation. This broad variation in expression means that the 
changes in WFDC2 expression were not significant between SR7826-treated organoids 
compared with untreated organoids or monolayer HuSL cells. The effect of SR7826 on 
WFDC2 expression is interesting as it implicates the gene in processes such as migration and 
invasion: if LIM-kinase is inhibited, cytoskeletal factors that mediate invasion/migration will be 
inhibited, but it is possible that other factors that are independent of the LIM-kinase pathway 
could be upregulated with the aim of restoring the inhibited function. WFDC2 has been 
implicated in promoting invasion in cancer cells (see Section 5.8.5).  
 
RT-qPCR analysis of WFDC2 expression in organoids treated with signalling pathway inhibitors. 
Organoids exposed to different signalling pathway inhibitors were analysed by RT-qPCR to quantify 
WFDC2 expression, which is represented as the fold change in expression compared to untreated 
HuSL cells grown as a monolayer. Data represents the mean ± SD (N=3; n=3).  
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RT-qPCR analysis of WFDC2 in cancer cell lines  
 
CT values from RT-qPCR quantification of WFDC2 gene expression. WFDC2 V1 expression in 4 
oral-derived and 6 lung-derived cancer cell lines was tested using RT-qPCR. The CT values for WFDC2 
expression are shown. Data represents the mean ± SD (N=3; n=3). 
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RT-qPCR analysis of V0 expression in cancer cell lines  
WFDC2 variant 0 expression was measured in ten cancer cell lines by RT-qPCR using Sybr 
Green and the same primers used for RT-PCR (see Table 2.2). U6 was used as the 
endogenous control (F primer: 5’ CTCGCTTCGGCAGCACA and R primer: 
AACGTTCACGAATTTGCGT) . The results show equivalent levels of expression between cell 
lines to those derived when analysing variant 1 expression using Taqman primers against 
B2M endogenous control. Taqman primers were used for all RT-qPCR experiments shown in 
results chapters as Taqman primers are considered to be more specific with results being 
reproducible and more accurately quantified. 
 
RT-qPCR quantification of WFDC2 gene expression in 10 cancer cell lines. WFDC2 expression in 
4 oral-derived and 6 lung-derived cancer cell lines was tested using RT-qPCR. WFDC2 expression is 
represented as the fold changed in expression compared to the U6 endogenous control. Data 
represents the mean ± SD (N=3; n=3) **** P ≤ 0.0001.  
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CT values for B2M expression in cancer cell lines treated with cytokines 
  
Fig 5.7. CT values from RT-qPCR quantification of WFDC2 gene expression in cells exposed to 
cytokines. WFDC2 expression in CAL27 and H357 cells was tested by RT-qPCR following exposure 
to inflammatory mediators: LPS (50 µg/ml), TNF-α (20 ng/ml), IL-1ß (20 ng/ml) and IFN-γ (5 ng/ml). The 
CT values of the B2M endogenous control are shown. The results suggest that the reduction in WFDC2 
expression identified following exposure to IFN-γ did not result from a reduction in cell viability, which 
would be indicated by an increase in the CT value of the B2M endogenous control. Results show the 
mean ± SD (N=3; n=3).    
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Clonal isolation analysis of CAL27 cells 
To determine whether CAL27 cells are capable of being used for clonal isolation i.e. are not 
attachment dependent, the cells were serially diluted within a 96-well plate and grown for 7 
days. The cells were fixed and stained which enabled easy identification of single cell colonies. 
The results showed that CAL27 cells were capable of growing without attachment to 
neighbouring cells and thus could be used for clonal selection of CRISPR gene edited cells.  
 
Clonal isolation test of CAL27 cells. CAL27 cells were serially diluted in a 96-well plate and their 
capacity to grow without attachment to neighbouring cells was tested. Cells were fixed, stained and 
imaged. The well highlighted shows a small colony of cells derived from a single cell.  
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Negative control slides for immunohistochemistry  
 
Control immunohistochemistry slides of murine tissues. Tissue sections show WT tissues stained 
with anti-rabbit-HRP secondary antibody only. Images show representative staining of control 
submandibular/sublingual gland (a), parotid gland (b), trachea and submucosal glands (c), lung (d), 
stomach (e), small intestine (f), large intestine (g), kidney (h), testis (i) epididymis (j), ovary (k) and 
fallopian tube (l). Minor non-specific staining was visible in the parotid gland (b), red blood cells in the 
lung (d), the chyme of the stomach (e) and the lamina propria of villi of the small intestine (f). Original 
magnification of the images was 10X (a, d, e, f, g, h, i, j, k, l) and 20X (b, c).   
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Aperio ImageScope quantification of positive immunohistochemistry staining 
 
Representative image of immunohistochemistry staining quantification using ImageScope. 
Scanned slides were analysed for positive DAB staining using Aperio ImageScope software (Leica 
Biosystems). Tissues were highlighted using the drawing tool and analysed using the Positive Pixel 
Count v9 algorithm. Positively stained pixels (orange/brown colour) were counted and used to 
determine percentage of positivity from all pixels. Negatively stained pixels are blue.   
 
 
  
 
